

CITATION REPORT

List of articles citing

2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines

DOI: 10.1016/j.jacc.2013.11.002

Journal of the American College of Cardiology, 2014, 63, 2889-934.

Source: <https://exaly.com/paper-pdf/58960133/citation-report.pdf>

Version: 2024-04-17

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2321	AUSTRALIA. 1929 , 92, 2116		
2320	New ACC/AHA cholesterol guidelines a major step forward. 2013 , 692, 11-11		
2319	Neue Cholesterin-Leitlinien werfen Zielwerte über Bord. 2013 , 13, 16-16		
2318	HIV Infection and Cardiovascular Disease. 2013 , 2013, 1-3		78
2317	Lipid Disorders in the Elderly. 2014 , 719-722		
2316	Pharmacogenetics of Statin-Induced Myopathy: A Focused Review of the Clinical Translation of Pharmacokinetic Genetic Variants. 2014 , 5,		15
2315	Statin for the primary prevention of cardiovascular disease in patients with diabetes mellitus. 2014 , 38, 32-4		15
2314	Improving medication adherence in hypercholesterolemia: challenges and solutions. 2014 , 10, 615-25		15
2313	Current guidelines for high-density lipoprotein cholesterol in therapy and future directions. 2014 , 10, 205-16		16
2312	DTC-and-Me: Patient, Provider, Proteins and Regulators. 2014 , 4, 79-87		4
2311	Lifestyle and diet. 2014 , 25, 298-301		3
2310	Effects of extended-release niacin/laropiprant, simvastatin, and the combination on correlations between apolipoprotein B, LDL cholesterol, and non-HDL cholesterol in patients with dyslipidemia. 2014 , 10, 279-90		8
2309	Eight challenges faced by general practitioners caring for patients after an acute coronary syndrome. 2014 , 201, S110-4		1
2308	Older patients: Latest guidelines, research, roles for pharmacists. 2014 , 20, 26-27		
2307	Centralized Pan-Middle East Survey on the Under-Treatment of Hypercholesterolemia: Results from the CEPHEUS Study in Egypt. 2014 , 3, 27-40		6
2306	The new cholesterol and blood pressure guidelines: perspective on the path forward. 2014 , 311, 1403-5		20
2305	Screening coronary CT angiography: possibilities and pitfalls. 2014 , 30, 1599-601		2

2304	Public health: An agenda to promote Hispanic cardiovascular health. 2014 , 11, 560-2	
2303	Type 1 diabetes through the life span: a position statement of the American Diabetes Association. 2014 , 37, 2034-54	547
2302	Niemann-Pick C1-Like 1 protein: Another target for treatment of dyslipidemia? Evidence from the Myocardial Infarction Genetic Consortium and IMPROVE-IT trials. 2014 , 2014, 355-9	3
2301	Industry sponsorship bias in research findings: a network meta-analysis of LDL cholesterol reduction in randomised trials of statins. 2014 , 349, g5741	34
2300	Simple, standardized incorporation of genetic risk into non-genetic risk prediction tools for complex traits: coronary heart disease as an example. 2014 , 5, 254	39
2299	Cardiovascular risk and statin use in the United States. 2014 , 12, 215-23	51
2298	Management of cardiovascular risk factors in adults with congenital heart disease. 2014 , 3, e001076	48
2297	What is new in the 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic risk in adults?. 2014 , 41, 304-5	3
2296	General practitioners' use of absolute risk versus individual risk factors in cardiovascular disease prevention: an experimental study. 2014 , 4, e004812	26
2295	Clinician's guide to the updated ABCs of cardiovascular disease prevention. 2014 , 3, e001098	17
2294	Dialysis: destination or journey. 2014 , 25, 1609-11	10
2293	Electronic health records may threaten blinding in trials of statins. 2014 , 349, g5239	3
2292	Diagnosis and management of lipodystrophy: a practical update. 2014 , 9, 235-259	6
2291	Achieving optimal lipid goals in the metabolic syndrome: a global health problem. 2014 , 237, 191-3	2
2290	Cardiovascular imaging: a glimpse into the future. 2014 , 10, 139-45	10
2289	Efficacy and safety of alirocumab, a monoclonal antibody to PCSK9, in statin-intolerant patients: design and rationale of ODYSSEY ALTERNATIVE, a randomized phase 3 trial. 2014 , 8, 554-561	110
2288	Estimaci3n del riesgo cardiovascular en Colombia: ¿qu3 tan cerca estamos?. 2014 , 21, 213-214	1
2287	Early onset hypercholesterolemia induced by the 2nd-generation tyrosine kinase inhibitor nilotinib in patients with chronic phase-chronic myeloid leukemia. 2014 , 99, 1197-203	91

2286	The 2013 American College of Cardiology/American Heart Association guidelines on treating blood cholesterol and assessing cardiovascular risk: a busy practitioner's guide. 2014 , 43, 869-92		4
2285	Long-term risk of cardiovascular events across a spectrum of adverse major plasma lipid combinations in the Framingham Heart Study. 2014 , 168, 878-83.e1		45
2284	Hypertension guidances published in 2013: a busy year with more to follow. 2014 , 16, 257-60		2
2283	Alice in lipidland: the 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol. <i>Journal of the American College of Cardiology</i> , 2014 , 64, 2193-5	15.1	2
2282	New cholesterol guidelines: worth the wait?. 2014 , 81, 11-9		22
2281	Implications of the 2013 ACC/AHA cholesterol guidelines for adults in contemporary cardiovascular practice: insights from the NCDR PINNACLE registry. <i>Journal of the American College of Cardiology</i> , 2014 , 64, 2183-92	15.1	80
2280	Rationale and design of LAPLACE-2: a phase 3, randomized, double-blind, placebo- and ezetimibe-controlled trial evaluating the efficacy and safety of evolocumab in subjects with hypercholesterolemia on background statin therapy. 2014 , 37, 195-203		10
2279	Genetics and causality of triglyceride-rich lipoproteins in atherosclerotic cardiovascular disease. <i>Journal of the American College of Cardiology</i> , 2014 , 64, 2525-40	15.1	149
2278	Why do statins reduce cardiovascular disease more than other lipid modulating therapies?. 2014 , 44, 1135-40		12
2277	JNC 8 or too much of a good thing. 2014 , 16, 263-4		
2276	National Lipid Association Annual Summary of Clinical Lipidology 2015. 2014 , 8, S1-36		56
2275	Measuring LDL cholesterol: for old and new calculations, is there an optimal formula?. 2014 , 60, 1466-8		5
2274	Executive summary: Guidelines (2013) for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Obesity Society published by the Obesity Society and American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Based on a systematic review from the The Obesity Expert Panel, 2013. 2014 , 22 Suppl 2, S5-39		151
2273	Validation of a proposed novel equation for estimating LDL cholesterol. 2014 , 60, 1519-23		47
2272	Statins in very elderly adults (debate). 2014 , 62, 943-5		21
2271	Medikamentöse Therapie zur Risikoreduktion und Progressionshemmung nicht interventionspflichtiger abdomineller Aortenaneurysmen. 2014 , 19, 568-572		
2270	Colesevelam, Ezetimibe, and Patients With Type 2 Diabetes Mellitus: Characteristics and Clinical Outcomes From a Health Care Database. 2014 , 48, 847-855		2
2269	Chemically induced mouse liver tumors are resistant to treatment with atorvastatin. 2014 , 14, 766		8

2268	Pooled RCTs: BP-lowering drugs reduced major CV events; absolute reductions were greater with higher baseline risk. 2014 , 161, JC5	
2267	How to identify HIV-infected individuals at risk for atherosclerotic events?. 2014 , 28, 2153-5	
2266	2013 American College of Cardiology/American Heart Association and 2004 Adult Treatment Panel III cholesterol guidelines applied to HIV-infected patients with/without subclinical high-risk coronary plaque. 2014 , 28, 2061-70	59
2265	A controversial step forward: A commentary on the 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults. 2014 , 25, 360-3	8
2264	Optimal medical therapy vs CT angiography screening for patients with diabetes. 2014 , 312, 2219-20	6
2263	Relations of change in plasma levels of LDL-C, non-HDL-C and apoB with risk reduction from statin therapy: a meta-analysis of randomized trials. 2014 , 3, e000759	74
2262	Statins and physical activity in older men: the osteoporotic fractures in men study. 2014 , 174, 1263-70	68
2261	Different time trends of caloric and fat intake between statin users and nonusers among US adults: gluttony in the time of statins?. 2014 , 174, 1038-45	90
2260	New pooled cohort risk equations and presence of asymptomatic brain infarction. 2014 , 45, 3521-6	7
2259	Further insight into the cardiovascular risk calculator: the roles of statins, revascularizations, and underascertainment in the Women's Health Study. 2014 , 174, 1964-71	123
2258	Prevention guidelines: bad process, bad outcome. 2014 , 174, 1972-3	18
2257	Overview of prescription omega-3 fatty acid products for hypertriglyceridemia. 2014 , 126, 7-18	50
2256	Prevalence of Dyslipidemia and Management in the Thai Population, National Health Examination Survey IV, 2009. 2014 , 2014, 249584	27
2255	HPS2-THRIVE, AIM-HIGH and dal-OUTCOMES: HDL-cholesterol under attack. 2014 , 2014, 235-40	3
2254	GAUSS-2, RUTHERFORD-2, LAPLACE-2, DESCARTES, and TESLA Part B: PCSK9 inhibitors gain momentum. 2014 , 2014, 360-6	7
2253	Comparison of low-dose rosuvastatin with atorvastatin in lipid-lowering efficacy and safety in a high-risk pakistani cohort: an open-label randomized trial. 2014 , 2014, 875907	8
2252	The Relationship between Serum Lipid Fractions and Heart Rate Variability in Diabetic Patients with Statin Therapy. 2014 , 87, 152-8	3
2251	Subclinical hypothyroidism in addition to common risk scores for prediction of cardiovascular disease: a 10-year community-based cohort study. 2014 , 171, 649-57	13

2250	2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. 2014 , 130, e199-267	1016
2249	CYP3A4*22 and CYP3A5*3 are associated with increased levels of plasma simvastatin concentrations in the cholesterol and pharmacogenetics study cohort. 2014 , 24, 486-91	29
2248	Statin underuse and low prevalence of LDL-C control among U.S. adults at high risk of coronary heart disease. 2014 , 348, 108-14	36
2247	Risk and the physics of clinical prediction. 2014 , 113, 1429-35	31
2246	New ACC/AHA lipid guidelines 2013 –Need for Indian guidelines!. 2014 , 4, 67-68	
2245	LDL-C levels in US patients at high cardiovascular risk receiving rosuvastatin monotherapy. 2014 , 36, 792-9	3
2244	Merits and potential downsides of the 2013 ACC/AHA cholesterol management guidelines. 2014 , 24, 573-6	7
2243	Integrated guidance on the care of familial hypercholesterolemia from the International FH Foundation. 2014 , 8, 148-72	79
2242	Implementing New Guidelines: Changing Paradigms for the Prevention of Cardiovascular Events. 2014 , 10, 293-301	1
2241	Statins and neuroprotection: basic pharmacology needed. 2014 , 50, 214-20	29
2240	Residual macrovascular risk in 2013: what have we learned?. 2014 , 13, 26	124
2239	Lipids, statins, and clinical outcomes in heart failure: rethinking the data. 2014 , 19, 695-8	4
2238	Coenzyme Q10 supplementation improves metabolic parameters, liver function and mitochondrial respiration in rats with high doses of atorvastatin and a cholesterol-rich diet. 2014 , 13, 22	24
2237	A Latin American perspective on the new ACC/AHA clinical guidelines for managing atherosclerotic cardiovascular disease. 2014 , 16, 400	7
2236	HDL hypothesis: where do we stand now?. 2014 , 16, 398	19
2235	LDL cholesterol performance of beta quantification reference measurement procedure. 2014 , 431, 288-93	15
2234	2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. <i>Journal of the American College of Cardiology</i> , 2014 , 64, e1-76	15.1 2768
2233	2013 ACC/AHA cholesterol treatment guideline: what was done well and what could be done better. <i>Journal of the American College of Cardiology</i> , 2014 , 63, 2674-8	15.1 47

2232	Complementary, alternative, and putative nontroponin biomarkers of acute coronary syndrome: new resources for future risk assessment calculators. 2014 , 67, 312-20		1
2231	2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. <i>Journal of the American College of Cardiology</i> , 2014 , 63, 2985-3023	15.1	1296
2230	Cardiovascular complications of diabetic kidney disease. 2014 , 21, 273-80		111
2229	The new ACC/AHA cardiovascular risk guidelines: impact and controversies. 2014 , 60, 1365-7		2
2228	Peeking into a cool future: genome editing to delete PCSK9 and control hypercholesterolemia in a single shot. 2014 , 115, 472-4		2
2227	Effect of statin therapy on cardiovascular outcomes after coronary revascularization in patients ≥ 80 years of age: observations from the CREDO-Kyoto Registry Cohort-2. 2014 , 237, 821-8		8
2226	A look at statin cost-effectiveness in view of the 2013 ACC/AHA cholesterol management guidelines. 2014 , 16, 438		13
2225	Cardiovascular disease associated with the human immunodeficiency virus: an update. 2014 , 16, 346		4
2224	Impact of baseline lipoprotein and C-reactive protein levels on coronary atheroma regression following high-intensity statin therapy. 2014 , 114, 1465-72		37
2223	Statin medications are associated with a lower probability of having an abnormal screening prostate-specific antigen result. 2014 , 84, 1058-65		10
2222	Contemporary evidence-based guidelines: practice based on the strongest evidence. 2014 , 89, 1176-82		3
2221	Lipid lowering with PCSK9 inhibitors. 2014 , 11, 563-75		167
2220	B-type natriuretic peptides improve cardiovascular disease risk prediction in a cohort of women. <i>Journal of the American College of Cardiology</i> , 2014 , 64, 1789-97	15.1	20
2219	N-terminal pro-B-type natriuretic peptide: a risk predictor for all. <i>Journal of the American College of Cardiology</i> , 2014 , 64, 1798-800	15.1	2
2218	Risk of coronary heart disease in patients with HIV infection. 2014 , 11, 728-41		73
2217	Statin therapy in lower limb peripheral arterial disease: Systematic review and meta-analysis. 2014 , 63, 79-87		38
2216	Geriatric cardiology: a fellow's perspective. <i>Journal of the American College of Cardiology</i> , 2014 , 64, 1401-3	15.1	3
2215	Starting primary prevention earlier with statins. 2014 , 114, 1437-42		22

2214	Bioimaging and subclinical cardiovascular disease in low- and middle-income countries. 2014 , 7, 701-10		7
2213	Review of clinical practice guidelines for the management of LDL-related risk. <i>Journal of the American College of Cardiology</i> , 2014 , 64, 196-206	15.1	43
2212	A systematic examination of the 2013 ACC/AHA pooled cohort risk assessment tool for atherosclerotic cardiovascular disease. <i>Journal of the American College of Cardiology</i> , 2014 , 64, 959-68	15.1	113
2211	Goal-directed treatment of osteoporosis in Europe. 2014 , 25, 2533-43		48
2210	The effects of statin medications on aerobic exercise capacity and training adaptations. 2014 , 44, 1519-30		22
2209	A protocol to evaluate the efficacy, perceptions, and cost of a cholesterol packaging approach to improve medication adherence. 2014 , 39, 106-12		5
2208	2014 AHA/ACC Guideline for the Management of Patients With Non-ST-Elevation Acute Coronary Syndromes: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. <i>Journal of the American College of Cardiology</i> , 2014 , 64, 2645-2687	15.1	132
2207	The 2013 ACC/AHA cardiovascular prevention guidelines improve alignment of statin therapy with coronary atherosclerosis as detected by coronary computed tomography angiography. 2014 , 237, 314-8		16
2206	Perspective on the 2013 American Heart Association/American College of Cardiology guideline for the use of statins in primary prevention of low-risk individuals. 2014 , 114, 758-60		4
2205	Epidemiological studies of CHD and the evolution of preventive cardiology. 2014 , 11, 276-89		367
2204	Accuracy of statin assignment using the 2013 AHA/ACC Cholesterol Guideline versus the 2001 NCEP ATP III guideline: correlation with atherosclerotic plaque imaging. <i>Journal of the American College of Cardiology</i> , 2014 , 64, 910-9	15.1	48
2203	The new cholesterol guidelines: finally more light than heat. <i>Journal of the American College of Cardiology</i> , 2014 , 64, 920-1	15.1	2
2202	Ischaemic heart disease: management of non-ST-elevation acute coronary syndrome. 2014 , 42, 505-511		
2201	The sins of the fathers (and mothers) and the 2013 guidelines. 2014 , 7, 687-9		1
2200	Clinical- and cost-effectiveness of LDL particle-guided statin therapy: a simulation study. 2014 , 236, 154-61		11
2199	Stable ischemic heart disease. 2014 , 32, 333-51		2
2198	LDL-cholesterol targets after the ACC/AHA 2013 guidelines: evidence that lower is better?. <i>Journal of the American College of Cardiology</i> , 2014 , 64, 495-7	15.1	6
2197	Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: results of a 24 week, double-blind, randomized Phase 3 trial. 2014 , 176, 55-61		204

2196	2013 ACC/AHA guideline recommends fixed-dose strategies instead of targeted goals to lower blood cholesterol. <i>Journal of the American College of Cardiology</i> , 2014 , 64, 601-12	15.1	50
2195	Message in a bottle: decoding medication injury patterns in the gastrointestinal tract. 2014 , 67, 903-12		17
2194	Triglycerides and cardiovascular disease. 2014 , 384, 626-635		698
2193	Adverse reactions to biologic agents and their medical management. 2014 , 10, 612-27		63
2192	High-intensity statin therapy alters the natural history of diabetic coronary atherosclerosis: insights from SATURN. 2014 , 37, 3114-20		45
2191	Combination therapy in dyslipidemia: where are we now?. 2014 , 237, 319-35		34
2190	Statins for all?. 2014 , 114, 1443-6		7
2189	Sex-related differences of coronary atherosclerosis regression following maximally intensive statin therapy: insights from SATURN. 2014 , 7, 1013-22		40
2188	Non-cardiovascular effects associated with statins. 2014 , 349, g3743		121
2187	PET/CT and MR imaging biomarker of lipid-rich plaques using [64Cu]-labeled scavenger receptor (CD68-Fc). 2014 , 177, 287-91		17
2186	Statins: do they have a potential role in cancer prevention and modifying cancer-related outcomes?. 2014 , 74, 1841-1848		23
2185	Associations of non-high density lipoprotein cholesterol and traditional blood lipid profiles with hyperuricemia among middle-aged and elderly Chinese people: a community-based cross-sectional study. 2014 , 13, 117		13
2184	Antiatherosclerotic effects of long-term maximally intensive statin therapy after acute coronary syndrome: insights from Study of Coronary Atheroma by Intravascular Ultrasound: Effect of Rosuvastatin Versus Atorvastatin. 2014 , 34, 2465-72		33
2183	2014 ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines. <i>Journal of the American College of Cardiology</i> , 2014 , 64, e77-137	15.1	855
2182	A perspective on the New American College of Cardiology/American Heart Association guidelines for cardiovascular risk assessment. 2014 , 89, 1244-56		21
2181	National Lipid Association recommendations for patient-centered management of dyslipidemia: part 1 - executive summary. 2014 , 8, 473-88		323
2180	2014 AHA/ACC Guideline for the Management of Patients with Non-ST-Elevation Acute Coronary Syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. <i>Journal of the American College of Cardiology</i> , 2014 , 64, e139-e228	15.1	1822
2179	Dietary supplementation with essential amino acids boosts the beneficial effects of rosuvastatin on mouse kidney. 2014 , 46, 2189-203		11

2178	Diabetes and cardiovascular disease: from evidence to clinical practice - position statement 2014 of Brazilian Diabetes Society. 2014 , 6, 58	14
2177	Impact of diet and exercise on lipid management in the modern era. 2014 , 28, 405-21	33
2176	The clinical pharmacogenetics implementation consortium guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update. 2014 , 96, 423-8	284
2175	2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: Executive Summary. <i>Journal of the American College of Cardiology</i> , 2014 , 64, 2246-2280	15.1 505
2174	Anionic biopolyelectrolytes of the syndecan/perlecan superfamily: physicochemical properties and medical significance. 2014 , 205, 275-318	20
2173	Adiposopathy, "sick fat," Ockham's razor, and resolution of the obesity paradox. 2014 , 16, 409	56
2172	Primary prevention of cardiovascular disease with statins in the elderly. 2014 , 16, 420	20
2171	The underlying chemistry of electronegative LDL's atherogenicity. 2014 , 16, 428	17
2170	Risks and benefits of statin use in young people with type 1 diabetes. 2014 , 14, 499	10
2169	Discordance in Lipid Measurements: Can we Capitalize to Better Personalize Cardiovascular Risk Assessment and Treatment?. 2014 , 8, 1	1
2168	Mipomersen is a promising therapy in the management of hypercholesterolemia: a meta-analysis of randomized controlled trials. 2014 , 14, 367-76	28
2167	Refining coronary heart disease event prediction in young and old individuals by coronary artery calcification imaging with computed tomography. 2014 , 89, 1324-7	0
2166	Update: Acute coronary syndromes (IX). Secondary prevention strategies for acute coronary syndrome. 2014 , 67, 844-8	3
2165	Management of Atherosclerotic Aortoiliac Occlusive Disease. 2014 , 3, 531-543	5
2164	What do carotid intima-media thickness and plaque add to the prediction of stroke and cardiovascular disease risk in older adults? The cardiovascular health study. 2014 , 27, 998-1005.e2	31
2163	Simplifying the medical prevention of cardiovascular disease. 2014 , 42, 491-494	
2162	Estrategias de prevención secundaria del síndrome coronario agudo. 2014 , 67, 844-848	13
2161	To Market, To Market—2013. 2014 , 49, 437-508	5

2160	2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. <i>Journal of the American College of Cardiology</i> , 2014 , 63, 2935-2959	15.1	1625
2159	Impact of age on the association between CKD and the risk of future coronary events. 2014 , 64, 375-82		14
2158	Prescribing statins for cardiovascular disease prevention in the old: an absence of evidence and an absence of guidelines. 2014 , 23, 619-24		9
2157	An assessment by the Statin Intolerance Panel: 2014 update. 2014 , 8, S72-81		107
2156	Biomarcadores no troponínicos, complementarios, alternativos y presuntos, para el síndrome coronario agudo: nuevos recursos para los futuros instrumentos de cálculo del riesgo. 2014 , 67, 312-320		6
2155	[Drugs that kill and organized crime]. 2014 , 46, 176-8		5
2154	2013 AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. <i>Journal of the American College of Cardiology</i> , 2014 , 63, 2960-84	15.1	860
2153	The 2013 American College of Cardiology/American Heart Association guidelines for the treatment of dyslipidemia: mind the gaps!. 2014 , 30, 1701-5		6
2152	Hepatic insulin receptor deficiency impairs the SREBP-2 response to feeding and statins. 2014 , 55, 659-67		27
2151	Strategies to support recruitment of patients with life-limiting illness for research: the Palliative Care Research Cooperative Group. 2014 , 48, 1021-30		40
2150	Why have the complications of diabetes mellitus declined over the past 30 years?. 2014 , 15, 449-453		1
2149	Potential drug targets for calcific aortic valve disease. 2014 , 11, 218-31		89
2148	A review of paradoxical HDL-C responses to fenofibrate, illustrated by a case report. 2014 , 8, 455-9		7
2147	Association between high sensitivity C-reactive protein and metabolic syndrome in subjects completing the National Health and Nutrition Examination Survey (NHANES) 2009-10. 2014 , 8, 88-90		21
2146	Effects of poly-bioactive compounds on lipid profile and body weight in a moderately hypercholesterolemic population with low cardiovascular disease risk: a multicenter randomized trial. 2014 , 9, e101978		41
2145	Cost-effectiveness of high, moderate and low-dose statins in the prevention of vascular events in the Brazilian public health system. 2015 , 104, 32-44		13
2144	Achievement of combined goals of low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol with three different statins: Results from VOYAGER. 2014 , 5, 61-66		1
2143	ACP Journal Club. ACC/AHA Pooled Cohort Risk Equations predicted 5-y risk for CV events in adults considered for statin initiation. 2014 , 161, JC12		

2142	Priority Paper Evaluation: Are antibodies against PCSK9 the statins of the 21st century?. 2014 , 9, 141-144	
2141	Is high-intensity statin therapy associated with lower statin adherence compared with low- to moderate-intensity statin therapy? Implications of the 2013 American College of Cardiology/American Heart Association Cholesterol Management Guidelines. 2014 , 37, 653-9	48
2140	Cardiovascular Risk and Cholesterol Management in Men: Implications of the New Guidelines. 2014 , 11, 51-52	
2139	How can coronary artery calcium be used to match statin therapy to cardiovascular risk in patients with dyslipidemia?. 2014 , 9, 5-7	1
2138	Understanding the new atherosclerotic cardiovascular disease prevention guidelines: going beyond the headlines. 2014 , 9, 121-123	
2137	Will new statin guidelines lead to overtreatment?. 2014 , 9, 125-128	1
2136	The Potential Effects of Implementing the 2013 ACC/AHA Cholesterol Guidelines on the Use of Statins in a Large Health Maintenance Organization in Israel. 2015 , 7, 22-26	0
2135	Epidemiologã de la prevenciã secundaria en Espaã: hechos y cifras. 2015 , 15, 2-6	
2134	US Hypertension Management Guidelines: A Review of the Recent Past and Recommendations for the Future. 2015 , 4,	42
2133	Insights Into Statin Intolerance. 2015 , 38, 520-6	8
2132	Statins Provide Less Benefit in Populations with High Noncardiovascular Mortality Risk: Meta-Regression of Randomized Controlled Trials. 2015 , 63, 1413-9	4
2131	Effect of Low-Density Lipoprotein Cholesterol Lowering by Ezetimibe/Simvastatin on Outcome Incidence: Overview, Meta-Analyses, and Meta-Regression Analyses of Randomized Trials. 2015 , 38, 763-9	7
2130	Docosahexanoic acid modifies low-density lipoprotein receptor abundance in HepG2 cells via suppression of the LXRβ pathway. 2015 , 11, 2329-33	3
2129	Differential Effects of Strong and Regular Statins on the Clinical Outcome of Patients With Chronic Kidney Disease Following Coronary Stent Implantation - The Kumamoto Intervention Conference Study (KICS) Registry. 2015 , 79, 1115-24	16
2128	Management of dyslipidemia for cardiovascular disease risk reduction: synopsis of the 2014 U.S. Department of Veterans Affairs and U.S. Department of Defense clinical practice guideline. 2015 , 163, 291-7	71
2127	Intensity of statin therapy and new hospitalizations for heart failure in patients with type 2 diabetes. 2015 , 3, e000137	3
2126	Investigation of cytokines, oxidative stress, metabolic, and inflammatory biomarkers after orange juice consumption by normal and overweight subjects. 2015 , 59, 28147	28
2125	Is there a role for genetic risk assessment in the treatment of dyslipidemia in primary and secondary prevention of coronary heart disease?. 2015 , 2015, 19	

2124	Treatment of Blood Cholesterol to Reduce Risk for Atherosclerotic Cardiovascular Disease: Grand Rounds Discussion From the Beth Israel Deaconess Medical Center. 2015 , 163, 280-90	2
2123	Something important is missing in the ACC/AHA cholesterol treatment guidelines. 2015 , 55, 324-9	2
2122	Omega-3-carboxylic acid (Epanova) for hypertriglyceridemia. 2015 , 23, 148-52	3
2121	Statins for Primary Prevention in Adults Aged 75 Years or Older. 2015 , 163, 481	
2120	Wie kriegt man das Gefäßisiko in den Griff?. 2015 , 9, 34-45	
2119	Dolor torácico en el centro de salud: ¿seguimos las nuevas guías?. 2015 , 4, 123-126	
2118	A new highly-enantioselective synthetic process for producing (S)-2-hydroxybutyric acid methyl ester. 2015 , 20, 335-342	1
2117	RE: Breast Cancer, Heart Disease, and Whispering "Fire" in a Public Theater. 2015 , 107,	1
2116	PCSK9 Inhibitors: Are We on the Verge of a Breakthrough?. 2015 , 98, 590-601	3
2115	Statins versus placebo for people with chronic obstructive pulmonary disease (COPD). 2015 ,	0
2114	Combining citrulline with atorvastatin preserves glucose homeostasis in a murine model of diet-induced obesity. 2015 , 172, 4996-5008	12
2113	New Guidelines for Cardiovascular Disease. 2015 , 27, 166-168	
2112	Management of hyperlipidemia among patients with rheumatoid arthritis in the primary care setting. 2015 , 16, 237	16
2111	PCSK9 inhibition: the way forward in the treatment of dyslipidemia. 2015 , 13, 258	27
2110	Prevention of cardiovascular diseases. 2015 , 13, 261	5
2109	Influence of metabolic syndrome factors and insulin resistance on the efficacy of ezetimibe/simvastatin and atorvastatin in patients with metabolic syndrome and atherosclerotic coronary heart disease risk. 2015 , 14, 103	8
2108	Association of polymorphisms in the MAFB gene and the risk of coronary artery disease and ischemic stroke: a case-control study. 2015 , 14, 79	21
2107	Do women with statin-related myalgias have low vitamin D levels?. 2015 , 8, 449	6

2106	Single and mixed dyslipidaemia in Canadian primary care settings: findings from the Canadian primary care sentinel surveillance network database. 2015 , 5, e007954	10
2105	Evaluation of the Potential Role of Alirocumab in the Management of Hypercholesterolemia in Patients with High-Risk Cardiovascular Disease. 2015 , 35, 771-9	4
2104	Effect of Statin Therapy on Fibrous Cap Thickness in Coronary Plaques Using Optical Coherence Tomography: A Systematic Review and Meta-Analysis. 2015 , 28, 514-22	15
2103	Coronary computed tomography angiography predicts subsequent cardiac outcome events: results of the Visipaque CCTA registry study. 2015 , 26, 301-7	2
2102	LDL-cholesterol lowering and renal outcomes. 2015 , 26, 195-9	10
2101	Long-term follow-up of lipid-lowering trials. 2015 , 26, 572-9	14
2100	Use of statins by medicare beneficiaries post myocardial infarction: poor physician quality or patient-centered care?. 2015 , 52,	2
2099	New Fixed-Dose Combinations of Fenofibrate/Simvastatin Therapy Significantly Improve the Lipid Profile of High-Risk Patients with Mixed Dyslipidemia Versus Monotherapies. 2015 , 33, 329-37	7
2098	HIV infection is associated with an increased prevalence of coronary noncalcified plaque among participants with a coronary artery calcium score of zero: Multicenter AIDS Cohort Study (MACS). 2015 , 16, 635-9	22
2097	Individual and Combined Associations of Genetic Variants in CYP3A4, CYP3A5, and SLCO1B1 With Simvastatin and Simvastatin Acid Plasma Concentrations. 2015 , 66, 80-5	16
2096	The National Lipid Association Annual Summary of Clinical Lipidology 2015: one-stop shopping for the information age. 2015 , 10, 211-213	
2095	Low-density lipoprotein cholesterol of less than 70 mg/dL is associated with fewer cardiovascular events in acute coronary syndrome patients: a real-life cohort in Thailand. 2015 , 11, 659-67	8
2094	CYP3A5 genotyping for assessing the efficacy of treatment with simvastatin and atorvastatin. 2015 , 38, 129-37	3
2093	The Overall Evolution of Lebanese Patients with Type 2 Diabetes Over 5 Years: A Comparison from the International Diabetes Management Practices Study Results. 2015 , 04,	1
2092	Acute management of unstable angina and non-ST segment elevation myocardial infarction. 2015 , 13, 454-61	7
2091	The association between platelet/lymphocyte ratio and coronary artery disease severity. 2015 , 15, 640-7	59
2090	Reassessing lipid metabolism and its potentialities in the prediction of cardiovascular risk. 2015 , 59, 171-80	13
2089	Bioactive Plant Metabolites in the Management of Non-Communicable Metabolic Diseases: Looking at Opportunities beyond the Horizon. 2015 , 5, 733-65	17

2088	Doctors' knowledge, attitudes, and compliance with 2013 ACC/AHA guidelines for prevention of atherosclerotic cardiovascular disease in Singapore. 2015 , 11, 303-10	20
2087	Cholesterol confusion and statin controversy. 2015 , 7, 404-9	37
2086	The crux of the matter: Did the ABC's Catalyst program change statin use in Australia?. 2015 , 202, 591-5	44
2085	A Systematic Review of the Efficacy of Bioactive Compounds in Cardiovascular Disease: Phenolic Compounds. 2015 , 7, 5177-216	94
2084	Cardiovascular risk prediction: balancing complexity against simple practicality. 2015 , 65, 4-5	2
2083	Patient and physician factors influence decision-making in hypercholesterolemia: a questionnaire-based survey. 2015 , 14, 45	11
2082	Use of statins and the incidence of type 2 diabetes mellitus. 2015 , 61, 375-80	3
2081	Additive beneficial effects of valsartan combined with rosuvastatin in the treatment of hypercholesterolemic hypertensive patients. 2015 , 45, 225-33	18
2080	Appropriateness of diagnostic coronary angiography as a measure of cardiac ischemia testing in non-emergency patients - a retrospective cross-sectional analysis. 2015 , 10, e0117172	10
2079	Raltegravir non-inferior to nucleoside based regimens in second-line therapy with lopinavir/ritonavir over 96 weeks: a randomised open label study for the treatment of HIV-1 infection. 2015 , 10, e0118228	18
2078	The association of statin use after cancer diagnosis with survival in pancreatic cancer patients: a SEER-medicare analysis. 2015 , 10, e0121783	45
2077	Target values of cardiovascular risk factors are not associated with all-cause mortality in patients with type 2 diabetes mellitus. 2015 , 10, e0124536	3
2076	Lipid-lowering therapy in older persons. 2015 , 11, 43-56	14
2075	Clinical Impact of Rapid Reduction of Low-Density Lipoprotein Cholesterol Level on Long-Term Outcome of Acute Myocardial Infarction in the Statin Era: Subanalysis of the ALPS-AMI Study. 2015 , 10, e0127835	8
2074	Impact of Hydroxychloroquine on Atherosclerosis and Vascular Stiffness in the Presence of Chronic Kidney Disease. 2015 , 10, e0139226	16
2073	Meta-Analysis: Effects of Probiotic Supplementation on Lipid Profiles in Normal to Mildly Hypercholesterolemic Individuals. 2015 , 10, e0139795	103
2072	Combined Effects of Time Spent in Physical Activity, Sedentary Behaviors and Sleep on Obesity and Cardio-Metabolic Health Markers: A Novel Compositional Data Analysis Approach. 2015 , 10, e0139984	439
2071	Statin-Associated Adverse Events. 2015 , 7, CMT.S18865	2

2070 Nutrition Therapy for Adults with HIV on ART. **2015**, 307-337

2069 Serum Alkaline Phosphatase and Risk of Incident Cardiovascular Disease: Interrelationship with High Sensitivity C-Reactive Protein. **2015**, 10, e0132822 30

2068 Hypercholesterolemia âStatin Therapy âIndications, Side Effects, Common Mistakes in Handling, Last Evidence and Recommendations in Current Clinical Practice. **2015**,

2067 The 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk: a new paradigm supported by more evidence. **2015**, 36, 2110-2118 44

2066 Genetic testing in hyperlipidemia. **2015**, 33, 267-75 4

2065 Translational nephrology: what translational research is and a bird's-eye view on translational research in nephrology. **2015**, 8, 14-22 18

2064 Lipid-modifying therapy in the elderly. **2015**, 11, 251-63 11

2063 The pace of change in medical practice and health policy: collision or coexistence?. **2015**, 30, 848-52 14

2062 Implications of the new American College of Cardiology/American Heart Association cholesterol guidelines for primary atherosclerotic cardiovascular disease event prevention in a multi ethnic cohort: Multi-Ethnic Study of Atherosclerosis (MESA). **2015**, 169, 387-395.e3 26

2061 To what extent do high-intensity statins reduce low-density lipoprotein cholesterol in each of the four statin benefit groups identified by the 2013 American College of Cardiology/American Heart Association guidelines? A VOYAGER meta-analysis. **2015**, 241, 450-4 15

2060 Safety and lipid-altering efficacy of a new omega-3 fatty acid and antioxidant-containing medical food in men and women with elevated triacylglycerols. **2015**, 99, 41-6 5

2059 Efecto a largo plazo de los estanoles vegetales en el perfil lipídico de pacientes con hipercolesterolemia. Ensayo clínico aleatorizado. **2015**, 68, 665-671 11

2058 Las guías estadounidenses de dislipemia. Fortalezas y debilidades. **2015**, 15, 18-21

2057 Pleiotropic effects of fenofibrate therapy on rats with hypertriglycemia. **2015**, 14, 27 16

2056 Is there a clinically relevant interaction between clarithromycin and statins not metabolized by cytochrome P450 3A4?. **2015**, 187, 163-165 1

2055 Niacin as antidiyslipidemic drug. **2015**, 93, 1043-54 20

2054 Effect of daily glucose fluctuation on coronary plaque vulnerability in patients pre-treated with lipid-lowering therapy: a prospective observational study. **2015**, 8, 800-811 48

2053 Nutrition and Coronary Heart Disease Prevention. **2015**, 329-341

2052	Incremental prognostic utility of coronary CT angiography for asymptomatic patients based upon extent and severity of coronary artery calcium: results from the COronary CT Angiography EvaluatioN For Clinical Outcomes InteRnational Multicenter (CONFIRM) study. 2015 , 36, 501-8		87
2051	Statins and Nonadherence: Should We RELATE Better?. 2015 , 20, 447-56		13
2050	The Fuster-CNIC-Ferrer Cardiovascular Polypill: a polypill for secondary cardiovascular prevention. 2015 , 201 Suppl 1, S15-22		20
2049	Productivity loss and indirect costs associated with cardiovascular events and related clinical procedures. 2015 , 15, 245		40
2048	Effect of Financial Incentives to Physicians, Patients, or Both on Lipid Levels: A Randomized Clinical Trial. 2015 , 314, 1926-35		114
2047	American College of Cardiology: Environmental Scanning Report Update 2015. <i>Journal of the American College of Cardiology</i> , 2015 , 66, D1-44	15.1	3
2046	Primary Prevention With Statins: ACC/AHA Risk-Based Approach Versus Trial-Based Approaches to Guide Statin Therapy. <i>Journal of the American College of Cardiology</i> , 2015 , 66, 2699-2709	15.1	49
2045	Lipid Management in Diabetes with a Focus on Emerging Therapies. 2015 , 39 Suppl 5, S183-90		7
2044	Selecting Patients for Statin Therapy in Primary Prevention: If We Could Only Predict the Future. <i>Journal of the American College of Cardiology</i> , 2015 , 66, 2710-2712	15.1	1
2043	From the Editor: Is a goal a target?. 2015 , 9, 727-730		3
2042	Shared Decision-Making in Older Persons with Cardiovascular Disease. 2015 , 9, 1		0
2041	Lipids and Cerebrovascular Disease: Research and Practice. 2015 , 46, 3322-8		71
2040	Cardiovascular disease in rheumatoid arthritis: Current perspectives on assessing and mitigating risk in clinical practice. 2015 , 29, 597-613		20
2039	National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 2. 2015 , 9, S1-122.e1		293
2038	The Food and Drug Administration and pragmatic clinical trials of marketed medical products. 2015 , 12, 511-9		19
2037	Combined therapy with Xuezhikang and low-dose rosuvastatin provides an effective and safe therapeutic strategy for dyslipidemic patients. 2015 , 10, 243-250		4
2036	Introduction to Clinical Trials. 2015 , 1-23		6
2035	Different postprandial lipid metabolism and insulin resistance between non-diabetic patients with and without coronary artery disease. 2015 , 66, 435-44		17

2034	Is the Guideline Process Replicable and, if Not, What Does This Mean?. 2015 , 58, 3-9	2
2033	Toward a modern era in clinical prediction: the TRIPOD statement for reporting prediction models. 2015 , 65, 530-3	5
2032	Cancer and Its Association With the Development of Coronary Artery Calcification: An Assessment From the Multi-Ethnic Study of Atherosclerosis. 2015 , 4,	48
2031	Statin use and decline in gait speed in community-dwelling older adults. 2015 , 63, 124-9	9
2030	Type 2 diabetes mellitus, metabolic syndrome, and mixed dyslipidemia: how similar, how different, and how to treat?. 2015 , 13, 1-21	21
2029	Inhibition of xanthine oxidase to prevent statin-induced myalgia and rhabdomyolysis. 2015 , 239, 38-42	8
2028	Management and outcomes of patients with reduced ejection fraction after acute myocardial infarction in cardiac rehabilitation centers. 2015 , 31, 211-9	2
2027	EB carboxylic acids for hypertriglyceridemia. 2015 , 16, 123-33	8
2026	Plasma triglyceride determination can identify increased risk of statin-induced type 2 diabetes: a hypothesis. 2015 , 239, 401-4	5
2025	Statins and almonds to lower lipoproteins (the STALL Study). 2015 , 9, 58-64	24
2024	Navigating patient preference and guidelines as a fellow. <i>Journal of the American College of Cardiology</i> , 2015 , 65, 398-400	15.1 2
2023	Comparative effects of high-dose atorvastatin versus moderate-dose rosuvastatin on lipid parameters, oxidized-LDL and inflammatory markers in ST elevation myocardial infarction. 2015 , 239, 439-43	25
2022	Systematic investigation of cellular response and pleiotropic effects in atorvastatin-treated liver cells by MS-based proteomics. 2015 , 14, 1600-11	8
2021	Statin use and survival in elderly patients with endometrial cancer. 2015 , 137, 252-7	24
2020	Statin use in cancer patients with brain metastases: a missed communication opportunity at the end of life. 2015 , 23, 2643-8	9
2019	How statistical deception created the appearance that statins are safe and effective in primary and secondary prevention of cardiovascular disease. 2015 , 8, 201-10	37
2018	Statin use and risk of pancreatic cancer: results from a large, clinic-based case-control study. 2015 , 121, 1287-94	49
2017	Small-dense LDL/large-buoyant LDL ratio associates with the metabolic syndrome. 2015 , 48, 495-502	8

2016	Circulating gamma glutamyltransferase and prediction of cardiovascular disease. 2015 , 238, 356-64		42
2015	Gaps in guideline implementation: a cause for concern, time for action. <i>Journal of the American College of Cardiology</i> , 2015 , 65, 278-80	15.1	12
2014	[Contraindications to succinylcholine in the intensive care unit. A prevalence study]. 2015 , 39, 90-6		4
2013	Update in cardiology: vascular risk and cardiac rehabilitation. 2015 , 68, 136-43		2
2012	Reducing acute coronary events: the solution is not so difficult!. 2015 , 128, 105-6		4
2011	New Pooled Cohort Risk equations: application to a recent stroke patient population. 2015 , 348, 160-5		2
2010	Vaccination against atherosclerosis and abdominal aortic aneurysm. <i>Journal of the American College of Cardiology</i> , 2015 , 65, 557-9	15.1	4
2009	Cardiovascular risk stratification in overweight or obese patients in primary prevention. Implications for use of statins. 2015 , 62, 83-90		2
2008	Reply: Statin dose based on limited evidence. <i>Journal of the American College of Cardiology</i> , 2015 , 65, 760-1	15.1	2
2007	Novedades en cardiología: riesgo vascular y rehabilitación cardíaca. 2015 , 68, 136-143		5
2006	[Consensus document on the treatment of dyslipidemia in diabetes]. 2015 , 41, 89-98		5
2005	The efficacy and safety of statins for the treatment of non-alcoholic fatty liver disease. 2015 , 47, 4-11		99
2004	Underutilization of high-intensity statin therapy after hospitalization for coronary heart disease. <i>Journal of the American College of Cardiology</i> , 2015 , 65, 270-7	15.1	102
2003	Familial hypercholesterolemia--epidemiology, diagnosis, and screening. 2015 , 17, 482		81
2002	Statin adverse effects: patients' experiences and laboratory monitoring of muscle and liver injuries. 2015 , 37, 355-64		13
2001	Sudden cardiac death in the older athlete. <i>Journal of the American College of Cardiology</i> , 2015 , 65, 493-502	15.1	77
2000	PCSK9 inhibition: current concepts and lessons from human genetics. 2015 , 17, 487		8
1999	Updated guidelines for the management of dyslipidemia and prevention of cardiovascular disease by pharmacists. 2015 , 148, 21-8		4

1998	Frequency and practice-level variation in inappropriate aspirin use for the primary prevention of cardiovascular disease: insights from the National Cardiovascular Disease Registry's Practice Innovation and Clinical Excellence registry. <i>Journal of the American College of Cardiology</i> , 2015 , 65, 111-21	15.1	50
1997	Effect of a moderate fat diet with and without avocados on lipoprotein particle number, size and subclasses in overweight and obese adults: a randomized, controlled trial. 2015 , 4, e001355		61
1996	Heart disease and stroke statistics--2015 update: a report from the American Heart Association. 2015 , 131, e29-322		5259
1995	[Dyslipidaemia and vascular risk. A new evidence based review]. 2015 , 41, 435-45		2
1994	High-dose atorvastatin is superior to moderate-dose simvastatin in preventing peripheral arterial disease. 2015 , 101, 356-62		33
1993	A novel therapeutic effect of statins on nephrogenic diabetes insipidus. 2015 , 19, 265-82		24
1992	Cholesterol treatment and changes in guidelines in an academic medical practice. 2015 , 128, 403-9		20
1991	Statin use and self-reported swimming performance in US masters swimmers. 2015 , 33, 286-92		11
1990	Risikofaktoren für Schlaganfall und ihre therapeutische Beeinflussung. 2015 , 16, 32-44		
1989	Efficacy and safety of mipomersen in treatment of dyslipidemia: a meta-analysis of randomized controlled trials. 2015 , 9, 217-25		51
1988	Low-Density Lipoprotein Cholesterol Levels and Statin Treatment by HIV Status Among Multicenter AIDS Cohort Study Men. 2015 , 31, 593-602		17
1987	Prehypertension--prevalence, health risks, and management strategies. 2015 , 12, 289-300		112
1986	On the hypothetical universal use of statins in primary prevention: an observational analysis on low-risk patients and economic consequences of a potential wide prescription rate. 2015 , 71, 449-59		1
1985	Imaging coronary artery disease and the myocardial ischemic cascade: clinical principles and scope. 2015 , 53, 261-9		8
1984	Lowering LDL cholesterol is good, but how and in whom?. 2015 , 372, 1564-5		15
1983	Underappreciated opportunities for high-density lipoprotein particles in risk stratification and potential targets of therapy. 2015 , 29, 41-50		10
1982	A proposal to incorporate trial data into a hybrid ACC/AHA algorithm for the allocation of statin therapy in primary prevention. <i>Journal of the American College of Cardiology</i> , 2015 , 65, 942-8	15.1	16
1981	Primary risk prevention in the elderly: use clinician-patient discussions, not automatic statin prescribing. 2015 , 128, 804-6		3

1980	The ability of the 2013 American College of Cardiology/American Heart Association cardiovascular risk score to identify rheumatoid arthritis patients with high coronary artery calcification scores. 2015 , 67, 381-5		41
1979	Statin therapy in patients with acute coronary syndrome: low-density lipoprotein cholesterol goal attainment and effect of statin potency. 2015 , 11, 127-36		15
1978	Long-chain omega-3 fatty acids, fibrates and niacin as therapeutic options in the treatment of hypertriglyceridemia: a review of the literature. 2015 , 242, 647-56		45
1977	Impact of Dual Lipid-Lowering Strategy With Ezetimibe and Atorvastatin on Coronary Plaque Regression in Patients With Percutaneous Coronary Intervention: The Multicenter Randomized Controlled PRECISE-IVUS Trial. <i>Journal of the American College of Cardiology</i> , 2015 , 66, 495-507	15.1	246
1976	Adverse pregnancy outcomes and cardiovascular risk factor management. 2015 , 39, 268-75		20
1975	Association of Frailty and Cardiometabolic Risk Among Community-Dwelling Middle-Aged and Older People: Results from the I-Lan Longitudinal Aging Study. 2015 , 18, 564-72		28
1974	Cholesterol, not just cardiovascular risk, is important in deciding who should receive statin treatment. 2015 , 36, 2975-83		55
1973	Reply: getting guidelines correct: their evidence-based recommendations for use of nonstatins added to statins and the need for follow-up lipid testing. <i>Journal of the American College of Cardiology</i> , 2015 , 65, 2052-3	15.1	
1972	Residual dyslipidemia according to low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B among statin-treated US adults: National Health and Nutrition Examination Survey 2009-2010. 2015 , 9, 525-32		28
1971	Utility of Nontraditional Risk Markers in Individuals Ineligible for Statin Therapy According to the 2013 American College of Cardiology/American Heart Association Cholesterol Guidelines. 2015 , 132, 916-22		60
1970	Low-Density Lipoprotein Particle Number Is Associated With Cardiovascular Events Among Those Not Classified Into Statin Benefit Groups. <i>Journal of the American College of Cardiology</i> , 2015 , 65, 2571-3 ^{15.1}		5
1969	Prognostic role of LDL cholesterol in non-dialysis chronic kidney disease: Multicenter prospective study in Italy. 2015 , 25, 756-62		18
1968	Improving fitness to achieve health: shifting the focus from theory to practice. <i>Journal of the American College of Cardiology</i> , 2015 , 65, 2101-3	15.1	4
1967	The Capacity of Evidence to Inform Practice: The Rapid Registry Response (RRR) Initiative. <i>Journal of the American College of Cardiology</i> , 2015 , 65, 2252-3	15.1	8
1966	A 15-Year Warranty Period for Asymptomatic Individuals Without Coronary Artery Calcium: A Prospective Follow-Up of 9,715 Individuals. 2015 , 8, 900-9		139
1965	Liver fat, statin use, and incident diabetes: The Multi-Ethnic Study of Atherosclerosis. 2015 , 242, 211-7		32
1964	Ezetimibe and Plaque Regression: Cholesterol Lowering or Pleiotropic Effects?. <i>Journal of the American College of Cardiology</i> , 2015 , 66, 508-10	15.1	12
1963	Familial hypercholesterolemia in children and adolescents: A clinical perspective. 2015 , 9, S11-9		13

1962	Statins for Primary Prevention of Cardiovascular Disease in Elderly Patients: Systematic Review and Meta-Analysis. 2015 , 32, 649-61		51
1961	New Hope for Lipid-Lowering Beyond Statins: Effect of IMPROVE-IT on Understanding and Implementation of Atherosclerosis Prevention. 2015 , 31, 585-7		7
1960	Reply: Underutilization of High-Intensity Statin Therapy After Hospitalization for Coronary Heart Disease: A Cause for Concern, But a Few Words of Caution. <i>Journal of the American College of Cardiology</i> , 2015 , 65, 2770	15.1	
1959	Safety considerations with fenofibrate/simvastatin combination. 2015 , 14, 1481-93		18
1958	Utilization of and Adherence to Guideline-Recommended Lipid-Lowering Therapy After Acute Coronary Syndrome: Opportunities for Improvement. <i>Journal of the American College of Cardiology</i> , 2015 , 66, 184-92	15.1	65
1957	SALTIRE-RAAVE: targeting calcific aortic valve disease LDL-density-radius theory. 2015 , 13, 355-67		6
1956	Alirocumab as Add-On to Atorvastatin Versus Other Lipid Treatment Strategies: ODYSSEY OPTIONS I Randomized Trial. 2015 , 100, 3140-8		176
1955	Should CMR Become the New Darling of Noninvasive Imaging for the Monitoring of Progression and Regression of Coronary Heart Disease?. <i>Journal of the American College of Cardiology</i> , 2015 , 66, 257-260	15.1	2
1954	Implications of the Eighth Joint National Committee Guidelines for the Management of High Blood Pressure for Aging Adults: Atherosclerosis Risk in Communities Study. 2015 , 66, 474-80		10
1953	On-Statins, Resistin, Leptin, and Risk of Recurrent Coronary Events After Hospitalization for an Acute Coronary Syndrome (from the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Study). 2015 , 116, 694-8		11
1952	Evidence for metabolic aberrations in asymptomatic persons with type 2 diabetes after initiation of simvastatin therapy. 2015 , 166, 176-87		4
1951	Noninvasive Imaging of Atherosclerotic Plaque Progression: Status of Coronary Computed Tomography Angiography. 2015 , 8, e003316		45
1950	Cardiovascular Update: Risk, Guidelines, and Recommendations. 2015 , 63, 376-80		4
1949	Predictors of all-cause and cardiovascular disease mortality in type 2 diabetes: Diabetes Heart Study. 2015 , 7, 58		18
1948	Guideline-Based Statin Eligibility, Coronary Artery Calcification, and Cardiovascular Events. 2015 , 314, 134-41		97
1947	The statin diabetes conundrum: short-term gain, long-term risk or inconvenient truth?. 2015 , 20, 121-3		3
1946	Use of ETC-1002 to treat hypercholesterolemia in patients with statin intolerance. 2015 , 9, 295-304		90
1945	Statins in Intracerebral Hemorrhage. 2015 , 17, 46		20

1944	The perils of surrogate endpoints. 2015 , 36, 2212-8	41
1943	Screening and treatment of familial hypercholesterolemia - Lessons from the past and opportunities for the future (based on the Anitschkow Lecture 2014). 2015 , 241, 597-606	30
1942	Prevention of cardiovascular disease in rheumatoid arthritis. 2015 , 14, 952-69	57
1941	A Systematic Review of the Efficacy of Bioactive Compounds in Cardiovascular Disease: Carbohydrates, Active Lipids and Nitrogen Compounds. 2015 , 66, 168-181	16
1940	Identifying an Optimal Cutpoint for the Diagnosis of Hypertriglyceridemia in the Nonfasting State. 2015 , 61, 1156-63	38
1939	Response to Comment on Stegman et al. High-intensity statin therapy alters the natural history of diabetic coronary atherosclerosis: insights from SATURN. <i>Diabetes Care</i> 2014;37:3114-3120. 2015 , 38, e28-9	1
1938	Short Communication: Coronary Heart Disease Risk by Framingham Risk Score in Hepatitis C and HIV/Hepatitis C-Coinfected Persons. 2015 , 31, 718-22	20
1937	Primary prevention: do the very elderly require a different approach?. 2015 , 25, 228-39	15
1936	Effect of atorvastatin on C-reactive protein and benefits for cardiovascular disease in patients with type 2 diabetes: analyses from the Collaborative Atorvastatin Diabetes Trial. 2015 , 58, 1494-502	23
1935	GATM polymorphism associated with the risk for statin-induced myopathy does not replicate in case-control analysis of 715 dyslipidemic individuals. 2015 , 21, 622-7	28
1934	Cardiovascular disease risk assessment and prevention: current guidelines and limitations. 2015 , 99, 711-31	27
1933	Situaci3n actual de la dislipemia en Espa1a: La visi3n del card3logo. 2015 , 15, 2-7	0
1932	IMPROVE-IT clinical implications. Should the "high-intensity cholesterol-lowering therapy" strategy replace the "high-intensity statin therapy"?. 2015 , 240, 161-2	41
1931	Clinical management of comorbid diabetes and psychotic disorders. 2015 , 2, 465-476	17
1930	Statin treatment: can genetics sharpen the focus?. 2015 , 385, 2227-9	9
1929	La gu1a europea de dislipemia. Fortalezas y debilidades. 2015 , 15, 14-17	
1928	Risk identification and possible countermeasures for muscle adverse effects during statin therapy. 2015 , 26, 82-8	56
1927	Using age- and sex-specific risk thresholds to guide statin therapy: one size may not fit all. <i>Journal of the American College of Cardiology</i> , 2015 , 65, 1633-1639	15.1 41

1926	Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies in Adults With Hypercholesterolemia: A Systematic Review and Meta-analysis. 2015 , 163, 40-51		281
1925	Cholesterol guidelines do not endorse "one size fits all": the strategy begins with a discussion. <i>Journal of the American College of Cardiology</i> , 2015 , 65, 1640-1643	15.1	1
1924	Genetic and immunologic susceptibility to statin-related myopathy. 2015 , 240, 260-71		26
1923	COCATS 4 Task Force 2: Training in Preventive Cardiovascular Medicine. <i>Journal of the American College of Cardiology</i> , 2015 , 65, 1754-62	15.1	9
1922	Estatinas en pacientes con síndrome coronario agudo. Más allá de las lipoproteínas de baja densidad. 2015 , 15, 28-33		
1921	Treatment of dyslipidemia in allogeneic hematopoietic stem cell transplant patients. 2015 , 21, 809-20		16
1920	A Practitioner's Simple Mnemonic for Managing Diabetes: "GLUCOSE BAD" 2015 , 11, 451-455		
1919	Guías de práctica clínica de manejo de la dislipemia en diabéticos y otros grupos de riesgo. 2015 , 15, 8-13		
1918	Ezetimibe plus moderate-dose simvastatin after acute coronary syndrome: what are we improving on?. 2015 , 128, 914.e1-4		9
1917	Visit-to-visit low-density lipoprotein cholesterol variability and risk of cardiovascular outcomes: insights from the TNT trial. <i>Journal of the American College of Cardiology</i> , 2015 , 65, 1539-48	15.1	104
1916	Long-term Cost-effectiveness of Statin Treatment for Primary Prevention of Cardiovascular Disease in the Elderly. 2015 , 29, 187-97		12
1915	Recommendations for the management of patients with familial hypercholesterolemia. 2015 , 17, 473		9
1914	The promise of proprotein convertase subtilisin/kexin 9 inhibitors for the treatment of familial hypercholesterolemia. 2015 , 17, 508		
1913	Debate: Testosterone Therapy Reduces Cardiovascular Risk in Men with Diabetes. Against the Motion. 2015 , 9, 1		
1912	Tools for Cardiovascular Risk Assessment in Clinical Practice. 2015 , 9, 1		
1911	Utility of both carotid intima-media thickness and endothelial function for cardiovascular risk stratification in patients with angina-like symptoms. 2015 , 190, 90-8		4
1910	Prevalence, Vascular Distribution, and Multiterritorial Extent of Subclinical Atherosclerosis in a Middle-Aged Cohort: The PESA (Progression of Early Subclinical Atherosclerosis) Study. 2015 , 131, 2104-13		239
1909	Guía de práctica clínica para la prevención, detección temprana, diagnóstico, tratamiento y seguimiento de las dislipidemias: tratamiento farmacológico con estatinas. 2015 , 22, 14-21		5

1908	Statin reloading before noncardiac surgery: a simple, safe and effective approach for reducing the risk of perioperative myocardial infarction. 2015 , 131, 51-2		1
1907	Eligibility for statin therapy according to new cholesterol guidelines and prevalent use of medication to lower lipid levels in an older US Cohort: the Atherosclerosis Risk in Communities Study Cohort. 2015 , 175, 138-40		17
1906	The effect of cardiorespiratory fitness on age-related lipids and lipoproteins. <i>Journal of the American College of Cardiology</i> , 2015 , 65, 2091-100	15.1	53
1905	Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition and the Future of Lipid Lowering Therapy. 2015 , 58, 19-31		37
1904	Reply to Letters Regarding Article, "Prognostic Value of Fasting Versus Nonfasting Low-Density Lipoprotein Cholesterol Levels on Long-Term Mortality: Insight From the National Health and Nutrition Examination Survey III (NHANES-III)". 2015 , 131, e473		1
1903	Cardiovascular risk assessment: a global perspective. 2015 , 12, 301-11		58
1902	Cardiovascular risk stratification in overweight or obese patients in primary prevention. Implications for use of statins. 2015 , 62, 83-90		2
1901	Low serum TNF-related apoptosis-inducing ligand (TRAIL) levels are associated with acute ischemic stroke severity. 2015 , 240, 228-33		12
1900	Prevalence, impact, and predictive value of detecting subclinical coronary and carotid atherosclerosis in asymptomatic adults: the BiImage study. <i>Journal of the American College of Cardiology</i> , 2015 , 65, 1065-74	15.1	256
1899	Diagnosis and management of acute coronary syndrome: an evidence-based update. 2015 , 28, 283-93		56
1898	[Prevention of cardiovascular diseases through sport and physical activity: A question of intensity?]. 2015 , 40, 361-8		4
1897	Statin use and survival after colorectal cancer: the importance of comprehensive confounder adjustment. 2015 , 107, djv045		72
1896	Quantifying atherosclerosis by "3D" ultrasound works!: But there is work to be done. <i>Journal of the American College of Cardiology</i> , 2015 , 65, 1075-7	15.1	6
1895	Familial Hypercholesterolemia and the 2013 American College of Cardiology/American Heart Association Guidelines: Myths, Oversimplification, and Misinterpretation Versus Facts. 2015 , 116, 481-4		14
1894	Lower cardiovascular mortality with atorvastatin and rosuvastatin vs simvastatin: Data from "moderate-intensity" statin users in an observational registry on chronic heart failure (Daunia Heart Failure Registry). 2015 , 194, 23-7		3
1893	Gender-related lipid and/or lipoprotein responses to statins in subjects in primary and secondary prevention. 2015 , 9, 226-33		17
1892	National lipid association recommendations for patient-centered management of dyslipidemia: part 1--full report. 2015 , 9, 129-69		478
1891	Cost-effectiveness of statins in older adults: further evidence that less is more. 2015 , 162, 590-1		2

1890	Getting guidelines correct: their evidence-based recommendations for use of nonstatins added to statins and the need for follow-up lipid testing. <i>Journal of the American College of Cardiology</i> , 2015 , 65, 2051-2	15.1	1
1889	Familial hypercholesterolemia. 2015 , 33, 169-79		47
1888	Statins and diabetes. 2015 , 33, 233-43		12
1887	Coronary artery calcium scanning: past, present, and future. 2015 , 8, 579-596		167
1886	Cholesterol-lowering therapy: Old evidence, new guidelines--Which one to follow? A critical appraisal. 2015 , 18, 176-9		1
1885	Statins and cognitive side effects: what cardiologists need to know. 2015 , 33, 245-56		6
1884	PAD in women: the ischemic continuum. 2015 , 17, 513		10
1883	Revisiting Disparities in Quality of Care Among US Adults With Diabetes in the Era of Individualized Care, NHANES 2007-2010. 2015 , 53, 25-31		19
1882	NHS health checks: an update on the debate and program implementation in England. 2015 , 38, 5-9		9
1881	Newer targets and therapies for hypertension and dyslipidemia in diabetic patients. 2015 , 4, 11-16		
1880	A randomized, double blind, placebo-controlled pilot trial of the safety and efficacy of atorvastatin in children with elevated low-density lipoprotein cholesterol (LDL-C) and type 1 diabetes. 2015 , 16, 79-89		28
1879	Lipids, blood pressure and kidney update 2014. 2015 , 95-96, 111-25		70
1878	Strategies to overcome statin intolerance. 2015 , 11, 851-5		12
1877	Clinician-patient risk discussion for atherosclerotic cardiovascular disease prevention: importance to implementation of the 2013 ACC/AHA Guidelines. <i>Journal of the American College of Cardiology</i> , 2015 , 65, 1361-1368	15.1	113
1876	Safety and benefit of discontinuing statin therapy in the setting of advanced, life-limiting illness: a randomized clinical trial. 2015 , 175, 691-700		300
1875	Long-term Effects of Plant Stanols on the Lipid Profile of Patients With Hypercholesterolemia. A Randomized Clinical Trial. 2015 , 68, 665-71		7
1874	A novel risk score to predict cardiovascular disease risk in national populations (Globorisk): a pooled analysis of prospective cohorts and health examination surveys. 2015 , 3, 339-55		125
1873	Recognizing and managing comorbidities in psoriatic arthritis. 2015 , 27, 118-26		116

1872	The stroke 8: a daily checklist for inpatient stroke management. 2015 , 14, 1-6		3
1871	Association between familial hypercholesterolemia and prevalence of type 2 diabetes mellitus. 2015 , 313, 1029-36		246
1870	Impact of statins on serial coronary calcification during atheroma progression and regression. <i>Journal of the American College of Cardiology</i> , 2015 , 65, 1273-1282	15.1	319
1869	Protective effect of microRNA-30b on hypoxia/reoxygenation-induced apoptosis in H9C2 cardiomyocytes. 2015 , 561, 268-75		10
1868	How long do your angiographically normal coronary arteries remain normal? A pilot study. 2015 , 66, 262-4		
1867	Statins and aspirin: do they really work in women?. 2015 , 15, 151-62		1
1866	A Systematic Review of the Usefulness of Statin Therapy in HIV-Infected Patients. 2015 , 115, 1760-6		68
1865	Cardiovascular calcification: current controversies and novel concepts. 2015 , 24, 207-12		48
1864	Treatment of Hypertension in Patients With Coronary Artery Disease: A Scientific Statement from the American Heart Association, American College of Cardiology, and American Society of Hypertension. <i>Journal of the American College of Cardiology</i> , 2015 , 65, 1998-2038	15.1	97
1863	Comparison of the effects of two low-density lipoprotein cholesterol goals for secondary prevention after acute myocardial infarction in real-world practice: a 50% reduction from baseline versus . 2015 , 187, 478-85		10
1862	RETRACTED: The principles & practice of LDL lowering therapy. 2015 , 5, S54-S57		
1861	Optimal approaches to diabetic patients with multivessel disease. 2015 , 25, 625-31		1
1860	The approach of general practitioners in Lagos to the detection and evaluation of hypertension. 2015 , 21, 10		
1859	Strategies for improving cardiovascular health in women with diabetes mellitus: a review of the evidence. 2015 , 15, 98		1
1858	Cardiovascular Imaging for the Primary Prevention of Atherosclerotic Cardiovascular Disease Events. 2015 , 8, 36		21
1857	The role of vascular biomarkers for primary and secondary prevention. A position paper from the European Society of Cardiology Working Group on peripheral circulation: Endorsed by the Association for Research into Arterial Structure and Physiology (ARTERY) Society. 2015 , 241, 507-32		420
1856	Nonstatin therapies for management of dyslipidemia: a review. 2015 , 37, 2153-79		29
1855	Can Antihypertensive Treatment Restore the Risk of Cardiovascular Disease to Ideal Levels?: The Coronary Artery Risk Development in Young Adults (CARDIA) Study and the Multi-Ethnic Study of Atherosclerosis (MESA). 2015 , 4, e002275		64

1854	Implications of Coronary Artery Calcium Testing Among Statin Candidates According to American College of Cardiology/American Heart Association Cholesterol Management Guidelines: MESA (Multi-Ethnic Study of Atherosclerosis). <i>Journal of the American College of Cardiology</i> , 2015 , 66, 1657-68	15.1	279
1853	Coronary Artery Calcium Scoring: Are We There Yet?. <i>Journal of the American College of Cardiology</i> , 2015 , 66, 1654-6	15.1	10
1852	Coronary Calcium Score and the New Guidelines: Back to Square One?. <i>Journal of the American College of Cardiology</i> , 2015 , 66, 1669-71	15.1	2
1851	Lipoprotein(a): Its relevance to the pediatric population. 2015 , 9, S57-66		21
1850	Alirocumab (Praluent) to Lower LDL-Cholesterol. 2015 , 314, 1284-5		3
1849	Inverse linear associations between liver aminotransferases and incident cardiovascular disease risk: The PREVEND study. 2015 , 243, 138-47		31
1848	Cardiac risk of noncardiac surgery. <i>Journal of the American College of Cardiology</i> , 2015 , 66, 2140-2148	15.1	31
1847	Nonstatin Low-Density Lipoprotein-Lowering Therapy and Cardiovascular Risk Reduction-Statement From ATVB Council. 2015 , 35, 2269-80		48
1846	Relationship between cardiovascular risk and lipid testing in one health care system: a retrospective cohort study. 2015 , 15, 281		6
1845	New Approaches in Detection and Treatment of Familial Hypercholesterolemia. 2015 , 17, 109		20
1844	Trends in Prescription Drug Use Among Adults in the United States From 1999-2012. 2015 , 314, 1818-31		689
1843	Gender, Cardiovascular Disease, and the Sexism of Obesity. <i>Journal of the American College of Cardiology</i> , 2015 , 66, 1958-1960	15.1	10
1842	Novel biomarkers for cardiovascular risk assessment: current status and future directions. 2015 , 11, 597-613		7
1841	Coronary Artery Calcium Improves Risk Classification in Younger Populations. 2015 , 8, 1285-93		43
1840	Biologic plausibility, cellular effects, and molecular mechanisms of eicosapentaenoic acid (EPA) in atherosclerosis. 2015 , 242, 357-66		114
1839	Results of the ROADSTER multicenter trial of transcatheter stenting with dynamic flow reversal. 2015 , 62, 1227-34		193
1838	A call for the better utilization of physical activity and exercise training in the defense against cardiovascular disease. 2015 , 43, 329-32		2
1837	Evaluating the Effects of an Interdisciplinary Practice Model with Pharmacist Collaboration on HIV Patient Co-Morbidities. 2015 , 29, 445-53		14

1836	Can Clinicians Improve on the Effectiveness of Statins with Additional Lipid-lowering Therapies?. 2015 , 128, 1160-1		
1835	The Burden of Australian Indigenous Cardiac Disease and the Emerging Role of Cardiac Imaging. 2015 , 8, 1		
1834	Implementation of Cardiovascular Disease Prevention Guidelines in Clinical Practice-Can We Do Better?. 2015 , 17, 58		6
1833	Clinical indicators for recurrent cardiovascular events in acute coronary syndrome patients treated with statins under routine practice in Thailand: an observational study. 2015 , 15, 55		2
1832	Role of Ezetimibe in Lipid-Lowering and Cardiovascular Disease Prevention. 2015 , 17, 72		10
1831	New Therapies in the Treatment of High Cholesterol: An Argument to Return to Goal-Based Lipid Guidelines. 2015 , 314, 1443-4		29
1830	Design and rationale for the Patient and Provider Assessment of Lipid Management (PALM) registry. 2015 , 170, 865-71		20
1829	Should we consider ezetimibe to reach even lower LDL-C targets?. 2015 , 31, 459-60		5
1828	Treatment of Dyslipidemia in Elderly Patients With Coronary Heart Disease: There Are Miles to Go Before We Sleep. <i>Journal of the American College of Cardiology</i> , 2015 , 66, 1873-5	15.1	4
1827	Sociodemographic and diagnostic characteristics of prescribing a second-line lipid-lowering medication: ezetimibe used as initial medication, switch from statins, or add-on medication. 2015 , 71, 1245-54		6
1826	Next Steps in Primary Prevention of Coronary Heart Disease: Rationale for and Design of the ECAD Trial. <i>Journal of the American College of Cardiology</i> , 2015 , 66, 1828-1836	15.1	36
1825	Safety and efficacy of anti-PCSK9 antibodies: a meta-analysis of 25 randomized, controlled trials. 2015 , 13, 123		154
1824	Efficacy and safety of fixed dose combination of atorvastatin and hydroxychloroquine: a randomized, double-blind comparison with atorvastatin alone among Indian patients with dyslipidemia. 2015 , 31, 2105-17		22
1823	Patient and Physician Perspectives on Mode of Administration of the PCSK9 Monoclonal Antibody Alirocumab, an Injectable Medication to Lower LDL-C Levels. 2015 , 37, 1945-1954.e6		21
1822	Risk of Cardiovascular Disease in an Aging HIV Population: Where Are We Now?. 2015 , 12, 375-87		49
1821	Historical perspective and contemporary management of acute coronary syndromes: from MONA to THROMBINS2. 2015 , 127, 855-62		8
1820	Breast Density and Benign Breast Disease: Risk Assessment to Identify Women at High Risk of Breast Cancer. 2015 , 33, 3137-43		118
1819	Integrated Care at the Interface of Psychiatry and Primary Care: Prevention of Cardiovascular Disease. 2015 , 38, 463-74		1

1818	Pathways Forward in Cardiovascular Disease Prevention One and a Half Years After Publication of the 2013 ACC/AHA Cardiovascular Disease Prevention Guidelines. 2015 , 90, 1262-71		15
1817	Perspectives on Cholesterol Guidelines. 2015 , 313-327		
1816	PCSK9 Inhibitors and Cardiovascular Events. 2015 , 373, 774		27
1815	Prognostic Value of Stress Echocardiography in Patients With Low-Intermediate or High Short-Term (10 Years) Versus Low (. 2015 , 116, 725-9		2
1814	The CardioMetabolic Health Alliance: Working Toward a New Care Model for the Metabolic Syndrome. <i>Journal of the American College of Cardiology</i> , 2015 , 66, 1050-67	15.1	158
1813	Comorbidities in Psoriatic Arthritis. 2015 , 41, 677-98		83
1812	What to Expect From the Evolving Field of Geriatric Cardiology. <i>Journal of the American College of Cardiology</i> , 2015 , 66, 1286-1299	15.1	72
1811	Extended-Release Niacin Versus Fenofibrate in HIV-Infected Participants With Low High-Density Lipoprotein Cholesterol: Effects on Endothelial Function, Lipoproteins, and Inflammation. 2015 , 61, 840-9		16
1810	Effect of High-Dose Statin Therapy on Drug-Eluting Stent Strut Coverage. 2015 , 35, 2460-7		10
1809	LDL cholesterol, statins and PCSK 9 inhibitors. 2015 , 67, 419-24		10
1808	Cardiorespiratory fitness attenuates risk for major adverse cardiac events in hyperlipidemic men and women independent of statin therapy: The Henry Ford Exercise Testing Project. 2015 , 170, 390-9		14
1807	Nonfasting Lipid Profiles: The Way of the Future. 2015 , 61, 1123-5		20
1806	Meta-analysis comparing the effects of rosuvastatin versus atorvastatin on regression of coronary atherosclerotic plaques. 2015 , 116, 1521-6		23
1805	Antilipidemic Drug Therapy Today and in the Future. 2016 , 233, 373-435		3
1804	Fasting plasma triglyceride concentration: A possible approach to identify increased risk of statin-induced type 2 diabetes. 2015 , 12, 373-6		3
1803	[Importance of dyslipidaemia in cardiovascular disease: a point of view]. 2015 , 27, 301-8		10
1802	[Secondary prevention of ischemic non cardioembolic stroke]. 2015 , 27, 287-300		1
1801	Favorable effect of optimal lipid-lowering therapy on neointimal tissue characteristics after drug-eluting stent implantation: qualitative optical coherence tomographic analysis. 2015 , 242, 553-9		29

1800	Screening and advanced lipid phenotyping in familial hypercholesterolemia: The Very Large Database of Lipids Study-17 (VLDL-17). 2015 , 9, 676-83	12
1799	Counterpoint: The evidence does not support universal screening and treatment in children. 2015 , 9, S101-6	3
1798	Multisite extracoronary calcification indicates increased risk of coronary heart disease and all-cause mortality: The Multi-Ethnic Study of Atherosclerosis. 2015 , 9, 406-14	50
1797	suPAR: A Cardiac Biomarker With a Future?. 2015 , 31, 1223-4	6
1796	Consensus statement on the management of dyslipidemia in Indian subjects: A different perspective. 2015 , 67, 95-102	3
1795	Effects of icosapent ethyl on lipoprotein particle concentration and size in statin-treated patients with persistent high triglycerides (the ANCHOR Study). 2015 , 9, 377-83	32
1794	Clinical Update on Nursing Home Medicine: 2015. 2015 , 16, 911-22	1
1793	CVD prevention in 2014: Advances in the prevention of cardiovascular disease. 2015 , 12, 71-3	8
1792	When compliance is an issue-how to enhance statin adherence and address adverse effects. 2015 , 17, 471	15
1791	2013 ACC/AHA cholesterol treatment guideline: Paradigm shifts in managing atherosclerotic cardiovascular disease risk. 2015 , 25, 340-7	17
1790	Do we need guideline-driven specific lipid goals to achieve regression of coronary atherosclerosis and maximize therapy benefits?. 2015 , 115, 280	
1789	Platelet-to-lymphocyte ratio and no-reflow phenomenon in patients undergoing primary percutaneous coronary intervention. 2015 , 115, 280-1	4
1788	The effect of ezetimibe-statin combination on steroid hormone production in men with coronary artery disease and low cholesterol levels. 2015 , 67, 305-9	5
1787	Effects of niacin, statin, and fenofibrate on circulating proprotein convertase subtilisin/kexin type 9 levels in patients with dyslipidemia. 2015 , 115, 178-82	46
1786	Refined nine-lead total QRS voltage with body mass index might offer a better diagnostic accuracy!. 2015 , 115, 279-80	2
1785	Ongoing challenges for pharmacotherapy for dyslipidemia. 2015 , 16, 347-56	4
1784	Diabetic kidney disease: a clinical update from Kidney Disease: Improving Global Outcomes. 2015 , 87, 20-30	155
1783	Statins and Cataracts--a visual insight. 2015 , 17, 477	11

1782	Stroke: an emphasis on guidelines. 2015 , 14, 2-3	7
1781	Gender disparities in evidence-based statin therapy in patients with cardiovascular disease. 2015 , 115, 21-6	96
1780	Contemporary medical management of peripheral arterial disease: a focus on risk reduction and symptom relief for intermittent claudication. 2015 , 33, 111-37	13
1779	[Inappropriate prescribing in polymedicated patients over 64 years-old in primary care]. 2015 , 47, 38-47	12
1778	Nonglycemic targets in diabetes. 2015 , 99, 187-200	0
1777	Estimating time to ESRD using kidney failure risk equations: results from the African American Study of Kidney Disease and Hypertension (AASK). 2015 , 65, 394-402	30
1776	The new dyslipidemia guidelines: what is the debate?. 2015 , 31, 605-12	32
1775	HDL cholesterol performance using an ultracentrifugation reference measurement procedure and the designated comparison method. 2015 , 439, 185-90	10
1774	Impact on cognitive function-are all statins the same?. 2015 , 17, 466	6
1773	Diagnosing and managing diabetes in HIV-infected patients: current concepts. 2015 , 60, 453-62	70
1772	Do clinicians recommend aspirin to patients for primary prevention of cardiovascular disease?. 2015 , 30, 155-60	9
1771	Outpatient management of transient ischaemic attack. 2016 , 57, 658-663	1
1770	Koronarerkrankungen âaktuelle Momentaufnahme in Deutschland. 2016 , 24, 95-97	
1769	When is OTC niacin appropriate?. 2016 , 22, 20	
1768	Chancen und Risiken von e-Health in der Labormedizin. 2016 , 40,	4
1767	Antihyperlipidemic Medication Treatment Patterns and Statin Adherence Among Patients with ASCVD in a Managed Care Plan After Release of the 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol. 2016 , 22, 892-900	24
1766	Reduction in total recurrent cardiovascular events in acute coronary syndrome patients with low-density lipoprotein cholesterol goal . 2016 , 12, 353-60	1
1765	Lipoprotein abnormalities in South Asians and its association with cardiovascular disease: Current state and future directions. 2016 , 8, 247-57	45

1764	Comparison of Clevidipine Versus Sodium Nitroprusside for the Treatment of Postoperative Hypertension in Cardiac Surgery Patients. 2016 , 51, 461-7	3
1763	Development of proprotein convertase subtilisin/kexin type 9 inhibitors and the clinical potential of monoclonal antibodies in the management of lipid disorders. 2016 , 12, 421-433	7
1762	AMCP Partnership Forum: Driving New Advances in Dyslipidemia Management. 2016 , 22, 426-33	
1761	Factors associated with lipid goal attainment among acute coronary syndrome patients. 2016 , 10, 1631-7	1
1760	Cholesterol: Absorption, Function and Metabolism. 2016 , 47-52	3
1759	The New Face of Hyperlipidemia Management: Proprotein Convertase Subtilisin/Kexin Inhibitors (PCSK-9) and Their Emergent Role As An Alternative To Statin Therapy. 2016 , 19, 137-46	5
1758	Clinical efficacy and safety of evolocumab for low-density lipoprotein cholesterol reduction. 2016 , 12, 163-9	8
1757	Patterns of Statin Use in a Real-World Population of Patients at High Cardiovascular Risk. 2016 , 22, 685-98	43
1756	Relationship between Non-High-Density Lipoprotein Cholesterol and Low-Density Lipoprotein Cholesterol in the General Population. 2016 , 23, 477-90	21
1755	Primary Prevention of Cardiovascular Disease. 2016 , 1, 379-389	
1754	The Relationship between 10-Year Cardiovascular Risk Calculated Using the Pooled Cohort Equation and the Severity of Non-Alcoholic Fatty Liver Disease. 2016 , 31, 86-92	17
1753	Regular Evaluation for Patients with Diabetes Mellitus. 2016 , 17, 238	
1752	Drug Treatment of Stable Coronary Artery Disease. 2016 , 167-177	0
1751	The Role of Common Pharmaceutical Agents on the Prevention and Treatment of Pancreatic Cancer. 2016 , 10, 665-71	16
1750	Response to perioperative statin therapy in cardiac surgery: a matter of race and timing?. 2016 , 8, 2344-2347	2
1749	Analysis of laboratory tests results of patients submitted to a clinical screening program. 2016 ,	
1748	Statin-induced diabetes: incidence, mechanisms, and implications. 2016 , 5,	17
1747	Impact of the 2013 Cholesterol Guideline on Patterns of Lipid-Lowering Treatment in Patients with Atherosclerotic Cardiovascular Disease or Diabetes After 1 Year. 2016 , 22, 901-8	22

1746	The association between cognitive function and objective adherence to dietary sodium guidelines in patients with heart failure. 2016 , 10, 233-41	16
1745	Extending the Use of Coronary Calcium Scanning to Clinical Rather Than Just Screening Populations: Ready for Prime Time?. 2016 , 9,	6
1744	Prevention/detection/management of abdominal aortic aneurysm. 2016 , 1, 4-4	
1743	The Role of TLR2, TLR4, and TLR9 in the Pathogenesis of Atherosclerosis. 2016 , 2016, 1532832	83
1742	Suboptimal Control of Lipid Levels: Results from 29 Countries Participating in the Centralized Pan-Regional Surveys on the Undertreatment of Hypercholesterolaemia (CEPHEUS). 2016 , 23, 567-87	38
1741	Modulation of Hypercholesterolemia-Induced Oxidative/Nitrative Stress in the Heart. 2016 , 2016, 3863726	55
1740	Disorders of Lipid Metabolism. 2016 , 1660-1700	4
1739	Impact of statins on risk of new onset diabetes mellitus: a population-based cohort study using the Korean National Health Insurance claims database. 2016 , 12, 1533-1543	20
1738	Triglyceride-rich lipoproteins as a causal factor for cardiovascular disease. 2016 , 12, 171-83	123
1737	Pharmacogenomics of statins: understanding susceptibility to adverse effects. 2016 , 9, 97-106	38
1736	Effect of comprehensive cardiovascular disease risk management on longitudinal changes in carotid artery intima-media thickness in a community-based prevention clinic. 2016 , 12, 728-35	11
1735	Hypertriglyceridemia and Cardiovascular Diseases: Revisited. 2016 , 46, 135-44	31
1734	Lipids in Coronary Heart Disease. 2016 , 67-80	
1733	Cardiovascular Problems in Women. 2016 , 379-405	
1732	Impact of Community-Based Cardiac Rehabilitation on Clinical Parameters of Patients with Cardiovascular Diseases. 2016 , 24, 5	3
1731	Adding tests to risk based guidelines: evaluating improvements in prediction for an intermediate risk group. 2016 , 354, i4450	4
1730	Limitations of the SCORE-guided European guidelines on cardiovascular disease prevention. 2017 , 38, 2259-2263	24
1729	National Assessment of Statin Therapy in Patients Hospitalized with Acute Myocardial Infarction: Insight from China PEACE-Retrospective AMI Study, 2001, 2006, 2011. 2016 , 11, e0150806	8

1728	Inflammation Activation Contributes to Adipokine Imbalance in Patients with Acute Coronary Syndrome. 2016 , 11, e0151916		8
1727	Trends in Statin Use in Seniors 1999 to 2013: Time Series Analysis. 2016 , 11, e0158608		16
1726	Recalibration of the ACC/AHA Risk Score in Two Population-Based German Cohorts. 2016 , 11, e0164688		17
1725	The impact of statin therapy on plasma levels of von Willebrand factor antigen. Systematic review and meta-analysis of randomised placebo-controlled trials. 2016 , 115, 520-32		110
1724	ACC/AHA Guidelines for Cardiovascular Disease Prevention and Cholesterol Management: Implications of New Therapeutic Agents. 2016 , 1, 399-408		1
1723	Hypertriglyceridemia and Cardiovascular Outcomes. 2016 , 23, e862-70		3
1722	Statins in Familial Hypercholesterolemia: Consequences for Coronary Artery Disease and All-Cause Mortality. <i>Journal of the American College of Cardiology</i> , 2016 , 68, 252-260	15.1	103
1721	Statins and Exercise Training Response in Heart Failure Patients: Insights From HF-ACTION. 2016 , 4, 617-24		7
1720	PCSK9 Inhibitors: An Innovative Approach to Treating Hyperlipidemia. 2016 , 24, 141-52		8
1719	Advances in Lipid Testing: A Practical Step Forward. 2016 , 62, 905-6		5
1718	The Metabolic Risk in Patients Newly Diagnosed with Acromegaly Is Related to Fat Distribution and Circulating Adipokines and Improves after Treatment. 2016 , 103, 197-206		21
1717	Lifestyle Modification for the Prevention of Morbidity and Mortality in Adult Congenital Heart Disease. 2016 , 11, 189-98		11
1716	Inflammatory/hemostatic biomarkers and coronary artery calcification in midlife women of African-American and White race/ethnicity: the Study of Women's Health Across the Nation (SWAN) heart study. 2016 , 23, 653-61		14
1715	Effects of eicosapentaenoic acid and docosahexaenoic acid on lipoproteins in hypertriglyceridemia. 2016 , 23, 145-9		9
1714	Inflammation, immune activation, and cardiovascular disease in HIV. 2016 , 30, 1495-509		107
1713	Pharmacogenetics in Cardiovascular Medicine. 2016 , 4, 119-129		8
1712	Population Effect of Differences in Cholesterol Guidelines in Eastern Europe and the United States. 2016 , 1, 700-7		10
1711	Regression of coronary atheroma with statin therapy. 2016 , 23, 131-7		9

1710	Risk assessment and periodontal prevention in primary care. 2016 , 71, 10-21	13
1709	A Baby in the Bathwater: Preserving Evidence-Based Medicine. <i>Journal of the American College of Cardiology</i> , 2016 , 68, 214-6	15.1 1
1708	The Next Phase for Point-of-Care Testing in Resource-Limited Settings. 2016 , 15, 93-95	1
1707	Independent association of subclinical coronary artery disease and emphysema in HIV-infected patients. 2016 , 17, 178-87	10
1706	Prevalence of the American College of Cardiology/American Heart Association statin eligibility groups, statin use, and low-density lipoprotein cholesterol control in US adults using the National Health and Nutrition Examination Survey 2011-2012. 2016 , 10, 1109-18	43
1705	Hipercolesterolemia familiar: artículo de revisión. 2016 , 23, 4-26	2
1704	Deprescribing: An Application to Medication Management in Older Adults. 2016 , 36, 774-80	16
1703	IMPROVE-IT: what have we learned?. 2016 , 31, 426-33	15
1702	Blood pressure guidelines. 2016 , 5, 1-3	
1701	LDL cholesterol is not a good marker of cardiovascular risk in Type 1 diabetes. 2016 , 33, 316-23	17
1700	Implications of Total to High-Density Lipoprotein Cholesterol Ratio Discordance With Alternative Lipid Parameters for Coronary Atheroma Progression and Cardiovascular Events. 2016 , 118, 647-55	17
1699	Metabolic Control in Older Dependent People: Need for Improvement?. 2016 , 17, 777-8	
1698	Atorvastatin and fluvastatin are associated with dose-dependent reductions in cirrhosis and hepatocellular carcinoma, among patients with hepatitis C virus: Results from ERCHIVES. 2016 , 64, 47-57	110
1697	Effects of extended-release niacin/laropiprant on correlations between apolipoprotein B, LDL-cholesterol and non-HDL-cholesterol in patients with type 2 diabetes. 2016 , 15, 116	3
1696	Association between ischemic heart disease and colorectal neoplasm: a systematic review and meta-analysis. 2016 , 5, 1664	15
1695	Multicenter Cohort Study of Acute Myocardial Infarction in Korea - Interim Analysis of the Korea Acute Myocardial Infarction Registry-National Institutes of Health Registry. 2016 , 80, 1427-36	111
1694	Integrative mutation, haplotype and G x G interaction evidence connects ABGL4, LRP8 and PCSK9 genes to cardiometabolic risk. 2016 , 6, 37375	4
1693	Relation of statin use with non-melanoma skin cancer: Prospective results from the Women's Health Initiative. 2016 , 12, 453-455	5

1692	Cardiovascular disease in patients with chronic kidney disease: a neglected subgroup. 2016 , 8, 56-61	55
1691	Cholesterol levels and long-term rates of community-acquired sepsis. 2016 , 20, 408	41
1690	Abdominal obesity is strongly associated with Cardiovascular Disease and its Risk Factors in Elderly and very Elderly Community-dwelling Chinese. 2016 , 6, 21521	64
1689	Using pharmacists to improve risk stratification and management of stage 3A chronic kidney disease: a feasibility study. 2016 , 17, 168	12
1688	Short-term and long-term cardiovascular risk, metabolic syndrome and HIV in Tanzania. 2016 , 102, 1200-5	23
1687	Plaque progression assessed by a novel semi-automated quantitative plaque software on coronary computed tomography angiography between diabetes and non-diabetes patients: A propensity-score matching study. 2016 , 255, 73-79	37
1686	Nutritional management of hyperapoB. 2016 , 29, 202-233	16
1685	Statins alone or polypill for primary prevention of cardiovascular diseases. 2016 , 15, 55	1
1684	Genetic identification of familial hypercholesterolemia within a single U.S. health care system. 2016 , 354,	229
1683	Statin Therapy on the Basis of HOPE: A European Perspective. <i>Journal of the American College of Cardiology</i> , 2016 , 68, 2903-2906	15.1 2
1682	Hydroxychloroquine for the prevention of recurrent cardiovascular events in myocardial infarction patients: rationale and design of the OXI trial. 2017 , 3, 92-97	22
1681	Cerebrovascular Disease. 2016 , 673-682	
1680	High-Sensitivity Cardiac Troponin, Statin Therapy, and Risk of Coronary Heart Disease. <i>Journal of the American College of Cardiology</i> , 2016 , 68, 2719-2728	15.1 135
1679	Exchanging a few commercial, regularly consumed food items with improved fat quality reduces total cholesterol and LDL-cholesterol: a double-blind, randomised controlled trial. 2016 , 116, 1383-1393	30
1678	The Effects of Secondary Cardiovascular Prevention on Cancer Risk in Patients With Manifest Vascular Disease. <i>Journal of the American College of Cardiology</i> , 2016 , 68, 2588-2589	15.1 2
1677	Diagnosis and management of heart disease in the elderly. 2016 , 157-186	
1676	Advances in the field of proprotein convertase subtilisin kexin type 9 inhibitors. 2016 , 31, 644-653	4
1675	Atorvastatin inhibits insulin synthesis by inhibiting the Ras/Raf/ERK/CREB pathway in INS-1 cells. 2016 , 95, e4906	6

1674	The clinical dilemma of heart failure with preserved ejection fraction: an update on pathophysiology and management for physicians. 2016 , 92, 346-55		5
1673	Carotid wall imaging. 34-47		
1672	Use of low density lipoprotein particle number levels as an aid in statin treatment decisions for intermediate risk patients: a cost-effectiveness analysis. 2016 , 16, 251		3
1671	Efficacy and safety of Yirui capsule in patients with hyperlipidemia: study protocol for a multicenter, randomized, double-blind, placebo-controlled trial. 2016 , 17, 291		2
1670	Preventing and Experiencing Ischemic Heart Disease as a Woman: State of the Science: A Scientific Statement From the American Heart Association. 2016 , 133, 1302-31		151
1669	Diabetic Dyslipidemia Review: An Update on Current Concepts and Management Guidelines of Diabetic Dyslipidemia. 2016 , 351, 361-5		25
1668	The Diagnosis and Treatment of Fibromuscular Dysplasia: An Update for Cardiologists. 2016 , 18, 37		9
1667	Impact of PCSK9 inhibition on coronary atheroma progression: Rationale and design of Global Assessment of Plaque Regression with a PCSK9 Antibody as Measured by Intravascular Ultrasound (GLAGOV). 2016 , 176, 83-92		32
1666	Diagnostic Yield and Clinical Utility of Sequencing Familial Hypercholesterolemia Genes in Patients With Severe Hypercholesterolemia. <i>Journal of the American College of Cardiology</i> , 2016 , 67, 2578-89	15.1	458
1665	A lipidologist perspective of global lipid guidelines and recommendations, part 1: Lipid treatment targets and risk assessment. 2016 , 10, 228-39		4
1664	Comparative Effectiveness of Personalized Lifestyle Management Strategies for Cardiovascular Disease Risk Reduction. 2016 , 5, e002737		29
1663	All-cause mortality by age and gender based on coronary artery calcium scores. 2016 , 17, 1305-1314		38
1662	Diabetic dyslipidaemia. 2016 , 27, 313-22		35
1661	Fasting Is Not Routinely Required for Determination of a Lipid Profile: Clinical and Laboratory Implications Including Flagging at Desirable Concentration Cutpoints-A Joint Consensus Statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Medicine. 2016 , 62, 938-46		104
1660	Provider understanding of the 2013 ACC/AHA cholesterol guideline. 2016 , 10, 497-504.e4		54
1659	Statin therapy and inflammation in patients with diabetes treated with high dose aspirin. 2016 , 30, 1365-70		5
1658	2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). 2016 , 37, 2315-2381		3919
1657	Risky business: Personalizing the approach to percutaneous coronary intervention. 2016 , 178, 185-7		

1656	Managing dyslipidaemia in type 2 diabetes mellitus. 2016 , 30, 431-44	10
1655	Grado de control lipídico en pacientes coronarios y medidas adoptadas por los médicos. Estudio REPAR. 2016 , 69, 931-938	40
1654	Monoclonal Antibodies for Lipid Management. 2016 , 18, 39	6
1653	Spontaneous Coronary Artery Dissection. 2016 , 18, 60	27
1652	Pharmacologic Therapy of Type 2 Diabetes. 2016 , 100, 647-63	16
1651	Impact of Statin Therapy on Clinical Outcome in Patients With Coronary Spasm. 2016 , 5,	21
1650	Acute kidney injury secondary to rhabdomyolysis in a nonagenarian patient taking statins. Lessons to be considered. 2016 , 36, 181-2	
1649	Current practice in identifying and treating cardiovascular risk, with a focus on residual risk associated with atherogenic dyslipidaemia. 2016 , 18, C2-C12	56
1648	The changing face of diabetes complications. 2016 , 4, 537-47	247
1647	Statin Use and Prostate Cancer Aggressiveness: Results from the Population-Based North Carolina-Louisiana Prostate Cancer Project. 2016 , 25, 670-7	16
1646	Atorvastatin treatment and LDL cholesterol target attainment in patients at very high cardiovascular risk. 2016 , 105, 783-90	28
1645	A dataset to assess providers' knowledge and attitudes towards the 2013 American College of Cardiology/American Heart Association Cholesterol Management Guideline. 2016 , 7, 595-8	5
1644	Reply: Getting What the Guidelines Stated Matters. <i>Journal of the American College of Cardiology</i> , 2016 , 67, 120-1	15.1
1643	Long-term pharmacotherapy for elevated low density lipoprotein levels in children: A retrospective analysis. 2016 , 10, 265-72	4
1642	Degree of Lipid Control in Patients With Coronary Heart Disease and Measures Adopted by Physicians. REPAR Study. 2016 , 69, 931-938	3
1641	Effects of Sitagliptin on Lipid Profiles in Patients With Type 2 Diabetes Mellitus: A Meta-analysis of Randomized Clinical Trials. 2016 , 95, e2386	18
1640	Value Based Imaging for Coronary Artery Disease: Implications for Nuclear Cardiology and Cardiac CT. 2016 , 349-380	
1639	PCSK9 inhibitors and their role in high-risk patients in reducing LDL cholesterol levels: evolocumab. 2016 , 12, 139-48	5

1638	Coronary Artery Calcium Analysis and Reporting on Noncontrast Chest CT Scans: a Paradigm Shift in Prevention. 2016 , 9, 1		4
1637	2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents. <i>Journal of the American College of Cardiology</i> , 2016 , 68, 92-125	15.1	303
1636	Statins and Aspirin use in HIV-infected people: gap between European AIDS Clinical Society guidelines and clinical practice: the results from HIV-HY study. 2016 , 44, 589-97		33
1635	Disease Control Among Patients With Diabetes and Severe Depressive Symptoms. 2016 , 7, 130-4		6
1634	Cardiovascular Risk Factor Targets and Cardiovascular Disease Event Risk in Diabetes: A Pooling Project of the Atherosclerosis Risk in Communities Study, Multi-Ethnic Study of Atherosclerosis, and Jackson Heart Study. 2016 , 39, 668-76		71
1633	Biochemistry of Statins. 2016 , 73, 127-68		16
1632	Association of Lipoproteins, Insulin Resistance, and Rosuvastatin With Incident Type 2 Diabetes Mellitus : Secondary Analysis of a Randomized Clinical Trial. 2016 , 1, 136-45		38
1631	Evaluation of Statin Treatment for Nonalcoholic Fatty Liver Disease. 2016 , 32, 169-173		5
1630	Current and future trends in the lipid lowering therapy. 2016 , 68, 737-47		16
1629	The contemporary management of intracranial atherosclerotic disease. 2016 , 16, 701-9		2
1628	Lower might be better - It matters how you get there, and in whom. 2016 , 37, 1380-3		8
1627	"State-of-Art" paper of the Italian Working Group on Atherosclerosis: Preclinical assessment of early coronary atherosclerosis. 2016 , 214, 442-7		10
1626	Extrahepatic Manifestations of Nonalcoholic Fatty Liver Disease. 2016 , 15, 75-85		71
1625	Hypertension Is a Key Feature of the Metabolic Syndrome in Subjects Aging with HIV. 2016 , 18, 46		28
1624	Accuracy of the Atherosclerotic Cardiovascular Risk Equation in a Large Contemporary, Multiethnic Population. <i>Journal of the American College of Cardiology</i> , 2016 , 67, 2118-2130	15.1	165
1623	The Critical Importance of Risk Score Calibration: Time for Transformative Approach to Risk Score Validation?. <i>Journal of the American College of Cardiology</i> , 2016 , 67, 2131-2134	15.1	12
1622	A Call to Action in Changing Times. <i>Journal of the American College of Cardiology</i> , 2016 , 67, 2183-2185	15.1	1
1621	Coronary Artery Calcium and Shared Decision Making. 2016 , 9, 637-9		3

1620	Lifestyle management to prevent and treat atrial fibrillation. 2016 , 14, 799-809	17
1619	Association Between Use of Lipid-Lowering Therapy and Cardiovascular Diseases and Death in Individuals With Type 1 Diabetes. 2016 , 39, 996-1003	33
1618	Statin Utilization and Recommendations Among HIV- and HCV-infected Veterans: A Cohort Study. 2016 , 63, 407-13	36
1617	Effects of K-877, a novel selective PPAR α modulator (SPPARM α) in dyslipidaemic patients: A randomized, double blind, active- and placebo-controlled, phase 2 trial. 2016 , 249, 36-43	106
1616	Pleiotropic effects of statins: new therapeutic targets in drug design. 2016 , 389, 695-712	103
1615	Fat composition of vegetable oil spreads and margarines in the USA in 2013: a national marketplace analysis. 2016 , 67, 372-82	12
1614	Changes in cardiovascular risk factors after 5 years of implementation of a population-based program to reduce cardiovascular disease: The Heart of New Ulm Project. 2016 , 175, 66-76	15
1613	Residual Ischemic Risk and Its Determinants in Patients With Previous Myocardial Infarction and Without Prior Stroke or TIA: Insights From the REACH Registry. 2016 , 39, 670-677	29
1612	Efficacy of alirocumab in high cardiovascular risk populations with or without heterozygous familial hypercholesterolemia: Pooled analysis of eight ODYSSEY Phase 3 clinical program trials. 2016 , 223, 750-757	48
1611	Assessing Cardiovascular Risk to Guide Hypertension Diagnosis and Treatment. 2016 , 1, 864-871	20
1610	Diabetes, diabetes severity, and coronary heart disease risk equivalence: REasons for Geographic and Racial Differences in Stroke (REGARDS). 2016 , 181, 43-51	22
1609	Harder-to-Treat Patients: Recognizing Them and Adapting Treatment Strategies. 2016 , 118, 13A-8A	1
1608	Novel Therapies for Low-Density Lipoprotein Cholesterol Reduction. 2016 , 118, 19A-32A	7
1607	Atorvastatin and rosuvastatin improve physiological parameters and alleviate immune dysfunction in metabolic disorders. 2016 , 478, 1242-7	8
1606	Use of Frailty in Deciding Clinical Treatment Goals for Chronic Disease in Elderly Patients in the Community. 2016 , 17, 967-969	4
1605	Effect of extended-release niacin on plasma lipoprotein(a) levels: A systematic review and meta-analysis of randomized placebo-controlled trials. 2016 , 65, 1664-1678	45
1604	Comparative effectiveness of outpatient cardiovascular disease and diabetes care delivery between advanced practice providers and physician providers in primary care: Implications for care under the Affordable Care Act. 2016 , 181, 74-82	48
1603	Icosapent ethyl (eicosapentaenoic acid ethyl ester): Effects on remnant-like particle cholesterol from the MARINE and ANCHOR studies. 2016 , 253, 81-87	33

1602	Potential Clinical Impact of Abdominal Aortic Calcification on Bone Density Lateral Spine Images. 2016 , 19, 436-443	3
1601	Evidence-Based Perioperative Management of Cardiac Medications in Patients Presenting for Noncardiac Surgery. 2016 , 34, 161-180	1
1600	Risk Factor Optimization and Guideline-Directed Medical Therapy in US Veterans With Peripheral Arterial and Ischemic Cerebrovascular Disease Compared to Veterans With Coronary Heart Disease. 2016 , 118, 1144-1149	33
1599	Tratamiento de la diabetes mellitus (I). 2016 , 12, 1001-1012	0
1598	Synergistic and Non-synergistic Associations for Cigarette Smoking and Non-tobacco Risk Factors for Cardiovascular Disease Incidence in the Atherosclerosis Risk In Communities (ARIC) Study. 2017 , 19, 826-835	9
1597	Efficacy and safety of gemcabene as add-on to stable statin therapy in hypercholesterolemic patients. 2016 , 10, 1212-22	42
1596	Current treatment of heart failure with reduction of left ventricular ejection fraction. 2016 , 9, 1619-1631	5
1595	Clinical outcome of statin plus ezetimibe versus high-intensity statin therapy in patients with acute myocardial infarction propensity-score matching analysis. 2016 , 225, 50-59	12
1594	Reply: Lipid Measurements: Fasting or Nonfasting, Women or Men. <i>Journal of the American College of Cardiology</i> , 2016 , 68, 1710-1711	15.1
1593	Refining Statin Prescribing in Lower-Risk Individuals: Informing Risk/Benefit Decisions. <i>Journal of the American College of Cardiology</i> , 2016 , 68, 1690-1697	15.1 17
1592	Effects of low molecular weight procyanidin rich extract from french maritime pine bark on cardiovascular disease risk factors in stage-1 hypertensive subjects: Randomized, double-blind, crossover, placebo-controlled intervention trial. 2016 , 23, 1451-1461	35
1591	Managing cardiovascular risk in patients with inflammatory arthritis: practical considerations. 2016 , 8, 180-191	17
1590	Lipid effects of switching from prescription EPA+DHA (omega-3-acid ethyl esters) to prescription EPA only (icosapent ethyl) in dyslipidemic patients. 2016 , 128, 859-864	4
1589	Use of high-intensity statins for patients with atherosclerotic cardiovascular disease in the Veterans Affairs Health System: Practice impact of the new cholesterol guidelines. 2016 , 182, 97-102	34
1588	Finding the High-Risk Patient in Primary Prevention Is Not as Easy as a Conventional Risk Score!. 2016 , 129, 1329.e1-1329.e7	2
1587	The clinical relevance of omega-3 fatty acids in the management of hypertriglyceridemia. 2016 , 15, 118	91
1586	Statin non-adherence and residual cardiovascular risk: There is need for substantial improvement. 2016 , 225, 184-196	110
1585	Hypertriglyceridemia: the importance of identifying patients at risk. 2016 , 128, 848-858	27

1584	The Diagnosis and Management of Lipodystrophy Syndromes: A Multi-Society Practice Guideline. 2016 , 101, 4500-4511	205
1583	Cardiovascular Risk Reduction in Patients with Nonalcoholic Fatty Liver Disease: The Potential Role of Ezetimibe. 2016 , 61, 3425-3435	12
1582	Progressing Insights into the Role of Dietary Fats in the Prevention of Cardiovascular Disease. 2016 , 18, 111	43
1581	The Case For and Against a Coronary Artery Calcium Trial: Means, Motive, and Opportunity. 2016 , 9, 994-1002	20
1580	Statins worsen glycemic control of T2DM in target LDL-c level and LDL-c reduction dependent manners: a meta-analysis. 2016 , 17, 1839-49	18
1579	Therapeutic efficacy of PCSK9 monoclonal antibodies in statin-nonresponsive patients with hypercholesterolemia and dyslipidemia: A systematic review and meta-analysis. 2016 , 222, 119-129	19
1578	Cholesterol Guidelines: More Similar Than Different. 2016 , 59, 190-199	2
1577	The Risk of Hepatotoxicity, New Onset Diabetes and Rhabdomyolysis in the Era of High-Intensity Statin Therapy: Does Statin Type Matter?. 2016 , 59, 145-152	15
1576	Nonstatins and Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors: Role in Non-Familial Hypercholesterolemia. 2016 , 59, 165-171	9
1575	Prevalence and Factors Associated With Statin Use Among a Nationally Representative Sample of US Adults: National Health and Nutrition Examination Survey, 2011-2012. 2016 , 39, 491-6	34
1574	Prognosis of Patients With Familial Hypercholesterolemia After Acute Coronary Syndromes. 2016 , 134, 698-709	79
1573	Statin use after intracerebral hemorrhage: a 10-year nationwide cohort study. 2016 , 6, e00487	15
1572	Cost-Effectiveness of LDL-C Lowering With Evolocumab in Patients With High Cardiovascular Risk in the United States. 2016 , 39, 313-20	64
1571	Discussion around statin discontinuation in older adults and patients with wasting diseases. 2016 , 7, 396-9	31
1570	Association of the variants and haplotypes in the DOCK7, PCSK9 and GALNT2 genes and the risk of hyperlipidaemia. 2016 , 20, 243-65	18
1569	The very high cardiovascular risk in heterozygous familial hypercholesterolemia: Analysis of 734 French patients. 2016 , 10, 1129-1136.e3	18
1568	A Simple Disease-Guided Approach to Personalize ACC/AHA-Recommended Statin Allocation in Elderly People: The Biolmage Study. <i>Journal of the American College of Cardiology</i> , 2016 , 68, 881-91	15.1 72
1567	Risk Statins or Risk "Zero" on Atherosclerosis Imaging for Risk Stratification?. <i>Journal of the American College of Cardiology</i> , 2016 , 68, 892-4	15.1

1566	Meta-Analysis of 29 Experiments Evaluating the Effects of Rapamycin on Life Span in the Laboratory Mouse. 2017 , 72, 1024-1032	14
1565	Managing the lipid profile of coronary heart disease patients. 2016 , 14, 1263-1271	5
1564	Glycemic Control for Patients With Type 2 Diabetes Mellitus: Our Evolving Faith in the Face of Evidence. 2016 , 9, 504-12	88
1563	Ayurvedic herbal preparations for hypercholesterolaemia. 2016 ,	1
1562	Atherosclerotic Cardiovascular Disease and Anti-Retroviral Therapy. 2016 , 13, 297-308	15
1561	Non-HDL Cholesterol and Triglycerides: Implications for Coronary Atheroma Progression and Clinical Events. 2016 , 36, 2220-2228	86
1560	Identifying the progression of coronary artery disease: prediction of cardiac events. 2016 , 2, 105-114	4
1559	The Uncharted Frontier: Preventive Cardiology Between the Ages of 15 and 35 Years. 2016 , 10, 1	8
1558	Safety of atorvastatin in Asian patients within clinical trials. 2016 , 34, 431-440	14
1557	Triglyceride Treatment in the Age of Cholesterol Reduction. 2016 , 59, 107-118	9
1556	Lipid Guidelines: What's Best for My Patient?. 2016 , 4, 40-45	
1555	Evaluation of adherence to current guidelines for treatment of hyperlipidemia in adults in an outpatient setting. 2016 , 73, S133-S140	7
1554	Chronotherapy versus conventional statins therapy for the treatment of hyperlipidaemia. 2016 , 11, CD009462	11
1553	Statin use in patients with peripheral arterial disease. 2016 , 64, 1881-1888	33
1552	The Risk Continuum of Atherosclerosis and its Implications for Defining CHD by Coronary Angiography. <i>Journal of the American College of Cardiology</i> , 2016 , 68, 2467-2478	15.1 47
1551	Determining When to Add Nonstatin Therapy: A Quantitative Approach. <i>Journal of the American College of Cardiology</i> , 2016 , 68, 2412-2421	15.1 95
1550	Bringing Structure to the Art of Lipid-Lowering Therapy. <i>Journal of the American College of Cardiology</i> , 2016 , 68, 2422-2424	15.1 1
1549	Low-density lipoprotein cholesterol in a global cohort of 57,885 statin-treated patients. 2016 , 255, 200-209	66

1548	Biomarkers and degree of atherosclerosis are independently associated with incident atherosclerotic cardiovascular disease in a primary prevention cohort: The ARIC study. 2016 , 253, 156-163	9
1547	Pharmacogenomics of Rosuvastatin: A Glocal (Global+Local) African Perspective and Expert Review on a Statin Drug. 2016 , 20, 498-509	9
1546	Fusidic Acid Inhibits Hepatic Transporters and Metabolic Enzymes: Potential Cause of Clinical Drug-Drug Interaction Observed with Statin Coadministration. 2016 , 60, 5986-94	11
1545	Collective impact of conventional cardiovascular risk factors and coronary calcium score on clinical outcomes with or without statin therapy: The St Francis Heart Study. 2016 , 255, 193-199	19
1544	Efficacy and Safety of Alirocumab 150 mg Every 4 Weeks in Patients With Hypercholesterolemia Not on Statin Therapy: The ODYSSEY CHOICE II Study. 2016 , 5,	59
1543	PCSK9 Inhibitors: An Emerging Class of Medications. 2016 , 32, 201-209	78
1542	Polypills for the prevention of Cardiovascular diseases. 2016 , 25, 1255-1264	15
1541	Severity of statin-induced adverse effects on muscle and associated conditions: data from the DAMA study. 2016 , 15, 1583-1587	13
1540	2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). 2016 , 252, 207-274	341
1539	Cardiovascular Disease Risk Prediction in the HIV Outpatient Study. 2016 , 63, 1508-1516	75
1538	Practice-Level Variation in Statin Use Among Patients With Diabetes: Insights From the PINNACLE Registry. <i>Journal of the American College of Cardiology</i> , 2016 , 68, 1368-9	15.1 34
1537	Moving beyond regression techniques in cardiovascular risk prediction: applying machine learning to address analytic challenges. 2017 , 38, 1805-1814	166
1536	[Statin and cardiovascular diseases after 75 years]. 2016 , 37, 625-31	1
1535	Common medications used by patients with type 2 diabetes mellitus: what are their effects on the lipid profile?. 2016 , 15, 95	39
1534	Cardiovascular risk and treatment for adults with intellectual or developmental disabilities. 2016 , 221, 371-5	12
1533	The changes of individual carotid artery wall layer by aging and carotid intima-media thickness value for high risk. 2016 , 34, 397-403	9
1532	Remembering Statins: Do Statins Have Adverse Cognitive Effects?. 2016 , 39 Suppl 2, S253-9	19
1531	Underutilization of Statin Therapy Among Patients with NAFLD in the USA: Validation with Big Data. 2016 , 61, 2760	5

1530	Trends in Cardiovascular Health Metrics in Obese Adults: National Health and Nutrition Examination Survey (NHANES), 1988-2014. 2016 , 5,	21
1529	Mortality reduction in patients treated with long-term intensive lipid therapy: 25-year follow-up of the Familial Atherosclerosis Treatment Study-Observational Study. 2016 , 10, 1091-7	4
1528	Folic Acid Therapy Reduces the First Stroke Risk Associated With Hypercholesterolemia Among Hypertensive Patients. 2016 , 47, 2805-2812	51
1527	Rationale and design of the Progression of Atherosclerotic Plaque Determined by Computed Tomographic Angiography IMaging (PARADIGM) registry: A comprehensive exploration of plaque progression and its impact on clinical outcomes from a multicenter serial coronary computed tomographic angiography study. 2016 , 182, 72-79	49
1526	Amendment of the low-density lipoprotein cholesterol target in the 'Chinese Guidelines for the Prevention and Treatment of Adult Dyslipidemia': Opinion. 2016 , 2, 7-9	4
1525	Intensive statin therapy in India: Demonstrating efficacy and safety. 2016 , 68, 756-757	
1524	Consensus clinical recommendations for the management of plasma lipid disorders in the Middle East. 2016 , 225, 268-283	10
1523	Blood Pressure and Cholesterol-lowering Efficacy of a Fixed-dose Combination With Irbesartan and Atorvastatin in Patients With Hypertension and Hypercholesterolemia: A Randomized, Double-blind, Factorial, Multicenter Phase III Study. 2016 , 38, 2171-2184	15
1522	Rationale and design of the SLCO1B1 genotype guided statin therapy trial. 2016 , 17, 1873-1880	3
1521	Cardiovascular Safety of Evolocumab: a Systematic Review and Meta-Analysis. 2016 , 30, 645-646	1
1520	Statins for Prevention of Cardiovascular Disease in Adults: Evidence Report and Systematic Review for the US Preventive Services Task Force. 2016 , 316, 2008-2024	301
1519	Computed Tomography and Cardiac Magnetic Resonance in Ischemic Heart Disease. <i>Journal of the American College of Cardiology</i> , 2016 , 68, 2201-2216	15.1 32
1518	Increasing trend of diabetes combined with hypertension or hypercholesterolemia: NHANES data analysis 1999-2012. 2016 , 6, 36093	29
1517	Heterogeneity of therapeutic effects. 2016 , 255, 124-125	
1516	Reductions in Atherogenic Lipids and Major Cardiovascular Events: A Pooled Analysis of 10 ODYSSEY Trials Comparing Alirocumab With Control. 2016 , 134, 1931-1943	84
1515	Higher prevalence of elevated LDL-C than non-HDL-C and low statin treatment rate in elderly community-dwelling Chinese with high cardiovascular risk. 2016 , 6, 34268	5
1514	Rhabdomyolysis After Coadministration of Atorvastatin and Sacubitril/Valsartan (Entresto®) in a 63-Year-Old Woman. 2016 , 3, 14	8
1513	Current Consensus and Controversies in Guidelines for Lipid and Hypertension Management in Diabetes. 2016 , 18, 114	3

1512	Improving cardiovascular outcomes by intensifying low density lipoprotein lowering therapy in high-risk patients. 2016 , 37, 3585-3587	2
1511	Applying metabolomics to cardiometabolic intervention studies and trials: past experiences and a roadmap for the future. 2016 , 45, 1351-1371	15
1510	Protective Effects of Statins in Cancer: Should They Be Prescribed for High-Risk Patients?. 2016 , 18, 72	11
1509	Rationale and Design of the Standard Versus Intensive Statin Therapy for Hypercholesterolemic Patients with Diabetic Retinopathy (EMPATHY) Study: a Randomized Controlled Trial. 2016 , 23, 976-90	19
1508	Low-density lipoprotein cholesterol goals: still not in patients' best interest. 2016 , 21, 128-33	1
1507	Could androgens be relevant to partly explain why men have lower life expectancy than women?. 2016 , 70, 324-8	21
1506	Discontinuation and restarting in patients on statin treatment: prospective open cohort study using a primary care database. 2016 , 353, i3305	72
1505	Distribution of lifespan gain from primary prevention intervention. 2016 , 3, e000343	11
1504	China may hold answers to addressing cardiovascular disease epidemic. 2016 , 4, 11-13	3
1503	Decreasing prevalence of no known major risk factors for cardiovascular disease among Mississippi adults, Mississippi Behavioral Risk Factor Surveillance System, 2001 and 2009. 2016 , 16, 1220	
1502	Oral health and coronary heart disease. 2016 , 16, 122	17
1501	A randomized clinical trial evaluating a proprietary mixture of Lactobacillus plantarum strains for lowering cholesterol1. 2016 , 9, 125-135	16
1500	Guideline Recommended Medical Therapy for Cardiovascular Diseases in the Obese: Insights From the Veterans Affairs Clinical Assessment, Reporting, and Tracking (CART) Program. 2016 , 5,	4
1499	Type 1 diabetes & cardiovascular disease. 2016 , 41, 18-25	
1498	Creatine kinase in the U.S. population: Impact of demographics, comorbidities, and body composition on the normal range. 2016 , 95, e4344	34
1497	What to say and how to say it: effective communication for cardiovascular disease prevention. 2016 , 31, 537-44	13
1496	The effect of statin therapy on plaque regression following acute coronary syndrome: a meta-analysis of prospective trials. 2016 , 27, 636-649	11
1495	Elevated plasma migration inhibitory factor in hypertension-hyperlipidemia patients correlates with impaired endothelial function. 2016 , 95, e5207	7

1494	Adherence to statin therapy and the incidence of ischemic stroke in patients with diabetes. 2016 , 25, 161-9	24
1493	Simvastatin increases AQP2 urinary excretion in hypercholesterolemic patients: A pleiotropic effect of interest for patients with impaired AQP2 trafficking. 2016 , 99, 528-37	19
1492	Statin use and cardiovascular risk factors in diabetic patients developing a first myocardial infarction. 2016 , 15, 81	12
1491	Imaging Reveals the Connection Between Spontaneous Coronary Plaque Ruptures, Atherothrombosis, and Myocardial Infarctions in HypoE/SRBI-/- Mice. 2016 , 57, 1420-7	10
1490	Low Radiation Dose Calcium Scoring: Evidence and Techniques. 2016 , 9, 12	40
1489	Multivariable analysis of total cholesterol levels in male Swiss Armed Forces conscripts 2006-2012 (N = 174,872). 2016 , 16, 43	8
1488	Bezafibrate for the treatment of dyslipidemia in patients with coronary artery disease: 20-year mortality follow-up of the BIP randomized control trial. 2016 , 15, 11	21
1487	A scoping review of weight bias by community pharmacists towards people with obesity and mental illness. 2016 , 149, 226-35	5
1486	Primary Prevention of Atherosclerotic Cardiovascular Disease in Women. 2016 , 10, 1	15
1485	Switching statin-treated patients from fenofibrate to the prescription omega-3 therapy icosapent ethyl: a retrospective case series. 2016 , 32, 162-169	
1484	A US Claims-Based Analysis of Real-World Lipid-Lowering Treatment Patterns in Patients With High Cardiovascular Disease Risk or a Previous Coronary Event. 2016 , 117, 495-500	19
1483	The 10(th) Annual Cardiometabolic Health Congress General Session Highlights. 2016 , 128 Suppl 1, 1-10	1
1482	Changing Adjuvant Breast-Cancer Therapy with a Signal for Prevention. 2016 , 375, 274-5	1
1481	Variability of low-density lipoprotein cholesterol response with different doses of atorvastatin, rosuvastatin, and simvastatin: results from VOYAGER. 2016 , 2, 212-7	65
1480	Statins Associated With Decreased Risk of New Onset Inflammatory Bowel Disease. 2016 , 111, 1416-1423	35
1479	Lipid profile associated with coronary plaque regression in patients with acute coronary syndrome: Subanalysis of PRECISE-IVUS trial. 2016 , 251, 367-372	17
1478	LOWER, a registry of lomitapide-treated patients with homozygous familial hypercholesterolemia: Rationale and design. 2016 , 10, 273-82	27
1477	Fasting is not routinely required for determination of a lipid profile: clinical and laboratory implications including flagging at desirable concentration cut-points-a joint consensus statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Medicine. 2016 , 27, 1844-58	353

1476	Relation of Alanine Aminotransferase Levels to Cardiovascular Events and Statin Efficacy. 2016 , 118, 49-55	2
1475	Large high-density lipoprotein particle number is independently associated with microvascular function in patients with well-controlled low-density lipoprotein concentration: A vasodilator stress magnetic resonance perfusion study. 2016 , 10, 314-22	4
1474	Prevalencia de infarto de miocardio en un programa de riesgo cardiovascular de una instituci3n prestadora de salud en Armenia. 2016 , 23, 561-567	2
1473	The role of acid-base imbalance in statin-induced myotoxicity. 2016 , 174, 140-160.e14	22
1472	Development and Validation of Algorithms to Identify Statin Intolerance in a US Administrative Database. 2016 , 19, 852-860	10
1471	Acute kidney injury secondary to rhabdomyolysis in a nonagenarian patient taking statins. Lessons to be considered. 2016 , 36, 181-182	0
1470	Inflammatory/Hemostatic Biomarkers and Coronary Artery Calcium Progression in Women at Midlife (from the Study of Women's Health Across the Nation, Heart Study). 2016 , 118, 311-8	4
1469	[An updated overview of the high intensity lipid lowering therapy in high cardiovascular risk patients]. 2016 , 28, 19-30	2
1468	Perfil epidemiol3gico y prevenci3n secundaria en la primera visita del paciente claudicante a la consulta de angiolog3a y cirug3a vascular: estudio ESCUTEPAC. 2016 , 68, 276-284	
1467	Changes in carotid plaque tissue composition in subjects who continued and discontinued statin therapy. 2016 , 10, 587-93	7
1466	Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib in Japanese patients with heterozygous familial hypercholesterolemia. 2016 , 249, 215-23	8
1465	My Approach to the Patient With Familial Hypercholesterolemia. 2016 , 91, 770-86	22
1464	Unmet need in the hyperlipidaemia population with high risk of cardiovascular disease: a targeted literature review of observational studies. 2016 , 16, 74	18
1463	Use of imaging and clinical data to screen for cardiovascular disease in asymptomatic diabetics. 2016 , 15, 28	16
1462	Efficacy study of olmesartan medoxomil on coronary atherosclerosis progression and epicardial adipose tissue volume reduction in patients with coronary atherosclerosis detected by coronary computed tomography angiography: study protocol for a randomized controlled trial. 2016 , 17, 10	5
1461	Expert opinion: the therapeutic challenges faced by statin intolerance. 2016 , 17, 1497-507	40
1460	Previous Statin Use and High-Resolution Magnetic Resonance Imaging Characteristics of Intracranial Atherosclerotic Plaque: The Intensive Statin Treatment in Acute Ischemic Stroke Patients With Intracranial Atherosclerosis Study. 2016 , 47, 1789-96	23
1459	Making the Case for Universal Treatment of Hypercholesterolemia. 2016 , 118, 303-4	1

1458	Statin use and all-cancer survival: prospective results from the Women's Health Initiative. 2016 , 115, 129-35		64
1457	A framework for quantifying the influence of adherence and dose individualization. 2016 , 99, 452-9		8
1456	The molecular mechanism of the cholesterol-lowering effect of dill and kale: The influence of the food matrix components. 2016 , 37, 1805-13		10
1455	Skeletal muscle ultrastructure and function in statin-tolerant individuals. 2016 , 53, 242-51		13
1454	Gender Disparities in Lipid-Lowering Therapy in Cardiovascular Disease: Insights from a Managed Care Population. 2016 , 25, 697-706		15
1453	Long-Term Prognosis After Coronary Artery Calcium Scoring Among Low-Intermediate Risk Women and Men. 2016 , 9, e003742		47
1452	2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts): Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). 2016 , 23, NP1-NP96		445
1451	Cholesterol trials and mortality. 2016 , 82, 168-77		13
1450	PROVE-IT to IMPROVE-IT: Why LDL-C Goals Still Matter in Post-ACS Patients. <i>Journal of the American College of Cardiology</i> , 2016 , 67, 362-364	15.1	2
1449	Role of Coronary Artery Calcium Score of Zero and Other Negative Risk Markers for Cardiovascular Disease: The Multi-Ethnic Study of Atherosclerosis (MESA). 2016 , 133, 849-58		234
1448	Aspirin for the Primary Prevention of Cardiovascular Disease: In Need of Clarity. 2016 , 18, 4		13
1447	The ASCVD Risk Estimator App: From Concept to the Current State. <i>Journal of the American College of Cardiology</i> , 2016 , 67, 350-2	15.1	15
1446	Anatomy and physiology in ischaemic heart disease: a second honeymoon?. 2016 , 37, 1228-31		8
1445	Overcoming Challenges With Statin Therapy. 2016 , 5,		34
1444	Treatment with ETC-1002 alone and in combination with ezetimibe lowers LDL cholesterol in hypercholesterolemic patients with or without statin intolerance. 2016 , 10, 556-67		87
1443	2015 ACC/AHA Focused Update of Secondary Prevention Lipid Performance Measures: A Report of the American College of Cardiology/American Heart Association Task Force on Performance Measures. <i>Journal of the American College of Cardiology</i> , 2016 , 67, 558-87	15.1	40
1442	Men's Health in Primary Care. 2016 ,		1
1441	Comparative impact of implementing the 2013 or 2014 cholesterol guideline on vascular events in a quality improvement network. 2016 , 10, 56-66		

1440	Exercise capacity and biological age. 2016 , 102, 415	2
1439	The Role of Ezetimibe in the Treatment of Cardiovascular Disease. 2016 , 18, 8	3
1438	The 2013 ACC/AHA Cholesterol Treatment Guidelines: Applicability to Patients with Diabetes. 2016 , 16, 13	6
1437	Does IMPROVE-IT prove it?. 2016 , 85, 32-35	2
1436	Comparison of Adherence to Guideline-Based Cholesterol Treatment Goals in Men Versus Women. 2016 , 117, 48-53	16
1435	Stable Ischemic Heart Disease. 2016 , 12, 11-29	2
1434	Increased statin eligibility based on ACC/AHA versus NCEP guidelines for high cholesterol management in Chile. 2016 , 10, 192-8.e1	2
1433	Self-Rated Health Among Patients with Coronary Artery Disease Enrolled in a Cardiovascular Risk Reduction Service. 2016 , 19, 24-30	6
1432	History and future of omega-3 fatty acids in cardiovascular disease. 2016 , 32, 301-11	22
1431	Immune-mediated statin myopathy. 2016 , 12, 33-8	14
1430	No evidence to support high-intensity statin in Chinese patients with coronary heart disease. 2016 , 204, 57-8	15
1429	Statin therapy across the lifespan: evidence in major age groups. 2016 , 14, 341-66	11
1428	Defining the Role of PCSK9 Inhibitors in the Treatment of Hyperlipidemia. 2016 , 16, 83-92	6
1427	Health beliefs and desire to improve cholesterol levels among patients with hyperlipidemia. 2016 , 99, 830-5	5
1426	Trends in Risk Factors and Treatments in Patients With Stable Ischemic Heart Disease Seen at Cardiology Clinics Between 2006 and 2014. 2016 , 69, 401-7	4
1425	Should Statin Therapy Be Guided by Cardiovascular Risk Models?. 2016 , 129, 235-7	5
1424	Heart Failure Prevention: Special Considerations for Women. 2016 , 10, 1	
1423	Optimal serum cholesterol concentrations are associated with accelerated bone loss in African ancestry men. 2016 , 27, 1577-1584	6

1422	Drug-Induced Mitochondrial Toxicity. 2016 , 39, 661-74	38
1421	Assessment of statin therapy, LDL-C levels, and cardiovascular events among high-risk patients in the United States. 2016 , 10, 63-71.e1-3	8
1420	Improving the Monitoring and Care of Patients With Familial Hypercholesterolemia. <i>Journal of the American College of Cardiology</i> , 2016 , 67, 1286-8	15.1 6
1419	Influence of statins on distinct circulating microRNAs during prolonged aerobic exercise. 2016 , 120, 711-20	29
1418	[Pleurisy induced by atorvastatin]. 2016 , 33, 607-11	2
1417	Reduction of LDL-cholesterol: important at all ages. 2016 , 37, 1982-4	3
1416	CLINICAL PRACTICE. Peripheral Artery Disease. 2016 , 374, 861-71	149
1415	Counterpoint: Low-Density Lipoprotein Cholesterol Targets Are Not Needed in Lipid Treatment Guidelines. 2016 , 36, 586-90	14
1414	Emerging innovative therapeutic approaches targeting PCSK9 to lower lipids. 2016 , 99, 59-71	8
1413	Impact of Implementing the 2013 ACC/AHA Cholesterol Guidelines on Vascular Events in a Statewide Community-Based Practice Registry. 2016 , 18, 663-71	4
1412	LEADER 5: prevalence and cardiometabolic impact of obesity in cardiovascular high-risk patients with type 2 diabetes mellitus: baseline global data from the LEADER trial. 2016 , 15, 29	33
1411	Digital Mammography and Screening for Coronary Artery Disease. 2016 , 9, 350-60	62
1410	Statins and Cognitive Side Effects: What Cardiologists Need to Know. 2016 , 45, 101-16	6
1409	Genetic Testing in Hyperlipidemia. 2016 , 45, 129-40	3
1408	Niacin Alternatives for Dyslipidemia: Fool's Gold or Gold Mine? Part I: Alternative Niacin Regimens. 2016 , 18, 11	10
1407	Familial Hypercholesterolemia. 2016 , 45, 1-16	7
1406	Statins and Diabetes. 2016 , 45, 87-100	10
1405	A lipidologist perspective of global lipid guidelines and recommendations, part 2: Lipid treatment goals. 2016 , 10, 240-64	3

1404	Association between statin treatment and LDL-cholesterol levels on the rate of ST-elevation myocardial infarction among patients with acute coronary syndromes: ACS Israeli Survey (ACSIS) 2002-2010. 2016 , 210, 133-8		4
1403	Triglyceride-Rich Lipoproteins and Atherosclerotic Cardiovascular Disease: New Insights From Epidemiology, Genetics, and Biology. 2016 , 118, 547-63		433
1402	Guidelines for Management of Hyperlipidemia: Implications for Treatment of Patients with Stroke Secondary to Atherosclerotic Disease. 2016 , 16, 24		11
1401	Pathophysiology and management of cardiovascular disease in patients with HIV. 2016 , 4, 598-610		49
1400	Getting What the Guidelines Stated Matters. <i>Journal of the American College of Cardiology</i> , 2016 , 67, 119-20	15.1	
1399	Noninvasive Cardiovascular Risk Assessment of the Asymptomatic Diabetic Patient: The Imaging Council of the American College of Cardiology. 2016 , 9, 176-92		63
1398	Effect of glycemic and lipid achievements on clinical outcomes type 2 diabetic, Chinese patients with stable coronary artery disease. 2016 , 30, 115-20		6
1397	Protocol for analyses of adverse event data from randomized controlled trials of statin therapy. 2016 , 176, 63-9		20
1396	[Management of the cardiovascular disease risk during nilotinib treatment in chronic myeloid leukemia: 2015 recommendations from the France Intergroupe des Leucémies Myéloblastiques Chroniques]. 2016 , 103, 180-9		7
1395	Can the Reduction in Percent LDL Cholesterol or Attained LDL Cholesterol Levels or Both Add Incremental Prognostic Value?. 2016 , 129, 350-1		
1394	Antioxidant enzyme activity is associated with blood pressure and carotid intima media thickness in black men and women: The SABPA study. 2016 , 248, 91-6		8
1393	Peripheral Artery Disease: Evolving Role of Exercise, Medical Therapy, and Endovascular Options. <i>Journal of the American College of Cardiology</i> , 2016 , 67, 1338-57	15.1	103
1392	[Cardiovascular prevention in diabetes mellitus: A multifactorial challenge]. 2016 , 28, 154-63		2
1391	Serious Non-AIDS Events: Therapeutic Targets of Immune Activation and Chronic Inflammation in HIV Infection. 2016 , 76, 533-49		36
1390	Statin Use and Survival with Early-Stage Hepatocellular Carcinoma. 2016 , 25, 686-92		12
1389	Approach to Statin Use in 2016: an Update. 2016 , 18, 20		17
1388	Femoral and Carotid Subclinical Atherosclerosis Association With Risk Factors and Coronary Calcium: The AWHs Study. <i>Journal of the American College of Cardiology</i> , 2016 , 67, 1263-74	15.1	114
1387	Attainment of LDL-Cholesterol Treatment Goals in Patients With Familial Hypercholesterolemia: 5-Year SAFEHEART Registry Follow-Up. <i>Journal of the American College of Cardiology</i> , 2016 , 67, 1278-85	15.1	168

1386	Better lipid target achievement for secondary prevention through disease management programs for diabetes mellitus and coronary heart disease in clinical practice in Germany. 2016 , 32, 417-26		3
1385	Gender differences in statin prescription rates, adequacy of dosing, and association of statin therapy with outcome after heart failure hospitalization: a retrospective analysis in a community setting. 2016 , 72, 311-9		16
1384	Tendencias en factores de riesgo y tratamientos de pacientes con cardiopatía isquémica estable atendidos en consultas de cardiología entre 2006 y 2014. 2016 , 69, 401-407		47
1383	Percent reduction in LDL cholesterol following high-intensity statin therapy: potential implications for guidelines and for the prescription of emerging lipid-lowering agents. 2016 , 37, 1373-9		125
1382	Risk Stratification for Older Adults with Myocardial Infarction. 2016 , 10, 1		3
1381	Cardiovascular risk reduction: the future of cholesterol lowering drugs. 2016 , 27, 62-9		4
1380	Alirocumab: A Review in Hypercholesterolemia. 2016 , 16, 141-52		7
1379	Fasting or Nonfasting Lipid Measurements: It Depends on the Question. <i>Journal of the American College of Cardiology</i> , 2016 , 67, 1227-1234	15.1	43
1378	[The role of atherogenic dyslipidaemia in clinical practice guidelines]. 2016 , 28, 65-70		9
1377	National Lipid Association Annual Summary of Clinical Lipidology 2016. 2016 , 10, S1-43		74
1376	[Delphi consensus on management of dyslipidaemia in patients with impaired glucose metabolism: Diana study]. 2016 , 28, 132-40		3
1375	Metabolomic Profiling of Statin Use and Genetic Inhibition of HMG-CoA Reductase. <i>Journal of the American College of Cardiology</i> , 2016 , 67, 1200-1210	15.1	106
1374	Lipids and Diabetic Retinopathy. 2016 , 31, 10-8		12
1373	Improving cardiovascular protection: focus on a cardiovascular polypill. 2016 , 12, 181-96		6
1372	Considerations in Applying the Results of Randomized Controlled Clinical Trials to the Care of Older Adults With Kidney Disease in the Clinical Setting: The SHARP Trial. 2016 , 23, 29-35		1
1371	Prediction of Cardiovascular Disease Risk by Cardiac Biomarkers in 2 United Kingdom Cohort Studies: Does Utility Depend on Risk Thresholds For Treatment?. 2016 , 67, 309-15		23
1370	Statin use, intensity, and 3-year clinical outcomes among older patients with coronary artery disease. 2016 , 173, 27-34		15
1369	Lipids and bariatric procedures part 1 of 2: Scientific statement from the National Lipid Association, American Society for Metabolic and Bariatric Surgery, and Obesity Medicine Association: FULL REPORT. 2016 , 10, 33-57		24

1368	Utility of Nontraditional Risk Markers in Atherosclerotic Cardiovascular Disease Risk Assessment. <i>Journal of the American College of Cardiology</i> , 2016 , 67, 139-147	15.1	161
1367	Predictive Models of Atherosclerotic Cardiovascular Disease: In Search of the Philosopher's Stone of Cardiology. <i>Journal of the American College of Cardiology</i> , 2016 , 67, 148-150	15.1	3
1366	Short-term cessation of statin therapy does not alter aerobic exercise performance in physically active middle-aged adults. 2016 , 44, 63-7		5
1365	Serum paraoxonase-1 activity and risk of incident cardiovascular disease: The PREVENT study and meta-analysis of prospective population studies. 2016 , 245, 143-54		59
1364	Lipids and bariatric procedures part 1 of 2: Scientific statement from the National Lipid Association, American Society for Metabolic and Bariatric Surgery, and Obesity Medicine Association: EXECUTIVE SUMMARY. 2016 , 10, 15-32		13
1363	Comparison of different statin therapy to change low-density lipoprotein cholesterol and high-density lipoprotein cholesterol level in Korean patients with and without diabetes. 2016 , 10, 528-537.e3		10
1362	Intensive LDL lowering therapy for prevention of recurrent cardiovascular events: a word of caution. 2016 , 37, 520-3		4
1361	Contribution of vitamin D deficiency to the risk of coronary heart disease in subjects with essential hypertension. 2016 , 244, 165-71		15
1360	Clinical implications of the IMPROVE-IT trial in the light of current and future lipid-lowering treatment options. 2016 , 17, 369-80		35
1359	A Comparison of Statin Therapies in Hypercholesterolemia in Women: A Subgroup Analysis of the STELLAR Study. 2016 , 25, 50-6		4
1358	Using Classification and Regression Trees (CART) to Identify Prescribing Thresholds for Cardiovascular Disease. 2016 , 34, 195-205		16
1357	Doses of rosuvastatin, atorvastatin and simvastatin that induce equal reductions in LDL-C and non-HDL-C: Results from the VOYAGER meta-analysis. 2016 , 23, 744-7		28
1356	Temporal trends in the utilisation of preventive medicines by older people: A 9-year population-based study. 2016 , 62, 103-11		13
1355	Coronary calcium scans and radiation exposure in the multi-ethnic study of atherosclerosis. 2016 , 32, 525-9		37
1354	Relations of Postload and Fasting Glucose With Incident Cardiovascular Disease and Mortality Late in Life: The Cardiovascular Health Study. 2016 , 71, 370-7		6
1353	Current treatment of hypertension in patients with coronary artery disease recommended by different guidelines. 2016 , 17, 205-15		1
1352	Efecto de las resinas secuestradoras de ácidos biliares en los desenlaces cardiovasculares y en los niveles séricos de lípidos. 2016 , 23, 35-41		
1351	Approach to diabetes management in patients with CVD. 2016 , 26, 165-79		28

1350	High-dose statin therapy with rosuvastatin reduces small dense LDL and MDA-LDL: The Standard versus high-dose therapy with Rosuvastatin for lipid lowering (SARD) trial. 2016 , 67, 340-6	20
1349	The beneficial effects of raising high-density lipoprotein cholesterol depends upon achieved levels of low-density lipoprotein cholesterol during statin therapy: Implications for coronary atheroma progression and cardiovascular events. 2016 , 23, 474-85	8
1348	Guideline Confusion for the Clinician. 2016 , 67, 5-9	4
1347	Implementation of a Student Pharmacist-Run Targeted Medication Intervention Program. 2017 , 30, 109-114	4
1346	Towards theory integration: Threshold model as a link between signal detection theory, fast-and-frugal trees and evidence accumulation theory. 2017 , 23, 49-65	13
1345	Determining optimal threshold for statins prescribing: individualization of statins treatment for primary prevention of cardiovascular disease. 2017 , 23, 241-250	4
1344	Risk stratification for large artery or chronic coronary artery disease-related ischemic stroke in octogenarians undergoing exercise stress myocardial perfusion imaging: A cohort study. 2017 , 24, 591-595	0
1343	Safety and Effectiveness of Statins for Prevention of Recurrent Myocardial Infarction in 12 156 Typical Older Patients: A Quasi-Experimental Study. 2017 , 72, 243-250	13
1342	Treatment of Hypercholesterolemia in 2015. 2017 , 24, e121-e129	2
1341	Cost-effectiveness of the polypill versus risk assessment for prevention of cardiovascular disease. 2017 , 103, 483-491	7
1340	Changes in cardiovascular medication after coronary artery calcium scanning and normal single photon emission computed tomography myocardial perfusion imaging in symptomatic patients. 2017 , 186, 56-62	2
1339	Clinical implications of the American College of Cardiology/American Heart Association guidelines for the treatment of blood cholesterol for a rural community: Data from the Heart of New Ulm Project. 2017 , 11, 94-101	3
1338	Asociación de la presencia de placa carotídea en la aparición de eventos cardiovasculares en pacientes con hipercolesterolemias genéticas. 2017 , 70, 551-558	7
1337	Gender related differences in treatment and response to statins in primary and secondary cardiovascular prevention: The never-ending debate. 2017 , 117, 148-155	33
1336	Influence of Statins and Cholesterol on Mortality Among Patients With Pancreatic Cancer. 2017 , 109,	33
1335	Monte Carlo decision curve analysis using aggregate data. 2017 , 47, 176-183	1
1334	Value of the Definition of Severe Familial Hypercholesterolemia for Stratification of Heterozygous Patients. 2017 , 119, 742-748	14
1333	Proportion of adults fasting for lipid testing relative to guideline changes in Alberta. 2017 , 50, 344-346	1

1332	Physician attitudes toward participating in a financial incentive program for LDL reduction are associated with patient outcomes. 2017 , 5, 119-124	3
1331	Intensive statin regimens for reducing risk of cardiovascular diseases among human immunodeficiency virus-infected population: A nation-wide longitudinal cohort study 2000-2011. 2017 , 230, 592-598	8
1330	Effect of aerobic exercise on the atherogenic index of plasma in middle-aged Chinese men with various body weights. 2017 , 230, 1-5	11
1329	Treatment of Dyslipidemias to Prevent Cardiovascular Disease in Patients with Type 2 Diabetes. 2017 , 19, 7	36
1328	Oral antiplatelet agents for the management of acute coronary syndromes: A review for nurses and allied healthcare professionals. 2017 , 29, 104-115	1
1327	Is There an Ideal Low-Density Lipoprotein Cholesterol Level? Confusion regarding Lipid Guidelines, Low-Density Lipoprotein Cholesterol Targets, and Medical Management. 2017 , 26, 73-77	4
1326	Efficacy, safety, Low density lipoprotein cholesterol lowering, and calculated 10-year cardiovascular risk reduction of alirocumab and evolocumab in addition to maximal tolerated cholesterol lowering therapy: a post-commercialization study. 2017 , 16, 19	6
1325	Risk of cardiovascular disease morbidity and mortality in frail and pre-frail older adults: Results from a meta-analysis and exploratory meta-regression analysis. 2017 , 35, 63-73	112
1324	Prescription omega-3 fatty acid products containing highly purified eicosapentaenoic acid (EPA). 2017 , 16, 23	44
1323	Statins and primary prevention of venous thromboembolism: a systematic review and meta-analysis. 2017 , 4, e83-e93	59
1322	An evaluation of the completeness of drug-drug interaction-related information in package inserts. 2017 , 73, 165-174	2
1321	Impact of coronary heart disease on cognitive decline in Alzheimer's disease: a prospective longitudinal cohort study in primary care. 2017 , 67, e111-e117	20
1320	Prevention and management of glucocorticoid-induced side effects: A comprehensive review: Ocular, cardiovascular, muscular, and psychiatric side effects and issues unique to pediatric patients. 2017 , 76, 201-207	43
1319	Medicare Formulary Changes After the 2013 American College of Cardiology/American Heart Association Cholesterol Guideline. <i>Journal of the American College of Cardiology</i> , 2017 , 69, 244-246	15.1 2
1318	Comprehensive efforts to increase adherence to statin therapy. 2017 , 38, 2473-2479	29
1317	Predictors of Nonuse of a High-Potency Statin After an Acute Coronary Syndrome: Insights From the Stabilization of Plaques Using Darapladib-Thrombolysis in Myocardial Infarction 52 (SOLID-TIMI 52) Trial. 2017 , 6,	5
1316	Atherosclerosis. 2017 , 35-45	1
1315	Hyperlipidaemia alone and in combination with acidosis can increase the incidence and severity of statin-induced myotoxicity. 2017 , 100, 163-175	6

1314	Pitavastatin: A Review in Hypercholesterolemia. 2017 , 17, 157-168	17
1313	Is there a role for coronary artery calcification scoring in primary prevention of cerebrovascular disease?. 2017 , 257, 279-287	4
1312	Comments on the 2016 ESC/EAS Guidelines for the Management of Dyslipidemias. 2017 , 70, 72-77	3
1311	Evidence-based goals in LDL-C reduction. 2017 , 106, 237-248	55
1310	Cardiovascular Health Disparities in Underserved Populations. 2017 , 44, e37-e71	17
1309	Assessing Cardiovascular Risk and Testing in Type 2 Diabetes. 2017 , 19, 19	12
1308	. 2017 , 72, 39-49	0
1307	Primary prevention of cardiovascular disease: A review of contemporary guidance and literature. 2017 , 6, 2048004016687211	152
1306	Discordance between Circulating Atherogenic Cholesterol Mass and Lipoprotein Particle Concentration in Relation to Future Coronary Events in Women. 2017 , 63, 870-879	47
1305	Favorable cardiovascular risk factor profile is associated with lower healthcare expenditure and resource utilization among adults with diabetes mellitus free of established cardiovascular disease: 2012 Medical Expenditure Panel Survey (MEPS). 2017 , 258, 79-83	5
1304	Multi-modality imaging: Bird's eye view from the 2016 American Heart Association Scientific Sessions. 2017 , 24, 946-951	3
1303	Apolipoprotein B vs non-high-density lipoprotein cholesterol: Association with endothelial hemostatic markers and carotid intima-media thickness. 2017 , 11, 442-449	1
1302	Comentarios a la guía ESC/EAS 2016 sobre el tratamiento de las dislipemias. 2017 , 70, 72-77	8
1301	Decade-long temporal trends in the utilization of preventive medicines by centenarians. 2017 , 42, 165-169	3
1300	Serum Uromodulin and Mortality Risk in Patients Undergoing Coronary Angiography. 2017 , 28, 2201-2210	51
1299	Blood cholesterol in late-life and cognitive decline: a longitudinal study of the Chinese elderly. 2017 , 12, 24	53
1298	Using lower cost statins improves outcomes for normal cholesterol non-diabetic patients. 2017 , 17, 495-501	1
1297	Impact of Pharmacist Intervention to Increase Compliance With Guideline-Directed Statin Therapy During an Acute Coronary Syndrome Hospitalization. 2017 , 51, 394-400	3

1296	Clinical indications for coronary artery calcium scoring in asymptomatic patients: Expert consensus statement from the Society of Cardiovascular Computed Tomography. 2017 , 11, 157-168	159
1295	Statin use and all-cause and cancer mortality: BioBank Japan cohort. 2017 , 27, S84-S91	19
1294	A quality by design approach for the development of lyophilized liposomes with simvastatin. 2017 , 25, 981-992	20
1293	Acupuncture and Lifestyle Modification Treatment for Obesity: A Meta-Analysis. 2017 , 45, 239-254	25
1292	Late effects of blood and marrow transplantation. 2017 , 102, 614-625	90
1291	Adoption of the 2013 American College of Cardiology/American Heart Association Cholesterol Management Guideline in Cardiology Practices Nationwide. 2017 , 2, 361-369	64
1290	Trends in the Use of Moderate-Intensity to High-Intensity Statin and Nonstatin Lipid-Lowering Therapy: Turning Off the Faucet Is Much More Valuable Than Mopping Up the Floor. 2017 , 2, 355-356	4
1289	From the Editor: New guidelines are coming. 2017 , 11, 1-2	1
1288	2017 Taiwan lipid guidelines for high risk patients. 2017 , 116, 217-248	87
1287	New onset diabetes mellitus induced by statins: current evidence. 2017 , 129, 430-435	25
1286	Analysis and comparison of the cost-effectiveness of statins according to the baseline low-density lipoprotein cholesterol level in Korea. 2017 , 42, 292-300	5
1285	Can Functional Testing for Ischemia and Viability Guide Revascularization?. 2017 , 10, 354-364	13
1284	Coronary artery calcium score as a predictor for incident stroke: Systematic review and meta-analysis. 2017 , 236, 473-477	23
1283	Claimed effects, outcome variables and methods of measurement for health claims proposed under European Community Regulation 1924/2006 in the framework of protection against oxidative damage and cardiovascular health. 2017 , 27, 473-503	24
1282	Plasma levels of vasostatin-1, a chromogranin A fragment, are associated with carotid artery maximum stenosis: A pilot study. 2017 , 236, 438-443	6
1281	Statin Therapy Reduces Future Risk of Lower-Limb Amputation in Patients With Diabetes and Peripheral Artery Disease. 2017 , 102, 2373-2381	43
1280	Association between neighbourhood walkability and metabolic risk factors influenced by physical activity: a cross-sectional study of adults in Toronto, Canada. 2017 , 7, e013889	28
1279	Medical management of acute coronary syndromes. 2017 , 29, 224-235	1

1278	Epidemiology in diabetes mellitus and cardiovascular disease. 2017 , 6, 8-16	52
1277	Effect of 2013 ACC/AHA Blood Cholesterol Guidelines on Statin Treatment Patterns and Low-Density Lipoprotein Cholesterol in Atherosclerotic Cardiovascular Disease Patients. 2017 , 6,	36
1276	Statin Eligibility and Outpatient Care Prior to ST-Segment Elevation Myocardial Infarction. 2017 , 6,	6
1275	PCSK9 as a therapeutic target for cardiovascular disease. 2017 , 13, 810-814	9
1274	Membrane lipid alterations in the metabolic syndrome and the role of dietary oils. 2017 , 1859, 1690-1703	47
1273	Modifiable Risk Factors Versus Age on Developing High Predicted Cardiovascular Disease Risk in Blacks. 2017 , 6,	5
1272	To Fast or Not to Fast?: Comments on the Consensus Statement From the European Atherosclerosis Society/European Federation of Clinical Chemistry and Laboratory Medicine. 2017 , 141, 487-489	4
1271	Genetics of Dyslipidemia and Ischemic Heart Disease. 2017 , 19, 46	13
1270	Liver Transplantation: the Role of Metabolic Syndrome. 2017 , 15, 316-331	4
1269	Statin use and other factors associated with mortality after major lower extremity amputation. 2017 , 66, 216-225	19
1268	Low-density lipoprotein cholesterol targeting with pitavastatin + ezetimibe for patients with acute coronary syndrome and dyslipidaemia: the HIJ-PROPER study, a prospective, open-label, randomized trial. 2017 , 38, 2264-2276	62
1267	Innovations in Population Health Surveillance: Using Electronic Health Records for Chronic Disease Surveillance. 2017 , 107, 853-857	30
1266	Applicability of the IMPROVE-IT Trial to Current Patients With Acute Coronary Syndrome: An NCDR Research to Practice Project. 2017 , 177, 887-889	6
1265	Management of Patients with Coronary Disease and Cancer: Interactions Between Cancer, Cancer Treatment, and Ischemia. 2017 , 175-214	
1264	Contemporary Approaches to Patients with Heart Failure. 2017 , 35, 261-271	15
1263	Alirocumab for the treatment of hypercholesterolaemia. 2017 , 10, 571-582	6
1262	Cardiac Imaging in the Diagnosis of Coronary Artery Disease. 2017 , 42, 316-366	23
1261	Early, intensive statin treatment reduces 'hard' cardiovascular outcomes after acute coronary syndrome. 2017 , 24, 1294-1296	22

1260	Comparison of validation and application on various cardiovascular disease mortality risk prediction models in Chinese rural population. 2017 , 7, 43227	4
1259	Prevalence of Elevated Cardiovascular Risks in Young Adults: A Cross-sectional Analysis of National Health and Nutrition Examination Surveys. 2017 , 166, 876-882	11
1258	Using Predicted Cardiovascular Disease Risk in Conjunction With Blood Pressure to Guide Antihypertensive Medication Treatment. <i>Journal of the American College of Cardiology</i> , 2017 , 69, 2446-2456	45
1257	Initiation Patterns of Statins in the 2 Years After Release of the 2013 American College of Cardiology/American Heart Association (ACC/AHA) Cholesterol Management Guideline in a Large US Health Plan. 2017 , 6,	17
1256	Do triglyceride-lowering drugs decrease risk of cardiovascular disease?. 2017 , 28, 374-379	9
1255	Cardiovascular health in an aging HIV population. 2017 , 31 Suppl 2, S157-S163	17
1254	Novel regulators of plasma lipid levels. 2017 , 28, 231-240	7
1253	CE: Triglycerides: Do They Matter?. 2017 , 117, 24-31	4
1252	Clinical Outcomes in Trials Evaluating Lipid-Lowering Drugs. 2017 , 17, 447-452	2
1251	Effect of alirocumab dose increase on LDL-lowering and lipid goal attainment: is treatment to goal the way to go?. 2017 , 28, 186-187	
1250	Role of Nonstatin Therapies for Low-Density Lipoprotein Cholesterol Lowering in Management of Atherosclerotic Cardiovascular Disease Risk. 2017 , 2, 218-219	1
1249	Metabolic outcomes of bergamot polyphenolic fraction administration in patients treated with second-generation antipsychotics: a pilot study. 2017 , 40, 32-35	9
1248	Discontinuation of Statins at the End of Life #322. 2017 , 20, 199-200	4
1247	Lipophilic Statins and the Risk of Intracranial Hemorrhage Following Ischemic Stroke: A Population-Based Study. 2017 , 40, 887-893	9
1246	Moderator's view: Predictive models: a prelude to precision nephrology. 2017 , 32, 756-758	3
1245	Differential and Joint Effects of Metformin and Statins on Overall Survival of Elderly Patients with Pancreatic Adenocarcinoma: A Large Population-Based Study. 2017 , 26, 1225-1232	20
1244	Evidence for more intensive cholesterol lowering. 2017 , 28, 291-299	11
1243	Pharmacist-to-prescriber intervention to close therapeutic gaps for statin use in patients with diabetes: A randomized controlled trial. 2017 , 57, S236-S242.e1	18

1242	Efficacy of Berberine Alone and in Combination for the Treatment of Hyperlipidemia: A Systematic Review. 2017 , 22, 956-968	17
1241	Society for Vascular Nursing-Carotid endarterectomy (CEA) updated nursing clinical practice guideline. 2017 , 35, 90-111	3
1240	Effect of Statin Treatment vs Usual Care on Primary Cardiovascular Prevention Among Older Adults: The ALLHAT-LLT Randomized Clinical Trial. 2017 , 177, 955-965	88
1239	Statin prescription strategies and atherogenic cholesterol goals attainment in Lebanese coronary artery disease patients. 2017 , 39, 919-926	2
1238	Cardiovascular Risk Stratification in Patients with Metabolic Syndrome Without Diabetes or Cardiovascular Disease: Usefulness of Metabolic Syndrome Severity Score. 2017 , 24, 297-303	7
1237	PCSK9 Inhibitors Show Value for Patients and the US Health Care System. 2017 , 20, 1270-1278	4
1236	Television viewing time among statin users and non-users. The Polish Norwegian Study (PONS). 2017 , 7, 106-109	
1235	Still a reasonable goal: Targeting cholesterol in dialysis and advanced chronic kidney disease patients. 2017 , 30, 390-394	9
1234	Translating Guidelines Into Practice: Interpreting the 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk. 2017 , 51, 914-920	3
1233	Statin Prescribing Practices in the Comprehensive Care for HIV-Infected Patients. 2017 , 76, e26-e29	15
1232	Familial hypercholesterolemia in a European Mediterranean population-Prevalence and clinical data from 2.5 million primary care patients. 2017 , 11, 1013-1022	41
1231	Pharmacologic approaches for the management of patients with moderately elevated triglycerides (150-499 mg/dL). 2017 , 11, 872-879	7
1230	Statin treatment is associated with survival in a nationally representative population of elderly women with epithelial ovarian cancer. 2017 , 146, 340-345	21
1229	Trends in prescribing rate of statins at discharge and modifiable factors in patients with atherosclerotic cardiovascular disease. 2017 , 12, 1121-1129	6
1228	Who Benefits From Implantable Cardioverter-Defibrillators?: Integrating Absolute, Proportional, and Competing Risk. <i>Journal of the American College of Cardiology</i> , 2017 , 69, 2619-2621	15.1 2
1227	Triglycerides Revisited to the Serial. 2017 , 80, 1-44	3
1226	JCL roundtable: Future of the lipid laboratory: Using the laboratory to manage the patient (part 2). 2017 , 11, 846-854	1
1225	Coenzyme Q10 supplementation in the management of statin-associated myalgia. 2017 , 74, 786-793	7

1224	Use of Repeated Blood Pressure and Cholesterol Measurements to Improve Cardiovascular Disease Risk Prediction: An Individual-Participant-Data Meta-Analysis. 2017 , 186, 899-907		24
1223	Considerations and controversies in managing chronic kidney disease: An update. 2017 , 74, 795-810		6
1222	Geographic variation and risk factors for systemic and limb ischemic events in patients with symptomatic peripheral artery disease: Insights from the REACH Registry. 2017 , 40, 710-718		21
1221	A Deficiency of Nutrition Education and Practice in Cardiology. 2017 , 130, 1298-1305		48
1220	Trends in Use of High-Intensity Statin Therapy After Myocardial Infarction, 2011 to 2014. <i>Journal of the American College of Cardiology</i> , 2017 , 69, 2696-2706	15.1	53
1219	Statins in Secondary Prevention: Intensity Matters. <i>Journal of the American College of Cardiology</i> , 2017 , 69, 2707-2709	15.1	4
1218	Race-Sex Differences in Statin Use and Low-Density Lipoprotein Cholesterol Control Among People With Diabetes Mellitus in the Reasons for Geographic and Racial Differences in Stroke Study. 2017 , 6,		36
1217	The differences in the incidence of diabetes mellitus and prediabetes according to the type of HMG-CoA reductase inhibitors prescribed in Korean patients. 2017 , 26, 1156-1163		8
1216	Cardiorespiratory Fitness and Incidence of Type 2 Diabetes in United States Veterans on Statin Therapy. 2017 , 130, 1192-1198		17
1215	Effectiveness of Lipid-Lowering Statin Therapy in Patients With and Without Psoriasis. 2017 , 37, 775-785		8
1214	Non-high-density lipoprotein fractions are strongly associated with the presence of metabolic syndrome independent of obesity and diabetes: a population-based study among Iranian adults. 2017 , 16, 25		10
1213	Traditional Chinese Medicine for Cardiovascular Disease: Evidence and Potential Mechanisms. <i>Journal of the American College of Cardiology</i> , 2017 , 69, 2952-2966	15.1	206
1212	Thyroid Function, Cardiovascular Risk Factors, and Incident Atherosclerotic Cardiovascular Disease: The Atherosclerosis Risk in Communities (ARIC) Study. 2017 , 102, 3306-3315		35
1211	Treatment of Heart Failure with Abnormal Left Ventricular Systolic Function in Older Adults. 2017 , 13, 467-483		2
1210	Managing Cardiovascular Disease Risk in Rheumatoid Arthritis: Clinical Updates and Three Strategic Approaches. 2017 , 19, 16		21
1209	Alcohol Intake More than Doubles the Risk of Early Cardiovascular Events in Young Hypertensive Smokers. 2017 , 130, 967-974.e1		6
1208	Identification of vascular patients at very high risk for recurrent cardiovascular events: validation of the current ACC/AHA very high risk criteria. 2017 , 38, 3211-3218		23
1207	Statins and secondary prevention of venous thromboembolism: pooled analysis of published observational cohort studies. 2017 , 38, 1608-1612		38

1206	Statins may facilitate Parkinson's disease: Insight gained from a large, national claims database. 2017, 32, 913-917	48
1205	JCL roundtable: Cardiovascular disease risk reduction in menopausal women. 2017, 11, 316-324	0
1204	What's a Malignant Family History?: You'll Know It When You See It. 2017, 10, 1136-1138	1
1203	Planning a Research Agenda to Incorporate Imaging Into Clinical Practice. 2017, 10, 1039-1041	1
1202	Fixing the Prevention Gap Using Imaging-Guided Risk Estimates. 2017, 10, 214-216	2
1201	Evidence-based review of statin use in patients with HIV on antiretroviral therapy. 2017, 8, 6-14	23
1200	Cardiovascular risk factors burden in Saudi Arabia: The Africa Middle East Cardiovascular Epidemiological (ACE) study. 2017, 29, 235-243	44
1199	Extensive carotid atherosclerosis and the diagnostic accuracy of coronary risk calculators. 2017, 6, 182-186	14
1198	Consecuci3n de objetivos terap#uticos de colesterol LDL en ni#os y adolescentes con hipercolesterolemia familiar. Registro longitudinal SAFEHEART. 2017, 70, 444-450	32
1197	How to measure the net benefit of treatment?. 2017, 72, 51-61	2
1196	PCSK9 inhibitor access barriers-issues and recommendations: Improving the access process for patients, clinicians and payers. 2017, 40, 243-254	52
1195	Quantifying glucose and lipid components in human serum by Raman spectroscopy and multivariate statistics. 2017, 32, 787-795	27
1194	Association Between the Presence of Carotid Artery Plaque and Cardiovascular Events in Patients With Genetic Hypercholesterolemia. 2017, 70, 551-558	4
1193	Cholesterol levels of Japanese dyslipidaemic patients with various comorbidities: BioBank Japan. 2017, 27, S77-S83	2
1192	Association of very Low-density Lipoprotein Cholesterol with All-cause and Cardiovascular Mortality in Peritoneal Dialysis. 2017, 42, 52-61	11
1191	Seeking 'meta guidelines' for lipids. 2017, 24, 72-75	1
1190	Markov Decision Processes for Screening and Treatment of Chronic Diseases. 2017, 189-222	22
1189	Educational intervention to improve effectiveness in treatment and control of patients with high cardiovascular risk in low-resource settings in Argentina: study protocol of a cluster randomised controlled trial. 2017, 7, e014420	7

1188	TRIGLYCERIDES, ATHEROSCLEROSIS, AND CARDIOVASCULAR OUTCOME STUDIES: FOCUS ON OMEGA-3 FATTY ACIDS. 2017 , 23, 100-112		32
1187	Statins attenuate but do not eliminate the reverse epidemiology of total serum cholesterol in patients with non-ischemic chronic heart failure. 2017 , 238, 97-104		3
1186	Parental family history of dementia in relation to subclinical brain disease and dementia risk. 2017 , 88, 1642-1649		27
1185	Statin Intolerance and Risk of Coronary Heart Events and All-Cause Mortality Following Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2017 , 69, 1386-1395	15.1	173
1184	2016 AHA/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. <i>Journal of the American College of Cardiology</i> , 2017 , 69, e71-e126	15.1	301
1183	Nonobstructive Coronary Artery Disease by Coronary CT Angiography Improves Risk Stratification and Allocation of Statin Therapy. 2017 , 10, 1031-1038		20
1182	Can LDL cholesterol be too low? Possible risks of extremely low levels. 2017 , 281, 534-553		41
1181	Relation of Intensity of Statin Therapy and Outcomes After Transcatheter Aortic Valve Replacement. 2017 , 119, 1832-1838		17
1180	Prevalence and Determinants of the Use of Lipid-Lowering Agents in a Population of Older Hospitalized Patients: the Findings from the REPOSI (REgistro POLiterapie Societ` Italiana di Medicina Interna) Study. 2017 , 34, 311-319		7
1179	Coronary artery calcification is common on nongated chest computed tomography imaging. 2017 , 40, 498-502		5
1178	2016 European Guidelines on cardiovascular disease prevention in clinical practice : The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts). 2017 , 24, 321-419		54
1177	Effect of antiplatelet therapy on aneurysmal sac expansion associated with type II endoleaks after endovascular aneurysm repair. 2017 , 66, 396-403		11
1176	Management of Atherosclerotic Cardiovascular Disease Risk Factors in the Older Adult Patient With Diabetes. 2017 , 40, 476-484		7
1175	Lipid Changes Around the Final Menstrual Period Predict Carotid Subclinical Disease in Postmenopausal Women. 2017 , 48, 70-76		36
1174	Impacts of chronic kidney disease and diabetes on cardiovascular mortality in a general Japanese population: A 20-year follow-up of the NIPPON DATA90 study. 2017 , 24, 505-513		5
1173	Assessing and Refining Myocardial Infarction Risk Estimation Among Patients With Human Immunodeficiency Virus: A Study by the Centers for AIDS Research Network of Integrated Clinical Systems. 2017 , 2, 155-162		71
1172	Depression contributing to dyslipidemic cardiovascular risk in the metabolic syndrome. 2017 , 40, 539-546		6
1171	Omega-3 fatty acid fish oil dietary supplements contain saturated fats and oxidized lipids that may interfere with their intended biological benefits. 2017 , 483, 425-429		61

1170	Patterns and predictors of lipid-lowering therapy in patients with atherosclerotic cardiovascular disease and/or diabetes mellitus in 2014: Insights from a large US managed-care population. 2017 , 40, 155-162	29
1169	Early initiation of eicosapentaenoic acid and statin treatment is associated with better clinical outcomes than statin alone in patients with acute coronary syndromes: 1-year outcomes of a randomized controlled study. 2017 , 228, 173-179	51
1168	Addressing the Crisis in the Treatment of Osteoporosis: A Path Forward. 2017 , 32, 424-430	91
1167	Ginger extract increases muscle mitochondrial biogenesis and serum HDL-cholesterol level in high-fat diet-fed rats. 2017 , 29, 193-200	20
1166	Attainment of LDL Cholesterol Treatment Goals in Children and Adolescents With Familial Hypercholesterolemia. The SAFEHEART Follow-up Registry. 2017 , 70, 444-450	8
1165	Cost effectiveness of case-finding strategies for primary prevention of cardiovascular disease: a modelling study. 2017 , 67, e67-e77	20
1164	Thoracic aortic calcium, cardiovascular disease events, and all-cause mortality in asymptomatic individuals with zero coronary calcium: The Multi-Ethnic Study of Atherosclerosis (MESA). 2017 , 257, 1-8	19
1163	Statin potency and the risk of hospitalization for community-acquired pneumonia. 2017 , 83, 1319-1327	8
1162	Vascular Diseases for the Non-Specialist. 2017 ,	3
1161	Development and Content Validity of the Statin Experience Assessment Questionnaire (SEAQ) [®] . 2017 , 10, 321-334	9
1160	Atherogenic Dyslipidemia Remission 1 Year After Bariatric Surgery. 2017 , 27, 1548-1553	9
1159	Defining the Place of Ezetimibe/Atorvastatin in the Management of Hyperlipidemia. 2017 , 17, 169-181	13
1158	Optimal Low-Density Lipoprotein Cholesterol for Cardiovascular Prevention: How Low Should We Go?. 2017 , 33, 405-408	2
1157	A Review of Clinical Practice Guidelines for the Management of Hypertriglyceridemia: A Focus on High Dose Omega-3 Fatty Acids. 2017 , 34, 300-323	29
1156	2017 AHA/ACC Clinical Performance and Quality Measures for Adults With ST-Elevation and Non-ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Performance Measures. <i>Journal of the American College of Cardiology</i> , 2017 , 70, 2048-2090	15.1 91
1155	Long-term safety, tolerability, and efficacy of evolocumab in patients with heterozygous familial hypercholesterolemia. 2017 , 11, 1448-1457	32
1154	Design and implementation of population-based specialty care programs. 2017 , 74, 1437-1445	2
1153	Cardiovascular Risk Factors and Carotid Intima-Media Thickness in a Colombian Population With Psoriasis. 2017 , 108, 738-745	

1152	Clinical Guidance for Managing Statin and Antimicrobial Drug-Drug Interactions. 2017 , 19, 46		6
1151	Contemporary rates and correlates of statin use and adherence in nondiabetic adults with cardiovascular risk factors: The KP CHAMP study. 2017 , 194, 25-38		6
1150	High-sensitivity C-reactive protein levels and health status outcomes after myocardial infarction. 2017 , 266, 16-23		13
1149	Statin Prescribing in the Elderly: Special Considerations. 2017 , 19, 47		16
1148	Coronary Artery Calcium Scoring in Current Clinical Practice: How to Define Its Value?. 2017 , 19, 85		8
1147	Comparative study of probiotic effects of and strains on cholesterol levels, liver morphology and the gut microbiota in obese mice. 2017 , 8, 357-376		52
1146	Current evidence on the effect of dietary polyphenols intake on chronic diseases. 2017 , 110, 286-299		139
1145	How Low to Go With Glucose, Cholesterol, and Blood Pressure in Primary Prevention of CVD. <i>Journal of the American College of Cardiology</i> , 2017 , 70, 2171-2185	15.1	39
1144	Association of low-density lipoprotein pattern with mortality after myocardial infarction: Insights from the TRIUMPH study. 2017 , 11, 1458-1470.e4		10
1143	The Use of Primary Prevention Statin Therapy in Those Predisposed to Atherosclerosis. 2017 , 19, 48		10
1142	Almond ingestion contributes to improved cardiovascular health in sedentary older adults participating in a walking intervention: A pilot study. 2017 , 39, 58-62		4
1141	Are we successfully managing cardiovascular disease in people living with HIV?. 2017 , 12, 594-603		10
1140	Trial designs for statin muscle intolerance. 2017 , 28, 488-494		4
1139	2016 SCCT/STR guidelines for coronary artery calcium scoring of noncontrast noncardiac chest CT scans: A report of the Society of Cardiovascular Computed Tomography and Society of Thoracic Radiology. 2017 , 32, W54-W66		60
1138	Effects of statin therapy on platelet reactivity after percutaneous coronary revascularization in patients with acute coronary syndrome. 2017 , 44, 355-361		9
1137	Effects of age, gender and statin dose on lipid levels: Results from the VOYAGER meta-analysis database. 2017 , 265, 54-59		15
1136	Association between plant-based diets and plasma lipids: a systematic review and meta-analysis. 2017 , 75, 683-698		153
1135	Progression of asymptomatic mild carotid artery stenosis: Implications for frequency of surveillance. 2017 , 22, 411-417		3

1134	Association of Frequency of Lipid Testing With Changes in Lipid-Lowering Therapy. 2017 , 177, 1529-1531	1
1133	Comprehensive primary prevention of cardiovascular disease in women. 2017 , 40, 832-838	20
1132	Statin Therapy in Patients With Low Serum Levels of Low-Density Lipoprotein Cholesterol. 2017 , 120, 1947-1954	1
1131	Healthcare Policy Statement on the Utility of Coronary Computed Tomography for Evaluation of Cardiovascular Conditions and Preventive Healthcare: From the Health Policy Working Group of the Society of Cardiovascular Computed Tomography. 2017 , 11, 404-414	3
1130	Immune-mediated necrotizing myopathy associated with statins: history and recent developments. 2017 , 29, 604-611	21
1129	Laparoscopic vertical sleeve gastrectomy: A 5-year veterans affairs review. 2017 , 96, e7508	9
1128	A Test in Context: Lipid Profile, Fasting Versus Nonfasting. <i>Journal of the American College of Cardiology</i> , 2017 , 70, 1637-1646	15.1 93
1127	Incorporation of PCSK9 inhibitors into prevention of atherosclerotic cardiovascular disease. 2017 , 129, 801-810	1
1126	Impact of National Health Checkup Service on Hard Atherosclerotic Cardiovascular Disease Events and All-Cause Mortality in the General Population. 2017 , 120, 1804-1812	8
1125	Statins for Primary Prevention of Cardiovascular Events and Mortality in Older Men. 2017 , 65, 2362-2368	26
1124	Dyslipidemia. 2017 , 2, 633-650	2
1123	Circulating PCSK9 levels in acute coronary syndrome: Results from the PC-SCA-9 prospective study. 2017 , 43, 529-535	16
1122	Individual serum saturated fatty acids and markers of chronic subclinical inflammation: the Insulin Resistance Atherosclerosis Study. 2017 , 58, 2171-2179	7
1121	Antioxidant and hypolipidemic effects of soymilk fermented via <i>Lactococcus acidophilus</i> MF204. 2017 , 8, 4414-4420	15
1120	Residual Risk Factors to Predict Major Adverse Cardiovascular Events in Atherosclerotic Cardiovascular Disease Patients with and without Diabetes Mellitus. 2017 , 7, 9179	25
1119	Effect of Statins on COPD: A Meta-Analysis of Randomized Controlled Trials. 2017 , 152, 1159-1168	32
1118	Alirocumab Treatment and Achievement of Non-High-Density Lipoprotein Cholesterol and Apolipoprotein B Goals in Patients With Hypercholesterolemia: Pooled Results From 10 Phase 3 ODYSSEY Trials. 2017 , 6,	11
1117	2017 Focused Update of the 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. <i>Journal of the American College of Cardiology</i> , 2017 , 70, 1785-1882	15.1 247

1116	Ethyl acetate extract of crabapple fruit is the cholesterol-lowering fraction. 2017 , 7, 43114-43124	3
1115	Recent Insights into Pharmacologic Cardiovascular Risk Reduction in Type 2 Diabetes Mellitus. 2017 , 31, 459-470	2
1114	Effect of Baduanjin exercises on elevated blood lipid levels of middle-aged and elderly individuals: protocol for a systematic review and meta-analysis of randomised controlled trials. 2017 , 7, e017213	4
1113	Clinoptilolite for Treatment of Dyslipidemia: Preliminary Efficacy Study. 2017 , 23, 738-744	8
1112	Rationale and design of a randomized trial of apixaban vs warfarin to evaluate atherosclerotic calcification and vulnerable plaque progression. 2017 , 40, 807-813	13
1111	Practical Considerations for the Use of Subcutaneous Treatment in the Management of Dyslipidaemia. 2017 , 34, 1876-1896	8
1110	Comparative Outcomes After Percutaneous Coronary Intervention Among Black and White Patients Treated at US Veterans Affairs Hospitals. 2017 , 2, 967-975	18
1109	Statins and venous thromboembolism: do they represent a viable therapeutic agent?. 2017 , 15, 629-637	6
1108	Practical recommendations for the management of cardiovascular risk associated with atherogenic dyslipidemia, with special attention to residual risk. Spanish adaptation of a European Consensus of Experts. 2017 , 29, 168-177	5
1107	Long-term treatment adherence to the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab in 6 ODYSSEY Phase III clinical studies with treatment duration of 1 to 2 years. 2017 , 11, 986-997	17
1106	Treatment of Cholesterol in 2017. 2017 , 318, 417-418	22
1105	Inconsistent Guideline Recommendations for Cardiovascular Prevention and the Debate About Zeroing in on and Zeroing LDL-C Levels With PCSK9 Inhibitors. 2017 , 318, 419-420	8
1104	High-Intensity Statin Therapy Is Associated With Improved Survival in Patients With Peripheral Artery Disease. 2017 , 6,	30
1103	Implications of the 2013 ACC/AHA cholesterol guidelines on contemporary clinical practice for patients with atherosclerotic coronary and peripheral arterial disease. 2017 , 69, 464-468	6
1102	Dose-Response Relationship Between Severe Hypercholesterolemia and Body Mass Index in Healthy Young Adults. 2017 , 92, 1167-1168	
1101	Cardiovascular Risk Factors and Carotid Intima-Media Thickness in a Colombian Population With Psoriasis. 2017 , 108, 738-745	6
1100	Effects of dipeptidyl peptidase-4 inhibitor sitagliptin on coronary atherosclerosis as assessed by intravascular ultrasound in type 2 diabetes mellitus with coronary artery disease. 2017 , 16, 1-9	2
1099	Residual atherosclerotic cardiovascular disease risk in statin-treated adults: The Multi-Ethnic Study of Atherosclerosis. 2017 , 11, 1223-1233	25

1098	The elusive role of myocardial perfusion imaging in stable ischemic heart disease: Is ISCHEMIA the answer?. 2017 , 24, 1610-1618	2
1097	Application of the 2014 NICE cholesterol guidelines in the English population: a cross-sectional analysis. 2017 , 67, e598-e608	11
1096	Simulation of Lipid-Lowering Therapy Intensification in a Population With Atherosclerotic Cardiovascular Disease. 2017 , 2, 959-966	77
1095	Practical recommendations for the management of cardiovascular risk associated with atherogenic dyslipidemia, with special attention to residual risk. Spanish adaptation of a European Consensus of Experts. 2017 , 29, 168-177	1
1094	Statins use and the risk of liver dysfunction: A Chinese cohort study in real world clinical practice. 2017 , 16, 16-20	5
1093	Statin use and risk of recurrent venous thrombosis: results from the MEGA follow-up study. 2017 , 1, 112-119	6
1092	Defining Potential Use of Nonstatin Therapies to Lower Blood Cholesterol Levels. 2017 , 2, 946-947	
1091	Nutrition Education for Cardiologists: The Time Has Come. 2017 , 19, 77	10
1090	Factors associated with unattained LDL-cholesterol goals in Chinese patients with acute coronary syndrome one year after percutaneous coronary intervention. 2017 , 96, e5469	12
1089	Effect of alirocumab dose increase on LDL lowering and lipid goal attainment in patients with dyslipidemia. 2017 , 28, 190-197	17
1088	Plaque burden, microstructures and compositions underachieving very low LDL-C levels. 2017 , 24, 122-132	7
1087	Primary Prevention of Cardiovascular Disease in Diabetes Mellitus. <i>Journal of the American College of Cardiology</i> , 2017 , 70, 883-893	15.1 68
1086	Implications of Coronary Artery Calcium Testing for Treatment Decisions Among Statin Candidates According to the ACC/AHA Cholesterol Management Guidelines: A Cost-Effectiveness Analysis. 2017 , 10, 938-952	52
1085	An initiative to improve primary prevention of cardiovascular disease in adults with type II diabetes based on the ACC/AHA (2013) and ADA (2016) guidelines. 2017 , 29, 606-611	6
1084	Preoperative atorvastatin reduces bleeding and blood products use in patients undergoing on-pump coronary artery bypass grafting. 2017 , 18, 976-982	5
1083	Comparison of Pharmacokinetics and Safety of a Fixed-dose Combination of Rosuvastatin and Ezetimibe Versus Separate Tablets in Healthy Subjects. 2017 , 39, 1799-1810	9
1082	Association between statin therapy and amputation-free survival in patients with critical limb ischemia in the CRITISCH registry. 2017 , 66, 1534-1542	37
1081	GRADE equity guidelines 4: considering health equity in GRADE guideline development: evidence to decision process. 2017 , 90, 84-91	26

1080	Evolocumab for the treatment of hypercholesterolemia. 2017 , 17, 1447-1461	2
1079	Coronary Artery Calcium Scoring: a Valuable Aid in Shared Decision Making Among Non-traditional Risk Markers. 2017 , 10, 1	3
1078	Application of PCSK9 Inhibitors in Practice: Challenges and Opportunities. 2017 , 121, 499-501	22
1077	Hormone Replacement: The Fountain of Youth?. 2017 , 44, 481-498	5
1076	Can non-fasting and fasting lipid profile be mutually exclusive? An Indian perspective. 2017 , 65, e3	1
1075	An educational intervention to increase awareness reduces unnecessary laboratory testing in an internal medicine resident-run clinic. 2017 , 7, 168-172	6
1074	The 10-Year Prognostic Value of Zero and Minimal CAC. 2017 , 10, 957-958	22
1073	Circulating Thyroxine: A Major New Risk Marker for Atherosclerosis?. 2017 , 121, 1304-1306	1
1072	Cholesterol Ester Transfer Protein Inhibitor Review. 2017 , 52, 596-598	
1071	Alirocumab for the treatment of hyperlipidemia in high-risk patients: an updated review. 2017 , 15, 923-932	3
1070	Efficacy and safety of a combination of red yeast rice and olive extract in hypercholesterolemic patients with and without statin-associated myalgia. 2017 , 35, 140-144	6
1069	Propuesta personal de actualizaci3n para el tratamiento de la hipercolesterolemia en Colombia. 2017 , 24, 25-31	
1068	Indicaciones para el uso de los inhibidores de la PCSK9. 2017 , 24, 19-24	0
1067	Prioritising the application of genomic medicine. 2017 , 2, 35	18
1066	Thyroid Dysfunction Was Associated with Dyslipidemia, but Not Incident Myocardial Infarction or Stroke in a Large U.S. General Population-Based Cohort. 2017 , 29, 312-314	
1065	Effects of Guideline and Formulary Changes on Statin Prescribing in the Veterans Affairs. 2017 , 52, 1996-2017	7
1064	Real-world study of low-density lipoprotein cholesterol levels and cardiovascular outcomes in Chinese: A retrospective cohort study in post-percutaneous coronary intervention acute coronary syndrome patients. 2017 , 249, 18-24	11
1063	What is sufficient drug therapy for lipoprotein elevations?. 2017 , 11, 1300-1308	

1062	Lipid Management After First Diagnosis of Coronary Artery Disease: Contemporary Results From an Observational Cohort Study. 2017 , 39, 2311-2320.e2	6
1061	Statin Use and Risk of Community-Acquired Staphylococcus aureus Bacteremia: A Population-Based Case-Control Study. 2017 , 92, 1469-1478	13
1060	Use of rosuvastatin in HIV-associated chronic obstructive pulmonary disease. 2017 , 31, 539-544	10
1059	Asymptotic distribution of $\hat{A}UC$, NRIs, and IDI based on theory of U-statistics. 2017 , 36, 3334-3360	12
1058	High-Intensity Statins: Guideline Expectations and Clinical Application. 2017 , 317, 2543-2544	3
1057	Evaluating the Impact and Cost-Effectiveness of Statin Use Guidelines for Primary Prevention of Coronary Heart Disease and Stroke. 2017 , 136, 1087-1098	56
1056	Subclinical Atherosclerosis Burden by 3D Ultrasound in Mid-Life: The PESA Study. <i>Journal of the American College of Cardiology</i> , 2017 , 70, 301-313	15.1 53
1055	Cardiac Society of Australia and New Zealand Position Statement: Coronary Artery Calcium Scoring. 2017 , 26, 1239-1251	17
1054	Metabolic syndrome cluster does not provide incremental prognostic information in patients with stable cardiovascular disease: A post hoc analysis of the AIM-HIGH trial. 2017 , 11, 1201-1211	10
1053	Bridging the gap for lipid lowering therapy: plaque regression, coronary computed tomographic angiography, and imaging-guided personalized medicine. 2017 , 15, 547-558	5
1052	Editorial Commentary: Coronary artery calcification on non-cardiac chest CT: Incidental but impactful. 2017 , 27, 481-482	
1051	Secondary prevention of cardiovascular disease: Unmet medical need, implementation and innovation. 2017 , 24, 5-7	5
1050	Reliability of Cardiovascular Risk Calculators to Estimate Accurately the Risk of Cardiovascular Disease in Patients With Sarcoidosis. 2017 , 120, 868-873	6
1049	What Women (and Clinicians) Don't Know Hurts Them. <i>Journal of the American College of Cardiology</i> , 2017 , 70, 133-135	15.1
1048	What's in a Number? Risk Thresholds in Different Statin Guidelines. 2017 , 32, 1071-1073	1
1047	Application of short message service to control blood cholesterol: a field trial. 2017 , 17, 32	4
1046	Efficacy and safety of alirocumab in patients with hypercholesterolemia not adequately controlled with non-statin lipid-lowering therapy or the lowest strength of statin: ODYSSEY NIPPON study design and rationale. 2017 , 16, 121	5
1045	Commentary: Should Pharmacogenomic Evidence Be Considered in Clinical Decision Making? Focus on Select Cardiovascular Drugs. 2017 , 37, 1005-1013	6

1044	Translational science in chronic kidney disease. 2017 , 131, 1617-1629	13
1043	The Montreal-FH-SCORE: A new score to predict cardiovascular events in familial hypercholesterolemia. 2017 , 11, 80-86	45
1042	Rechallenging Statin Therapy in Veterans With Statin-Induced Myopathy Post Vitamin D Replenishment. 2017 , 30, 521-527	13
1041	Cholesterol- and blood-pressure-lowering drug use for secondary cardiovascular prevention in 2004-2013 Europe. 2017 , 24, 426-436	8
1040	Characteristics associated with nonadherence to medications for hypertension, diabetes, and dyslipidemia among breast cancer survivors. 2017 , 161, 161-172	21
1039	A Highly Durable RNAi Therapeutic Inhibitor of PCSK9. 2017 , 376, 41-51	397
1038	Perspective on Trends in Statin Use. 2017 , 2, 11-12	9
1037	Cardiovascular Risk in HIV-Infected and Uninfected Postmenopausal Minority Women: Use of the Framingham Risk Score. 2017 , 26, 241-248	8
1036	[LDL-cholesterol targets arrive at the American guidelines]. 2017 , 43, 238-239	
1035	Comparing Strategies for Lipid Lowering in Argentina: An Analysis from the CVD Policy Model-Argentina. 2017 , 32, 524-533	2
1034	Intensive LDL-cholesterol lowering therapy and neurocognitive function. 2017 , 170, 181-191	46
1033	Efficacy comparison of atorvastatin versus rosuvastatin on blood lipid and microinflammatory state in maintenance hemodialysis patients. 2017 , 39, 153-158	6
1032	Temporal shifts in clinical presentation and underlying mechanisms of atherosclerotic disease. 2017 , 14, 21-29	81
1031	Statin-associated muscle symptoms: position paper from the Luso-Latin American Consortium. 2017 , 33, 239-251	11
1030	Estimating Longitudinal Risks and Benefits From Cardiovascular Preventive Therapies Among Medicare Patients: The Million Hearts Longitudinal ASCVD Risk Assessment Tool: A Special Report From the American Heart Association and American College of Cardiology. <i>Journal of the American College of Cardiology</i> , 2017 , 69, 1617-1636	15.1 36
1029	Race/ethnic comparisons of waist-to-height ratio for cardiometabolic screening: The study of women's health across the nation. 2017 , 29, e22909	7
1028	Statin therapy and low-density lipoprotein cholesterol reduction in HIV-infected individuals after acute coronary syndrome: Results from the PACS-HIV lipids substudy. 2017 , 183, 91-101	18
1027	High-Intensity Atorvastatin-Induced Rhabdomyolysis in an Elderly Patient With NSTEMI: A Case Report and Review of the Literature. 2017 , 30, 658-662	2

1026	Predictors of electrocardiographic abnormalities in type 1 Diabetes: the Wisconsin Epidemiologic Study of Diabetic Retinopathy. 2017 , 40, 313-318	2
1025	Rationale, design features, and baseline characteristics: The Heart Institute of Japan-PROper level of lipid lOwering with Pitavastatin and Ezetimibe in acute coRonary syndrome (HIJ-PROPER). 2017 , 69, 536-541	7
1024	PCSK9 Inhibition With Monoclonal Antibodies: Modern Management of Hypercholesterolemia. 2017 , 57, 7-32	21
1023	Fractional flow reserve by computerized tomography and subsequent coronary revascularization. 2017 , 18, 145-152	13
1022	Predictors of Suboptimal Gain in Exercise Capacity After Cardiac Rehabilitation. 2017 , 119, 687-691	3
1021	Medication Nonadherence: The Role of Cost, Community, and Individual Factors. 2017 , 52, 1511-1533	9
1020	Quality indicators for acute myocardial infarction: A position paper of the Acute Cardiovascular Care Association. 2017 , 6, 34-59	69
1019	Ischemic Heart Disease. 2017 , 973-981	1
1018	CT calcium scoring. History, current status and outlook. 2017 , 98, 3-10	18
1017	A pan-coronary artery angiographic study of the association between diabetes mellitus and progression or regression of coronary atherosclerosis. 2017 , 32, 376-384	9
1016	Prevention of Carotid Artery Atherosclerosis: What is the Evidence?. 2017 , 68, 661-668	5
1015	Estimation of cardiovascular risk on routine chest CT: Ordinal coronary artery calcium scoring as an accurate predictor of Agatston score ranges. 2017 , 11, 8-15	42
1014	Incidence and Management of Cardiovascular Risk Factors in Psoriatic Arthritis and Rheumatoid Arthritis: A Population-Based Study. 2017 , 69, 51-57	68
1013	[Trend of lipid profile in general population from Caceres Health Area]. 2017 , 34, 17-23	
1012	Ethnogeriatrics. 2017 ,	
1011	Role of statins in delirium prevention in critical ill and cardiac surgery patients: A systematic review and meta-analysis. 2017 , 37, 189-196	21
1010	Risk Estimates for Atherosclerotic Cardiovascular Disease in Adults With Congenital Heart Disease. 2017 , 119, 112-118	37
1009	Impact of glucose tolerance status on the development of coronary artery disease among working-age men. 2017 , 43, 261-264	18

1008	Metabolic syndrome and C reactive protein in patients undergoing angiography: Inevitable association?. 2017 , 11, 89-93	
1007	Brain Function Is Linked to LDL Cholesterol in Older Adults with Cardiovascular Risk. 2017 , 65, e51-e55	8
1006	Association of plasma fetuin-a levels with peripheral arterial disease and lower extremity arterial calcification in subjects with type 2 diabetes mellitus. 2017 , 31, 599-604	14
1005	Clinical and economic consequences of statin intolerance in the United States: Results from an integrated health system. 2017 , 11, 70-79.e1	28
1004	The role of electronegative low-density lipoprotein in cardiovascular diseases and its therapeutic implications. 2017 , 27, 239-246	15
1003	Coronary Artery Calcium to Guide a Personalized Risk-Based Approach to Initiation and Intensification of Antihypertensive Therapy. 2017 , 135, 153-165	57
1002	Simvastatin promotes NPC1-mediated free cholesterol efflux from lysosomes through CYP7A1/LXR signalling pathway in oxLDL-loaded macrophages. 2017 , 21, 364-374	5
1001	Are recent statin recommendations to employ fixed doses and abandon targets effective for treatment of hypercholesterolaemia? Investigation based on number needed to treat. 2017 , 24, 76-83	22
1000	CAC Score Improves Coronary and CV Risk Assessment Above Statin Indication by ESC and AHA/ACC Primary Prevention Guidelines. 2017 , 10, 143-153	96
999	. 2017 ,	3
998	Long-term Management of the Liver Transplant Patient. 2017 , 1093-1106	
997	Exercise-Induced Anaphylaxis in an Air Force Aviator Taking a HMG-CoA Reductase Inhibitor: A Case Report and Review of the Presentation, Diagnoses, and Treatment. 2017 , 182, e1816-e1819	0
996	Skin immunization by microneedle patch overcomes statin-induced suppression of immune responses to influenza vaccine. 2017 , 7, 17855	12
995	From the Editor. 2017 , 11, 779-780	
994	Prüfung. 2017 , 24, 2-3	
993	Lipodystrophie-Erkrankungen. 2017 , 29, 374-388	1
992	Impact of clinical signs and genetic diagnosis of familial hypercholesterolaemia on the prevalence of coronary artery disease in patients with severe hypercholesterolaemia. 2017 , 38, 1573-1579	78
991	Using the Payoff Time in Decision-Analytic Models: A Case Study for Using Statins in Primary Prevention. 2017 , 37, 759-769	2

990	A Pilot Study: The Beneficial Effects of Combined Statin-exercise Therapy on Cognitive Function in Patients with Coronary Artery Disease and Mild Cognitive Decline. 2017 , 56, 641-649	7
989	Six-month adherence to Statin use and subsequent risk of major adverse cardiovascular events (MACE) in patients discharged with acute coronary syndromes. 2017 , 16, 155	9
988	Optimizing Cholesterol Treatment in Patients With Muscle Complaints. <i>Journal of the American College of Cardiology</i> , 2017 , 70, 1290-1301	15.1 133
987	Representation of cardiovascular magnetic resonance in the AHA / ACC guidelines. 2017 , 19, 70	35
986	Cholesterol Control Among Uninsured Adults Did Not Improve From 2001-2004 to 2009-2012 as Disparities With Both Publicly and Privately Insured Adults Doubled. 2017 , 6,	7
985	The Adherence Rate Threshold is Drug Specific. 2017 , 17, 645-653	11
984	HIV update: Impact on chronic diseases. 2017 , 23, 57-69	2
983	The association between coronary artery disease and glyphosate exposure found in pesticide factory workers. 2017 , 1, 4-4	4
982	Discovery and Development of Statins. 2017 , 12, 1934578X1701200	1
981	Low-Dose of Bergamot-Derived Polyphenolic Fraction (BPF) Did Not Improve Metabolic Parameters in Second Generation Antipsychotics-Treated Patients: Results from a 60-days Open-Label Study. 2017 , 8, 197	9
980	Simvastatin Promotes Cardiac Myocyte Relaxation in Association with Phosphorylation of Troponin I. 2017 , 8, 203	2
979	Association of genetic variations with pharmacokinetics and lipid-lowering response to atorvastatin in healthy Korean subjects. 2017 , 11, 1135-1146	19
978	Assessment of Cardiovascular Risk Beyond Lipid Panel in Cardio-Oncology Patients. 2017 , 237-247	
977	Pharmacokinetic and pharmacodynamic interaction between ezetimibe and rosuvastatin in healthy male subjects. 2017 , 11, 3461-3469	10
976	Effects of Statins on Cardiovascular Outcomes in Patients With Chronic Kidney Disease. 2017 , 9, 1179559X1771902	
975	Clinical utility of evolocumab in the management of hyperlipidemia: patient selection and follow-up. 2017 , 11, 2121-2129	8
974	The Effects of Tocotrienol and Lovastatin Co-Supplementation on Bone Dynamic Histomorphometry and Bone Morphogenetic Protein-2 Expression in Rats with Estrogen Deficiency. 2017 , 9,	15
973	Effect of Underlying Renal Disease on Nutritional and Metabolic Profile of Older Adults with Reduced Renal Function. 2017 , 4, 4	0

972	Statins Reduce Lipopolysaccharide-Induced Cytokine and Inflammatory Mediator Release in an In Vitro Model of Microglial-Like Cells. 2017 , 2017, 2582745	26
971	Pravastatin-Induced Eczematous Eruption Mimicking Psoriasis. 2017 , 2017, 3418204	5
970	Safety Evaluation of Red Koji (red yeast rice) in Healthy Adult Volunteers. 2017 , 14, 67-76	
969	Statin therapy for preventing cardiovascular diseases in patients treated with tacrolimus after kidney transplantation. 2017 , 13, 1513-1520	7
968	Diagnostic Accuracy. 2017 , 78-104	
967	Evaluation of coronary calcium score in patients with normocalcemic primary hyperparathyroidism. 2017 , 13, 225-229	11
966	Soluble Vascular Cell Adhesion Molecules May be Protective of Future Cardiovascular Disease Risk: Findings from the PREVEND Prospective Cohort Study. 2017 , 24, 804-818	16
965	PCSK9 inhibitors: A new era of lipid lowering therapy. 2017 , 9, 76-91	133
964	Patterns of statin non-prescription in patients with established coronary artery disease: A report from a contemporary multicenter Japanese PCI registry. 2017 , 12, e0182687	8
963	Cardiovascular disease risk prediction by the American College of Cardiology (ACC)/American Heart Association (AHA) Atherosclerotic Cardiovascular Disease (ASCVD) risk score among HIV-infected patients in sub-Saharan Africa. 2017 , 12, e0172897	24
962	Exploring differences in the use of the statin choice decision aid and diabetes medication choice decision aid in primary care. 2017 , 17, 118	9
961	Pemafibrate (K-877), a novel selective peroxisome proliferator-activated receptor alpha modulator for management of atherogenic dyslipidaemia. 2017 , 16, 124	77
960	Efficacy and safety of proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors, alirocumab and evolocumab, a post-commercialization study. 2017 , 16, 141	4
959	Lipid management in India: a nationwide, cross-sectional physician survey. 2017 , 16, 130	4
958	Coronary artery calcium score plays an important role for cardiovascular risk stratification in the statin benefit groups of asymptomatic individuals. 2017 , 16, 172	2
957	Utilization of the Behavior Change Wheel framework to develop a model to improve cardiometabolic screening for people with severe mental illness. 2017 , 12, 134	21
956	Tufts PACE Clinical Predictive Model Registry: update 1990 through 2015. 2017 , 1, 20	24
955	Lipid Lowering Therapy to Modify Plaque Microstructures. 2017 , 24, 360-372	6

954	[Health behaviors and preventive tests in adults with and without health insurance in Greater Metropolitan Belo Horizonte, Minas Gerais State, Brazil, 2003-2010]. 2017 , 33, e00130815	0
953	Effect of a Novel Clinical Decision Support Tool on the Efficiency and Accuracy of Treatment Recommendations for Cholesterol Management. 2017 , 8, 124-136	14
952	Ezetimibe Use and LDL-C Goal Achievement: A Retrospective Database Analysis of Patients with Clinical Atherosclerotic Cardiovascular Disease or Probable Heterozygous Familial Hypercholesterolemia. 2017 , 23, 1270-1276	11
951	Therapeutic effects of atorvastatin and ezetimibe compared with double-dose atorvastatin in very elderly patients with acute coronary syndrome. 2017 , 8, 41582-41589	7
950	Estimation of cardiovascular risk and detection of subclinical carotid atheromatosis in patients with diabetes without a history of cardiovascular disease. 2017 , 61, 122-129	1
949	Application of the 2013 American College of Cardiology/American Heart Association Cholesterol Guideline to the Korean National Health and Nutrition Examination Surveys from 1998 to 2012. 2017 , 41, 38-50	1
948	Real-world use of PCSK-9 inhibitors by early adopters: cardiovascular risk factors, statin co-treatment, and short-term adherence in routine clinical practice. 2017 , 13, 957-965	11
947	Cholesterol and Lipids. 2017 , 9-21	
946	Impact of electronic clinical decision support on adherence to guideline-recommended treatment for hyperlipidaemia, atrial fibrillation and heart failure: protocol for a cluster randomised trial. 2017 , 7, e019087	5
945	Ronda clíica y epidemiológica: club de revistas. 2017 , 30, 463-471	
944	Two Patients with Familial Hypercholesterolemia Who Were Successfully Weaned from Low-density Lipoprotein Apheresis after Treatment with Evolocumab. 2017 , 56, 1531-1535	1
943	Assessment of Coronary Artery Calcium Scoring for Statin Treatment Strategy according to ACC/AHA Guidelines in Asymptomatic Korean Adults. 2017 , 58, 82-89	8
942	Cholesterol Levels of Six Fractionated Serum Lipoproteins and its Relevance to Coronary Heart Disease Risk Scores. 2017 , 24, 928-939	6
941	Guideline-Based Statin Eligibility, Cancer Events, and Noncardiovascular Mortality in the Framingham Heart Study. 2017 , 35, 2927-2933	16
940	Cardiac Events After Radiation Therapy: Combined Analysis of Prospective Multicenter Trials for Locally Advanced Non-Small-Cell Lung Cancer. 2017 , 35, 1395-1402	176
939	Effect of Fenofibrate Medication on Renal Function. 2017 , 38, 192-198	13
938	Medication therapy disease management: Geisinger's approach to population health management. 2017 , 74, 1422-1435	16
937	Stability of extemporaneously prepared rosuvastatin oral suspension. 2017 , 74, 1579-1583	2

936	Statin-ezetimibe versus statin lipid-lowering therapy in patients with acute coronary syndromes undergoing percutaneous coronary intervention. 2017 , 9, 1345-1352	4
935	Advances in dyslipidemia management for prevention of atherosclerosis: PCSK9 monoclonal antibody therapy and beyond. 2017 , 7, S11-S20	11
934	Key Recent Advances in Atherosclerosis Treatment with Modern Lipid-lowering Drugs: The New Frontier with PCSK9 Inhibitors. 2017 , 12, 30-32	
933	Highly Selective and Rapid Breath Isoprene Sensing Enabled by Activated Alumina Filter. 2018 , 3, 677-683	56
932	Practice Paper of the Academy of Nutrition and Dietetics: Nutrition Intervention and Human Immunodeficiency Virus Infection. 2018 , 118, 486-498	15
931	Is It Time for New Thinking About High-Density Lipoprotein?. 2018 , 38, 484-486	15
930	The effects of short-term continuous subcutaneous insulin infusion treatment on fasting glucagon-like peptide-1 concentrations in newly diagnosed type 2 diabetes. 2018 , 138, 246-252	2
929	Statin Eligibility in Primary Prevention: From a Risk-Based Strategy to a Personalized Approach Based on the Predicted Benefit. 2018 , 121, 1315-1320	4
928	Evolocumab: Considerations for the Management of Hyperlipidemia. 2018 , 20, 17	4
927	Statin use is associated with carotid plaque composition: The Rotterdam Study. 2018 , 260, 213-218	22
926	De-novo nonalcoholic steatohepatitis is associated with long-term increased mortality in liver transplant recipients. 2018 , 30, 766-773	25
925	New insights into NAFLD and subclinical coronary atherosclerosis. 2018 , 68, 890-892	9
924	Statin-induced myalgia and myositis: an update on pathogenesis and clinical recommendations. 2018 , 14, 215-224	66
923	Trends and disparities in statin use and low-density lipoprotein cholesterol levels among US patients with diabetes, 1999-2014. 2018 , 139, 1-10	17
922	Transforming clinical practice guidelines and clinical pathways into fast-and-frugal decision trees to improve clinical care strategies. 2018 , 24, 1247-1254	20
921	Update of pathophysiology and management of diabetic kidney disease. 2018 , 117, 662-675	158
920	Junge Patienten mit Myokardinfarkt. 2018 , 12, 181-182	
919	Evolution of Omega-3 Fatty Acid Therapy and Current and Future Role in the Management of Dyslipidemia. 2018 , 36, 277-285	3

918	International Study of Comparative Health Effectiveness with Medical and Invasive Approaches (ISCHEMIA) trial: Rationale and design. 2018 , 201, 124-135		132
917	Effects of Statin Intensity on Clinical Outcome in Acute Myocardial Infarction Patients. 2018 , 82, 1112-1120		15
916	Visit-to-visit cholesterol variability correlates with coronary atheroma progression and clinical outcomes. 2018 , 39, 2551-2558		40
915	Sex Differences in High-Intensity Statin Use Following Myocardial Infarction in the United States. <i>Journal of the American College of Cardiology</i> , 2018 , 71, 1729-1737	15.1	57
914	Should Sex Matter When it Comes to High-Intensity Statins?. <i>Journal of the American College of Cardiology</i> , 2018 , 71, 1738-1740	15.1	1
913	Patterns of statin use and long-term adherence and persistence among older adults with diabetes. 2018 , 10, 699-707		23
912	Correlation of High-Density Lipoprotein-Associated Paraoxonase 1 Activity With Systemic Inflammation, Disease Activity, and Cardiovascular Risk Factors in Psoriatic Disease. 2018 , 70, 1240-1250		15
911	Intensive Treat-to-Target Statin Therapy in High-Risk Japanese Patients With Hypercholesterolemia and Diabetic Retinopathy: Report of a Randomized Study. 2018 , 41, 1275-1284		25
910	The Burden of Statin Therapy based on ACC/AHA and NCEP ATP-III Guidelines: An Iranian Survey of Non-Communicable Diseases Risk Factors. 2018 , 8, 4928		2
909	Lipid discordance and carotid plaque in obese patients in primary prevention. 2018 , 65, 39-44		
908	The prevalence, low-density lipoprotein cholesterol levels, and treatment of patients at very high risk of cardiovascular events in the United Kingdom: a cross-sectional study. 2018 , 34, 1441-1447		7
907	The Ossabaw Pig Is a Suitable Translational Model to Evaluate Dietary Patterns and Coronary Artery Disease Risk. 2018 , 148, 542-551		16
906	Statin guidelines: Friend or foes?. 2018 , 25, 867-869		
905	Sudden Creatine Kinase Elevation When an Athlete Starts Boxing: Looking Deeper Prior to Knocking the Statin Out. 2018 , 131, e333-e334		0
904	Temporal changes in statin prescription and intensity at discharge and impact on outcomes in patients with newly diagnosed atherosclerotic cardiovascular disease-Real-world experience within a large integrated health care system: The IMPRES study. 2018 , 12, 1008-1018.e1		4
903	Development of the American College of Rheumatology Electronic Clinical Quality Measures for Gout. 2018 , 70, 659-671		13
902	Transitions from Ideal to Intermediate Cholesterol Levels may vary by Cholesterol Metric. 2018 , 8, 2782		1
901	Coronary Artery Calcium Scoring in Young Adults: Evidence and Challenges. 2018 , 20, 10		9

900	Role of Noncommunicable Diseases (NCDs) in Resource-Limited Settings (RLS). 2018 , 15, 120-126	2
899	Long-term efficacy and safety of proprotein convertase subtilisin/kexin 9 monoclonal antibodies: A meta-analysis of 11 randomized controlled trials. 2018 , 12, 277-291.e3	12
898	Association of Statin Therapy With Risk of Epilepsy in 2 Propensity Score-Matched Cohorts. 2018 , 52, 546-553	5
897	Is Rheumatoid Arthritis a Cardiovascular Risk-Equivalent to Diabetes Mellitus?. 2018 , 70, 1694-1699	10
896	Perioperative Management of Cardiovascular Medications. 2018 , 32, 2289-2302	3
895	The potential role of statins in treating liver disease. 2018 , 12, 331-339	10
894	Effect of an increased dosage of statins on spinal degenerative joint disease: a retrospective cohort study. 2018 , 8, e017442	6
893	Associations of dyslipidaemia and lipid-lowering treatment with risk of postoperative cognitive dysfunction: a systematic review and meta-analysis. 2018 , 72, 499-506	8
892	Statins do not increase Markers of Cerebral Angiopathies in patients with Cardioembolic Stroke. 2018 , 8, 1492	8
891	Persistently high psychological well-being predicts better HDL cholesterol and triglyceride levels: findings from the midlife in the U.S. (MIDUS) longitudinal study. 2018 , 17, 1	72
890	Efficacy of a Chronic Care-Based Intervention on Secondary Stroke Prevention Among Vulnerable Stroke Survivors: A Randomized Controlled Trial. 2018 , 11, e003228	16
889	Triglyceride-rich lipoprotein cholesterol (TRL-C): the ugly stepsister of LDL-C. 2018 , 39, 620-622	8
888	PCSK9 inhibitors: a non-statin cholesterol-lowering treatment option. 2018 , 130, 287-298	6
887	Hypocholesterolemic Effects of Kenaf Seed Oil, Macroemulsion, and Nanoemulsion in High-Cholesterol Diet Induced Rats. 2018 , 83, 854-863	14
886	Gaps in Diagnosis and Treatment of Cardiovascular Risk Factors in Patients with Psoriatic Disease: An International Multicenter Study. 2018 , 45, 378-384	27
885	Efficacy and Safety of Alirocumab in High-Risk Patients With Clinical Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia (from 5 Placebo-Controlled ODYSSEY Trials). 2018 , 121, 940-948	13
884	Implications of New Cholesterol Treatment Guidelines on Statin Utilization, Intensity, and Costs in Active Duty Service Members. 2018 , 183, e66-e70	1
883	Trends in Diabetes Treatment and Monitoring among Medicare Beneficiaries. 2018 , 33, 471-480	12

882	A Comparative Analysis of Current Lipid Treatment Guidelines: Nothing Stands Still. <i>Journal of the American College of Cardiology</i> , 2018 , 71, 794-799	15.1	15
881	Unmet need for primary prevention in individuals with hypertriglyceridaemia not eligible for statin therapy according to European Society of Cardiology/European Atherosclerosis Society guidelines: a contemporary population-based study. 2018 , 39, 610-619		30
880	Hospitalization Rates, Prevalence of Cardiovascular Manifestations, and Outcomes Associated With Sarcoidosis in the United States. 2018 , 7,		29
879	Evolving Role of Non-Statins for the Management of Dyslipidemia and Cardiovascular Risk Reduction: Past, Present, and Future. 2018 , 38, 164-171		6
878	LDL cholesterol levels after switch from atorvastatin to rosuvastatin. 2018 , 34, 1717-1723		2
877	Intensive Diabetes Treatment and Cardiovascular Outcomes in Type 1 Diabetes Mellitus: Implications of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study 30-Year Follow-up. 2018 , 47, 65-79		19
876	Lipid discordance and carotid plaque in obese patients in primary prevention. 2018 , 65, 39-44		
875	Prehypertension is associated with peripheral arterial disease and low ankle-brachial index. 2018 , 70, 502-505		5
874	Cardiovascular Risk and Statin Eligibility of Young Adults After an MI: Partners YOUNG-MI Registry. <i>Journal of the American College of Cardiology</i> , 2018 , 71, 292-302	15.1	80
873	Short-term effect of rosuvastatin treatment on arterial stiffness in individuals with newly-diagnosed heterozygous familial hypercholesterolemia. 2018 , 255, 215-220		5
872	The effect of fasting status on lipids, lipoproteins, and inflammatory biomarkers assessed after hospitalization for an acute coronary syndrome: Insights from PROVE IT-TIMI 22. 2018 , 41, 68-73		3
871	Comparison of Changes in the Lipid Profiles of Eastern Chinese Postmenopausal Women With Early-Stage Breast Cancer Treated With Different Aromatase Inhibitors: A Retrospective Study. 2018 , 7, 837-843		4
870	Primary Prevention With Statins in the Elderly. <i>Journal of the American College of Cardiology</i> , 2018 , 71, 85-94	15.1	77
869	Genetic variation in statin intolerance and a possible protective role for UGT1A1. 2018 , 19, 83-94		5
868	A comparison of the effects of low- and high-dose atorvastatin on lipoprotein metabolism and inflammatory cytokines in type 2 diabetes: Results from the Protection Against Nephropathy in Diabetes with Atorvastatin (PANDA) randomized trial. 2018 , 12, 44-55		10
867	Comparison of Adherence to the 2013 ACC/AHA Cholesterol Guideline in a Teaching Versus Nonteaching Outpatient Clinic. 2018 , 52, 338-344		4
866	Evaluation of dyslipidaemia and the impact of hypolipidemic therapy on prognosis in high and very high risk patients through the Hyperlipidaemia Therapy in tERTiary Cardiological cEnTer (TERCET) Registry. 2018 , 132, 204-210		13
865	2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. <i>Journal of the American College of Cardiology</i> , 2018 , 71, 201-230	15.1	173

864	Discordance between lipoprotein particle number and cholesterol content: an update. 2018 , 25, 130-136	21
863	Appropriateness of statin prescription in the elderly. 2018 , 50, 33-40	27
862	Dyslipidaemia in the elderly: to treat or not to treat?. 2018 , 11, 259-278	5
861	Favorable effects of statins in the treatment of heart failure with preserved ejection fraction in patients without ischemic heart disease. 2018 , 255, 111-117	16
860	Rationale and design of the Statins Evaluation in Coronary procedUres and REvascularization: The SECURE-PCI Trial. 2018 , 198, 129-134	3
859	Management of Statin Intolerance in 2018: Still More Questions Than Answers. 2018 , 18, 157-173	86
858	Improving patient risk communication: Translating cardiovascular risk into standardized risk percentiles. 2018 , 198, 18-24	5
857	Comparisons of the Framingham and Pooled Cohort Equation Risk Scores for Detecting Subclinical Vascular Disease in Blacks Versus Whites. 2018 , 121, 564-569	16
856	Confirmation bias, conflicts of interest and cholesterol guidance: can we trust expert opinions?. 2018 , 111, 687-689	5
855	Clinical pharmacist understanding of the 2013 American College of Cardiology/American Heart Association cholesterol guideline. 2018 , 12, 367-374.e3	7
854	Inflammation and atherosclerosis: Cardiovascular evaluation in patients with autoimmune diseases. 2018 , 17, 703-708	49
853	Clinical Characteristics, Sex Differences, and Outcomes in Patients With Normal or Near-Normal Coronary Arteries, Non-Obstructive or Obstructive Coronary Artery Disease. 2018 , 7,	17
852	Genetic variants of SLC12A3 modulate serum lipid profiles in a group of Mongolian pedigree population. 2018 , 17, 83	2
851	Treatment Patterns and Lipid Profile in Patients with Familial Hypercholesterolemia in Japan. 2018 , 25, 580-592	6
850	Survival benefit of a low ratio of visceral to subcutaneous adipose tissue depends on LDL clearance versus production in sepsis. 2018 , 22, 58	5
849	Modeling Statin-Induced Reductions of Cardiovascular Events in Primary Prevention: A VOYAGER Meta-Analysis. 2018 , 140, 30-34	4
848	Drug-Coated Balloon vs. Conventional Balloon Angioplasty in Dialysis Patients With Symptomatic Femoropopliteal Disease - A Matched Comparison. 2018 , 82, 1908-1916	2
847	Control of serum triglyceride levels by the apolipoprotein C3 gene and its relationship to cardiovascular disease. 2018 , 29, 271-272	2

846	Can doctors and patients correctly estimate cardiovascular risk? A cross-sectional study in primary care. 2018 , 8, e017711		7
845	Disorders of Lipid Metabolism in Chronic Kidney Disease. 2018 , 46, 144-152		42
844	Low-density lipoprotein-cholesterol lowering in individuals at intermediate cardiovascular risk: Percent reduction or target level?. 2018 , 41, 333-338		1
843	Ten-year association of coronary artery calcium with atherosclerotic cardiovascular disease (ASCVD) events: the multi-ethnic study of atherosclerosis (MESA). 2018 , 39, 2401-2408		206
842	Under-utilization of statin medications in patients with peripheral artery disease or cerebrovascular disease. 2018 , 23, 241-242		1
841	Coronary Artery Disease in Patients ≥80 Years of Age. <i>Journal of the American College of Cardiology</i> , 2018 , 71, 2015-2040	15.1	81
840	Machine learning in cardiac CT: Basic concepts and contemporary data. 2018 , 12, 192-201		58
839	How does the TRS 2°P score relate to real-world patients?. 2018 , 4, 72-74		3
838	High-Intensity Statin Therapy Is "Too Much," Thus Not Indicated for Very Elderly Patients. 2018 , 6, 19-31		0
837	Impact of Water- and Lipid-Soluble Statins on Nonculprit Lesions in Patients with Acute Coronary Syndrome. 2018 , 59, 27-34		3
836	The 2017 AHA/ACC Performance and Quality Measures for Patients With Acute Myocardial Infarction. 2018 , 3, 659-660		1
835	Short-Term Global Cardiovascular Disease Risk Prediction in Older Adults. <i>Journal of the American College of Cardiology</i> , 2018 , 71, 2527-2536	15.1	29
834	New methods to image unstable atherosclerotic plaques. 2018 , 272, 118-128		42
833	CAC-DRS: Coronary Artery Calcium Data and Reporting System. An expert consensus document of the Society of Cardiovascular Computed Tomography (SCCT). 2018 , 12, 185-191		74
832	Unmet Patient Need in Statin Intolerance: the Clinical Characteristics and Management. 2018 , 32, 29-36		7
831	Optimizing Statins and Ezetimibe in Guideline-Focused Management. 2018 , 36, 221-223		2
830	Prevalence of dyslipidemia and achievement of low-density lipoprotein cholesterol targets in Chinese adults: A nationally representative survey of 163,641 adults. 2018 , 260, 196-203		78
829	Diabetes and Hypertension: Clinical Update. 2018 , 31, 515-521		9

828	First 24 h in the management of non-ST segment elevation myocardial infarction. 2018 , 20, B29-B38		1
827	Selective prescribing of statins and the risk of mortality, hospitalizations, and falls in aged care services. 2018 , 12, 652-661		13
826	Poor attainment of lipid targets in patients with symptomatic peripheral artery disease. 2018 , 12, 711-717		16
825	Molecular aspects of hypercholesterolemia treatment: current perspectives and hopes. 2018 , 50, 303-311		12
824	Usefulness of an Online Risk Estimator for Bronchopulmonary Dysplasia in Predicting Corticosteroid Treatment in Infants Born Preterm. 2018 , 197, 23-28.e2		10
823	Delayed flow-mediated vasodilation and critical coronary stenosis. 2018 , 66, 1-7		14
822	Diabetic Kidney Disease: A Determinant of Cardiovascular Risk in Type 1 Diabetes. 2018 , 41, 662-663		8
821	Atherosklerose-Screening der karotidalen und peripheren Arterien. 2020 , 25, 143-149		
820	Short-Term Progression of Multiterritorial Subclinical Atherosclerosis. <i>Journal of the American College of Cardiology</i> , 2020 , 75, 1617-1627	15.1	23
819	Low-Density Lipoprotein Cholesterol: Lower Is Totally Better. <i>Journal of the American College of Cardiology</i> , 2020 , 75, 2119-2121	15.1	9
818	Aloe-emodin exerts cholesterol-lowering effects by inhibiting proprotein convertase subtilisin/kexin type 9 in hyperlipidemic rats. 2020 , 41, 1085-1092		13
817	2019 vs. 2016 ESC/EAS statin guidelines for primary prevention of atherosclerotic cardiovascular disease. 2020 , 41, 3005-3015		17
816	MicroRNA 27a Is a Key Modulator of Cholesterol Biosynthesis. 2020 , 40,		13
815	Olinciguat, an Oral sGC Stimulator, Exhibits Diverse Pharmacology Across Preclinical Models of Cardiovascular, Metabolic, Renal, and Inflammatory Disease. 2020 , 11, 419		16
814	Ultrasonography involvement of carotid, upper and lower limb arteries in a large cohort of systemic sclerosis patients. 2020 , 23, 681-692		1
813	HDL-C is associated with mortality from all causes, cardiovascular disease and cancer in a J-shaped dose-response fashion: a pooled analysis of 37 prospective cohort studies. 2020 , 27, 1187-1203		28
812	Design and rationale of a randomized control trial testing the effectiveness of combined therapy with Statin plus FENOibrate and statin alone in non-diabetic, combined dyslipidemia patients with non-intervened intermediate coronary artery disease - STAFENO study. 2020 , 21, 353		1
811	Changes in nationwide Medicare and Medicaid expenditures on lipid-lowering therapies after proprotein convertase/subtilisin type 9 inhibitor availability. 2020 , 14, 315-321.e4		1

810	Degradation versus Inhibition: Development of Proteolysis-Targeting Chimeras for Overcoming Statin-Induced Compensatory Upregulation of 3-Hydroxy-3-methylglutaryl Coenzyme A Reductase. 2020 , 63, 4908-4928	17
809	Statin therapy in acute cardioembolic stroke with no guidance-based indication. 2020 , 94, e1984-e1995	11
808	Long-Term Benefit and Withdrawal Effect of Statins After Percutaneous Coronary Intervention: A Nationwide Population-Based Cohort Study. 2020 , 14, 717-724	2
807	Predicted Versus Observed Major Adverse Cardiac Event Risk in Women With Evidence of Ischemia and No Obstructive Coronary Artery Disease: A Report From WISE (Women's Ischemia Syndrome Evaluation). 2020 , 9, e013234	6
806	Hyperuricemia and its association with adiposity and dyslipidemia in Northwest China: results from cardiovascular risk survey in Xinjiang (CRS 2008-2012). 2020 , 19, 58	20
805	Healthcare resource utilization in patients on lipid-lowering therapies outside Western Europe and North America: findings of the cross-sectional observational International Cholesterol management Practice Study (ICLPS). 2020 , 19, 64	0
804	Unraveling Host-Gut Microbiota Dialogue and Its Impact on Cholesterol Levels. 2020 , 11, 278	20
803	Detection of subclinical atherosclerosis in peripheral arterial beds with B-mode ultrasound: a proposal for guiding the decision for medical intervention and an artifact-corrected volumetric scoring index. 2014 , 9, 367-78	9
802	The U.S. prevention of cardiovascular disease guidelines and implications for implementation in LMIC. 2014 , 9, 445-55	3
801	Increased awareness, inadequate treatment, and poor control of cardiovascular risk factors in American young adults: 2005-2016. 2020 , 2047487320905190	10
800	Concepts and Controversies: Lipid Management in Patients with Chronic Kidney Disease. 2021 , 35, 479-489	2
799	Cardiovascular Risk Scores in Axial Spondyloarthritis Versus the General Population: A Cross-sectional Study. 2021 , 48, 361-366	0
798	Verification of Low-Density Lipoprotein Cholesterol Levels Measured by Anion-Exchange High-Performance Liquid Chromatography in Comparison with Beta Quantification Reference Measurement Procedure. 2021 , 6, 654-667	2
797	Examining the Nocebo Effect of Statins Through Statin Adverse Events Reported in the Food and Drug Administration Adverse Event Reporting System. 2021 , 14, e007480	5
796	Diabetes associated residual atherosclerotic cardiovascular risk in statin-treated patients with prior atherosclerotic cardiovascular disease. 2021 , 35, 107767	2
795	A Telehealth-supported, Integrated care with CHWs, and Medication-access (TIME) Program for Diabetes Improves HbA1c: a Randomized Clinical Trial. 2021 , 36, 455-463	9
794	Prevalence and Predictors of Out-of-Target LDL Cholesterol 1 to 3 Years After Myocardial Infarction. A Subanalysis From the EYESHOT Post-MI Registry. 2021 , 26, 149-157	4
793	Can N-3 polyunsaturated fatty acids be considered a potential adjuvant therapy for COVID-19-associated cardiovascular complications?. 2021 , 219, 107703	31

792	Prior statin therapy and 30-day mortality in South Korean patients with acute respiratory distress syndrome. 2021 , 65, 236-243	
791	Higher oxidized high-density lipoprotein to apolipoprotein A-I ratio is associated with high-risk coronary plaque characteristics determined by CT angiography. 2021 , 324, 193-198	6
790	Precision population analytics: population management at the point-of-care. 2021 , 28, 588-595	3
789	Statin Therapy for Primary Prevention in the Elderly and Its Association with New-Onset Diabetes, Cardiovascular Events, and All-Cause Mortality. 2021 , 134, 643-652	3
788	Chronic kidney disease and statin eligibility. 2021 , 15, 173-180	1
787	The protective effect of statins against pressure ulcers in stroke patients: A propensity-score matched study based on a real-world database. 2021 , 317, 22-28	1
786	Statin use and new-onset of inflammatory bowel disease: A systematic review and meta-analysis of over ten million participants. 2021 , 891, 173750	2
785	Association Between Low-Density Lipoprotein Cholesterol Levels, Statin Use, and Dementia in Patients followed in German General Practices. 2021 , 79, 37-46	9
784	Serum lipoprotein(a) and risk of periprocedural myocardial injury in patients undergoing percutaneous coronary intervention. 2020 , 44, 176	4
783	Cardiac allograft vasculopathy: Differences of absolute and relative intimal hyperplasia in children versus adults in optical coherence tomography. 2021 , 328, 227-234	2
782	Analysis of Risk Factors for Hepatotoxicity Induced by Immune Checkpoint Inhibitors. 2021 , 44, 16-21	5
781	Evaluation of physician's knowledge in Jordan about the ACC/AHA blood cholesterol guidelines. 2021 , 75, e13784	1
780	Treatment intensification in type 2 diabetes management after the failure of two oral hypoglycemic agents: A non-interventional comparative study. 2021 , 75, e13802	
779	Lipid reference values in an Irish population. 2021 , 190, 117-127	2
778	Rates, determinants and success of implementing deprescribing in people with type 2 diabetes: A scoping review. 2021 , 38, e14408	5
777	Efficacy of oral rosuvastatin intervention on HDL and its associated proteins in men with type 2 diabetes mellitus. 2021 , 71, 76-86	2
776	A Pilot Study Embedding Clinical Pharmacists Within an Interprofessional Nephrology Clinic for the Initiation and Monitoring of Empagliflozin in Diabetic Kidney Disease. 2021 , 34, 428-437	5
775	Targeting the peptidase PCSK9 to reduce cardiovascular risk: Implications for basic science and upcoming challenges. 2021 , 178, 2168-2185	2

774	Most important advances in preventive cardiology during this past decade: Viewpoint from the American Society for Preventive Cardiology. 2021 , 31, 49-56	6
773	Effects of statins on cytokines levels in gingival crevicular fluid and saliva and on clinical periodontal parameters of middle-aged and elderly patients with type 2 diabetes mellitus. 2021 , 16, e0244806	2
772	An observational study on the effect of hypercholesterolemia developed after living donor liver transplantation on cardiac event and graft failure. 2021 , 11, 959	1
771	Kawasaki Disease. 2021 , 179-199	
770	Regulatory environment for novel therapeutic development in mitochondrial diseases. 2021 , 44, 292-300	
769	Reduced Serum Zinc Ion Concentration Is Associated with Coronary Heart Disease. 2021 , 199, 4109-4118	6
768	Significant Facility-Level Variation in Utilization of and Adherence with Secondary Prevention Therapies Among Patients with Premature Atherosclerotic Cardiovascular Disease: Insights from the VITAL (Veterans with premaTure Atherosclerosis) Registry7. 2021 , 1	2
767	Lipid Management and 2-Year Clinical Outcomes in Japanese Patients with Acute Coronary Syndrome: EXPLORE-J. 2021 , 28, 1307-1322	0
766	Effect of atorvastatin on testosterone levels. 2021 , 1, CD013211	2
765	Association of Sex and Cardiovascular Risk Factors with Atherosclerosis Distribution Pattern in Lower Extremity Peripheral Artery Disease.	
764	Bile Acid Sequestrants Are Contraindicated for Patients With Hypertrigly-ceridemia: A Case Report. 2021 , 116, 1352	
763	Shared Decision Making. 2021 , 169-192	
762	Therapies for the Treatment of Cardiovascular Disease Associated with Type 2 Diabetes and Dyslipidemia. 2021 , 22,	6
761	A Cross-Sectional Study of the Effects of Physical Activity and Nutrient Intakes on Blood Glucose Control Rates in Middle-Aged and Elderly Diabetes Patients: Korean National Health and Nutrition Examination Survey 2015-2017. 2021 , 58, 469580211035727	
760	Dyslipidemia and Cardiometabolic Syndrome. 2021 , 1, 18	1
759	Efficacy and safety of berberine for dyslipidemia: study protocol for a randomized double-blind placebo-controlled trial. 2021 , 22, 85	4
758	Statin eligibility based on the ACC/AHA guidelines among Middle Eastern patients with diabetes mellitus presenting with acute myocardial infarction. 2021 , 61, 148-154	0
757	Exploring the causal roles of circulating remnant lipid profile on cardiovascular and cerebrovascular diseases: Mendelian randomization study. 2021 ,	4

756	Cardiovascular Risk Assessment in Hypertensive Patients. 2021 , 34, 569-577	2
755	Statins and risk of diverticular disease: Nested case-control study. 2021 , 30, 770-778	
754	Effect of DLT-SML on Chronic Stable Angina Through Ameliorating Inflammation, Correcting Dyslipidemia, and Regulating Gut Microbiota. 2021 , 77, 458-469	4
753	Assessment and Management of Cardiovascular Risk Factors Among US Veterans With Prostate Cancer. 2021 , 4, e210070	6
752	Medical therapy for cardiovascular and limb-related risk reduction in critical limb ischemia. 2021 , 26, 210-224	1
751	Epidemiologic Profile of Hypertension in Northern Iranian Population: The PERSIAN Guilan Cohort Study (PGCS). 2021 , 87, 14	1
750	Comparative effect of physical exercise versus statins on improving arterial stiffness in patients with high cardiometabolic risk: A network meta-analysis. 2021 , 18, e1003543	2
749	Clinical Prediction Models for Primary Prevention of Cardiovascular Disease: Validity in Independent Cohorts.	
748	Lipid profile and prognosis in patients with coronary heart disease: a meta-analysis of prospective cohort studies. 2021 , 21, 69	3
747	Geographic Variation of Statin Use Among US Nursing Home Residents With Life-limiting Illness. 2021 , 59, 425-436	0
746	Association Between Statin Use at the Time of Intra-abdominal Surgery and Postoperative Adhesion-Related Complications and Small-Bowel Obstruction. 2021 , 4, e2036315	3
745	Clinician prescription of lipid-lowering drugs and achievement of treatment goals in patients with newly diagnosed type 2 diabetes mellitus. 2021 , 9,	
744	Assessment of atherosclerotic cardiovascular disease risks between people living with HIV receiving first-line and second-line antiretroviral therapy in a resource-limited setting. 2021 , 32, 421-426	0
743	Precision clinical trials: a framework for getting to precision medicine for neurobehavioural disorders. 2021 , 46, E97-E110	6
742	Learning latent heterogeneity for type 2 diabetes patients using longitudinal health markers in electronic health records. 2021 , 40, 1930-1946	
741	Analytical performance of Raman spectroscopy in assaying biochemical components in human serum. 2021 , 1	3
740	Absolute risk assessment for guiding cardiovascular risk management in a chest pain clinic. 2021 , 214, 266-271	3
739	Incorporating Coronary Calcium Scoring Into Risk Assessment For Primary Prevention. 2021 , 14, 422-425	1

738	Prevalence and Factors Associated With Statin Use Among Patients With Nonalcoholic Fatty Liver Disease in the TARGET-NASH Study. 2021,	6
737	Emerging approaches to polypharmacy among older adults. 2021, 1, 347-356	3
736	Preoperative coronary artery calcifications in veterans predict higher all-cause mortality in early-stage lung cancer: a cohort study. 2021, 13, 1427-1433	0
735	Effectiveness of an Intervention Aimed at Improving Information for Patients with High Cardiovascular Risk: INFORISK Clinical Trial. 2021, 18,	0
734	National Trends in Statin Use among the United States Nursing Home Population (2011-2016). 2021, 38, 427-439	1
733	Higher Diet Quality in African-American Adolescents Is Associated with Lower Odds of Metabolic Syndrome: Evidence from the NHANES. 2021, 151, 1609-1617	1
732	Invasive Management of Coronary Artery Disease in Advanced Renal Disease. 2021, 6, 1513-1524	3
731	Characterization of Gut Microbiome in Korean Patients with Metabolic Associated Fatty Liver Disease. 2021, 13,	4
730	Ten things to know about ten cardiovascular disease risk factors. 2021, 5, 100149	19
729	Sex- and Gender-Based Pharmacological Response to Drugs. 2021, 73, 730-762	27
728	Apolipoproteins and liver parameters optimize cardiovascular disease risk-stratification in nonalcoholic fatty liver disease. 2021, 53, 1610-1619	1
727	An Academic-Community Collaboration to Deliver Medication Therapy Management (MTM) Services to Patients Living in Rural Counties of a Southwestern State in the United States. 2021, 8971900211000219	
726	Effect of statins on the risk of recurrent venous thromboembolism: A systematic review and meta-analysis. 2021, 165, 105413	2
725	Cardiovascular Imaging Techniques for Detection of Vulnerable Plaques. 2021, 6, 21-26	
724	A Ketogenic Low-Carbohydrate High-Fat Diet Increases LDL Cholesterol in Healthy, Young, Normal-Weight Women: A Randomized Controlled Feeding Trial. 2021, 13,	8
723	Risk Stratification With the Use of Coronary Computed Tomographic Angiography in Patients With Nonobstructive Coronary Artery Disease. 2021, 14, 2186-2195	1
722	Recent Development in Nanomaterial-Based Electrochemical Sensors for Cholesterol Detection. 2021, 9, 98	5
721	Association between Serum Folic Acid Level and the Risk of Atherosclerotic Cardiovascular Disease within 10 Years: The 7th (2016-2018) Korean National Health and Nutrition Examination Survey. 2021, 11, 106-112	

720	Non-HDL-C Is More Stable Than LDL-C in Assessing the Percent Attainment of Non-fasting Lipid for Coronary Heart Disease Patients. 2021 , 8, 649181	3
719	Endothelial Dysfunction, Inflammation and Coronary Artery Disease: Potential Biomarkers and Promising Therapeutical Approaches. 2021 , 22,	32
718	Dyslipidemia and its associated factors in southern Iranian women, Bandare-Kong Cohort study, a cross-sectional survey. 2021 , 11, 9125	1
717	Cardiovascular Risk Misperception and Low Awareness of Familial Hypercholesterolemia in Individuals with Severe Hypercholesterolemia. 2021 , 116, 706-712	0
716	Clinical considerations after endovascular therapy of peripheral artery disease. 2021 , 19, 369-378	1
715	Indices of Cardiovascular Health, Body Composition and Aerobic Endurance in Young Women; Differential Effects of Two Endurance-Based Training Modalities. 2021 , 9,	3
714	Association between CVDs and initiation and adherence to statin treatment in patients with newly diagnosed hypercholesterolaemia: a retrospective cohort study. 2021 , 11, e045375	4
713	Differences in glycated hemoglobin levels and cholesterol levels in individuals with diabetes according to Helicobacter pylori infection. 2021 , 11, 8416	1
712	Hormone Therapy in Menopause: Concepts, Controversies, and Approach to Treatment. 2021 , 42, 720-752	6
711	Predictors of change in cardiovascular disease risk and events following gastric bypass: a 7-year prospective multicenter study. 2021 , 17, 910-918	
710	Evaluation of statin discontinuation stratified by primary versus secondary prevention following bariatric surgery: a retrospective cohort study. 2021 , 17, 939-946	
709	Prediction of future cardiovascular events by Framingham, SCORE and asCVD risk scores is less accurate in HIV-positive individuals from the HIV-HEART Study compared with the general population. 2021 , 22, 732-741	1
708	Gender differences in the associations among fish intake, lifestyle, and non-HDL-C level in Japanese subjects over the age of 50 years: Anti-atherosclerotic effect of fish consumption. 2021 , 31, 1434-1444	3
707	., Genes as Feasible Markers for Premature Coronary Heart Disease Risk. 2021 , 12, 598296	0
706	SACRED: Effect of simvastatin on hepatic decompensation and death in subjects with high-risk compensated cirrhosis: Statins and Cirrhosis: Reducing Events of Decompensation. 2021 , 104, 106367	2
705	Association between antecedent statin use and severe disease outcomes in COVID-19: A retrospective study with propensity score matching. 2021 , 15, 451-459	9
704	Association Between Renal Dysfunction and Low HDL Cholesterol Among the Elderly in China. 2021 , 8, 644208	0
703	Stroke risk prediction using machine learning: a prospective cohort study of 0.5 million Chinese adults. 2021 , 28, 1719-1727	6

702	High hydrostatic pressure extract of mulberry leaves ameliorates hypercholesterolemia via modulating hepatic microRNA-33 expression and AMPK activity in high cholesterol diet fed rats. 2021 , 65,	4
701	Cardiovascular disease (CVD) risk scores, age, or years since menopause to predict cardiovascular disease in the Women's Health Initiative. 2021 , 28, 610-618	5
700	Trends in the Utilization of Lipid-Lowering Medications in Australia: An Analysis of National Pharmacy Claims Data. 2021 , 100880	2
699	Role of coronary artery calcium score in the primary prevention of cardiovascular disease. 2021 , 373, n776	12
698	Prevalence of SLCO1B1 single nucleotide variations and their association with hypercholesterolaemia in hypercholesterolemic patients in Gauteng, South Africa. 2021 , 51, 949-959	
697	Racism and Kidney Health: Turning Equity Into a Reality. 2021 , 77, 951-962	8
696	Statin therapy is associated with epigenetic modifications in individuals with Type 2 diabetes. 2021 , 13, 919-925	2
695	Dietary phytochemical index associated with cardiovascular risk factor in patients with type 1 diabetes mellitus. 2021 , 21, 293	1
694	Effects of mineral oil administration on the pharmacokinetics, metabolism and pharmacodynamics of atorvastatin and pravastatin in mice and dogs. 2021 , 161, 105776	2
693	Atorvastatin Promotes Macrocalcification, But Not Microcalcification in Atherosclerotic Rabbits: An 18F-NaF PET/CT Study. 2021 , 78, 544-550	1
692	Antithrombotische Therapie der peripheren arteriellen Verschlusskrankheit. 2021 , 26, 415-428	
691	Utilizing coronary artery calcium to guide statin use. 2021 , 326, 17-24	2
690	Degree of arterial stiffness is comparable across inflammatory joint disease entities. 2021 , 1-10	1
689	The Johns Hopkins Ciccarone Center's expanded 'ABC's approach to highlight 2020 updates in cardiovascular disease prevention. 2021 , 6, 100181	
688	Switching, Persistence and Adherence to Statin Therapy: a Retrospective Cohort Study Using the Australian National Pharmacy Data. 2021 , 1	3
687	The risk of ischemic stroke and hemorrhagic stroke in Chinese adults with low-density lipoprotein cholesterol concentrations . 2021 , 19, 142	1
686	Statin Intolerance: Alternative Therapy for Lipid Management. 2021 , 9, 50-54	
685	Preoperative statin therapy is associated with higher 5-year survival after thoracic endovascular aortic repair. 2021 , 74, 1996-2005	1

684	Multimodality imaging for the prevention of cardiovascular events: Coronary artery calcium and beyond. 2021 , 11, 840-858		1
683	Effectiveness of Blood Lipid Management in Patients With Peripheral Artery Disease. <i>Journal of the American College of Cardiology</i> , 2021 , 77, 3016-3027	15.1	4
682	Is There a Role of Coronary CTA in Primary Prevention? Current State and Future Directions. 2021 , 23, 44		2
681	Hydroxychloroquine use and blood pressure below 130/80 are associated with remission in lupus nephritis: A cohort study. 2021 , 28, 109-109		
680	The Incidence, Risk Factors, and Patterns of Peripherally Inserted Central Catheter-Related Venous Thrombosis in Cancer Patients Followed Up by Ultrasound. 2021 , 13, 4329-4340		1
679	High-dose statin pretreatment decreases periprocedural myocardial infarction and cardiovascular events in East Asian patients undergoing percutaneous coronary intervention: A meta-analysis of fifteen randomized controlled trials. 2021 , 100, e26278		0
678	Prognostic Value of Intraplaque Neovascularization Detected by Carotid Contrast-Enhanced Ultrasound in Patients Undergoing Stress Echocardiography. 2021 , 34, 614-624		3
677	Appraisal of amiodarone-loaded PLGA nanoparticles for prospective safety and toxicity in a rat model. 2021 , 274, 119344		1
676	Targeting the Cholesterol Paradigm in the Risk Reduction for Atherosclerotic Cardiovascular Disease: Does the Mechanism of Action of Pharmacotherapy Matter for Clinical Outcomes?. 2021 , 26, 533-549		2
675	An exploratory survey on the awareness and usage of clinical practice guidelines among clinical pharmacists.. 2021 , 2, 100013		
674	Statins and clinical outcomes in hospitalized COVID-19 patients with and without Diabetes Mellitus: a retrospective cohort study with propensity score matching. 2021 , 20, 140		7
673	Statin use and survival in 16 098 patients with non-Hodgkin lymphoma or chronic lymphocytic leukaemia treated in the rituximab era. 2021 , 195, 552-560		1
672	Effects of Statins After Transcatheter Aortic Valve Implantation in Key Patient Populations. 2021 , 78, e669-e674		1
671	A cluster randomized trial to evaluate a centralized remote clinical pharmacy service in large, health system primary care clinics. 2021 , 4, 1287		
670	Oxysterol species generated by auto-oxidation in subclinical hypothyroidism. 2021 , 93, 73-79		1
669	Real-world Evidence for Preventive Effects of Statins on Cancer Incidence: A Trans-Atlantic Analysis.		
668	Use of Lipid-Lowering Drugs and Associated Outcomes According to Health State Profiles in Hospitalized Older Patients. 2021 , 16, 1251-1264		1
667	Use of statin for the primary prevention of cardiovascular outcomes in elderly patients: A propensity-matched cohort study. 2021 , 328, 92-99		2

666	Statins and cognitive decline in the Cardiovascular Health Study: A comparison of different analytical approaches. 2021 ,		0
665	Lipid Monitoring After Initiation of Lipid-Lowering Therapies: Return of Performance Measures?. 2021 , 23, 116		1
664	Department of Veterans Affairs (VA) and U.S. Department of Defense (DoD) guidelines for management of dyslipidemia and cardiovascular disease risk reduction: Putting evidence in context. 2021 , 68, 2-6		0
663	Hypertriglyceridemia during hospitalization independently associates with mortality in patients with COVID-19. 2021 ,		4
662	Celecoxib exhibits therapeutic potential in experimental model of hyperlipidaemia. 2021 , 16, e0247735		
661	Sudden cardiac death among Iranian population: a two decades follow-up of Tehran lipid and glucose study. 2021 , 11, 15720		0
660	Efficacy of a hypolipid diet in patients with primary antiphospholipid syndrome with dyslipidemia: a prospective study. 2021 , 1		0
659	The Combination Effect of Simvastatin and Virgin Coconut Oil on Total Cholesterol Levels in Dislipidemic Male Albino Rats (<i>Rattus norvegicus</i>). 2021 , 12, 72		
658	Metal-based nanoparticles: Promising tools for the management of cardiovascular diseases. 2021 , 36, 102433		4
657	Renal denervation as a management strategy for hypertension: current evidence and recommendations. 2021 , 19, 825-835		
656	Association between cardiovascular mortality and STOP-Bang questionnaire scores in a cohort of hospitalized patients: a prospective study. 2021 , 47, e20210039		0
655	Effects of high rosuvastatin doses on hepatocyte mitochondria of hypercholesterolemic mice. 2021 , 11, 15809		0
654	Contributions of Preterm Delivery to Cardiovascular Disease Risk Prediction in Women. 2021 , 30, 1431-1439		1
653	Mobile Technology Improves Adherence to Cardiac Rehabilitation: A Propensity Score-Matched Study. 2021 , 10, e020482		1
652	Managing Ischemic Heart Disease in Women: Role of a Women's Heart Center. 2021 , 23, 56		2
651	Barriers in utilizing lipid-lowering agents in non-institutionalized population in the U.S.: Application of a theoretical framework. 2021 , 16, e0255729		0
650	2021 ACC Expert Consensus Decision Pathway on the Management of ASCVD Risk Reduction in Patients With Persistent Hypertriglyceridemia: A Report of the American College of Cardiology Solution Set Oversight Committee. <i>Journal of the American College of Cardiology</i> , 2021 , 78, 960-993	15.1	28
649	Mentored implementation to initiate a diabetes program in an underserved community: a pilot study. 2021 , 9,		0

648	Lipoprotein(a) in hereditary hypercholesterolemia: Influence of the genetic cause, defective gene and type of mutation. 2021 ,	3
647	An evolutionarily-conserved promoter allele governs HMG-CoA reductase expression in spontaneously hypertensive rat. 2021 , 158, 140-152	0
646	Switch from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in People Living with HIV: Lipid Changes and Statin Underutilization. 2021 , 41, 955-965	1
645	Have We Learnt all from IMPROVE-IT? Part I. Core Results and Subanalyses on the Effects of Ezetimibe Added to Statin Therapy Related to Age, Gender and Selected Chronic Diseases (Kidney Disease, Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease). 2021 , 19, 451-468	2
644	Mortality associated with stopping statins in the oldest-old - with and without ischemic heart disease. 2021 , 100, e26966	0
643	Pharmacometabolomics: A New Horizon in Personalized Medicine.	1
642	Inflammation, Oxidative Stress, Vascular Aging And Atherosclerotic Ischemic Stroke. 2021 ,	0
641	Effect of Atorvastatin (10 mg) and Ezetimibe (10 mg) Combination Compared to Atorvastatin (40 mg) Alone on Coronary Atherosclerosis. 2021 , 154, 22-28	0
640	A Multicenter Prospective Hospital-based Cohort Study on the Efficacy and Safety of Pitavastatin. 2021 , 17, e122820189541	2
639	Pooled Cohort Equations and the competing risk of cardiovascular disease versus cancer: Multi-Ethnic study of atherosclerosis. 2021 , 7, 100212	2
638	Statin Use in Older Adults for Primary Cardiovascular Disease Prevention Across a Spectrum of Cardiovascular Risk. 2021 , 1	0
637	The impact of a population-based prevention program on cardiovascular events: Findings from the heart of new Ulm project. 2021 , 239, 38-51	0
636	A multistate transition model for statin-induced myopathy and statin discontinuation. 2021 , 10, 1236-1244	2
635	Altered Lipid Profile Is a Risk Factor for the Poor Progression of COVID-19: From Two Retrospective Cohorts. 2021 , 11, 712530	0
634	Coronary Microcalcification. 2022 , 139-175	
633	Barriers to healthy lifestyle behaviours and adherence to physical activity and dietary guidelines by older Australians: A descriptive analysis. 2021 , 25, 200127	1
632	Population health management of low-density lipoprotein cholesterol via a remote, algorithmic, navigator-executed program. 2022 , 243, 15-27	0
631	Nilotinib vs. imatinib in Japanese patients with newly diagnosed chronic myeloid leukemia in chronic phase: 10-year follow-up of the Japanese subgroup of the randomized ENESTnd trial. 2021 , 1	0

630	Atherosclerotic cardiovascular disease thresholds for statin initiation among people living with HIV in Thailand: A cost-effectiveness analysis. 2021 , 16, e0256926	
629	Lower-Intensity Statins Contributing to Gaps in Care for Patients With Primary Severe Hypercholesterolemia. 2021 , 10, e020800	2
628	The effects of the Dietary Approaches to Stop Hypertension (DASH) diet on metabolic risk factors in patients with chronic disease: A systematic review and meta-analysis of randomized controlled trials. 2021 , 31, 2766-2778	6
627	Effects of Statin Therapy and Dose on Cardiovascular and Limb Outcomes in Peripheral Arterial Disease: A Systematic Review and Meta-analysis. 2021 , 62, 450-461	3
626	Euphornin L promotes lipid clearance by dual regulation of LDLR and PCSK9. 2021 , 22, 1381	
625	Statins: Neurobiological underpinnings and mechanisms in mood disorders. 2021 , 128, 693-708	3
624	PROTACs technology for targeting non-oncoproteins: Advances and perspectives. 2021 , 114, 105109	5
623	Validation of the youth mood recurrences risk calculator in an adult sample with bipolar disorder. 2021 , 295, 1482-1488	0
622	Low Skeletal Muscle Mass Is Associated With the Presence, Incidence, and Progression of Coronary Artery Calcification. 2021 , 37, 1480-1488	1
621	Statins for Graves' orbitopathy (STAGO): a phase 2, open-label, adaptive, single centre, randomised clinical trial. 2021 , 9, 733-742	9
620	Dietary Lipids and Dyslipidemia in Chronic Kidney Disease. 2021 , 13,	2
619	Polygenic risk scores in the clinic: Translating risk into action.. 2021 , 2, 100047	2
618	Large-Scale Screening for Monogenic and Clinically Defined Familial Hypercholesterolemia in Iceland. 2021 , 41, 2616-2628	4
617	When is it Appropriate to Lower Low Density Lipoprotein-Cholesterol Levels to . 2021 , 157, 142-144	0
616	Sinomenine in Cardio-Cerebrovascular Diseases: Potential Therapeutic Effects and Pharmacological Evidences. 2021 , 8, 749113	1
615	Cardioprotective effects of resistance training add to those of total activity in Americans. 2021 , 62, 13-18	1
614	Gypenoside LVI improves hepatic LDL uptake by decreasing PCSK9 and upregulating LDLR expression. 2021 , 91, 153688	5
613	Familial Hypercholesterolaemia in the Malaysian Community: Prevalence, Under-Detection and Under-Treatment. 2021 , 28, 1095-1107	3

612	Comparative performance of the two pooled cohort equations for predicting atherosclerotic cardiovascular disease. 2021 , 334, 23-29	
611	Associations of solid fuel use and ambient air pollution with estimated 10-year atherosclerotic cardiovascular disease risk. 2021 , 157, 106865	2
610	Cardiac Computed Tomography. 2022 , 131-174	
609	Treatment and Management of Infectious, Granulomatous, and Toxic Neuromuscular Disorders. 2022 , 345-379	
608	Adherence to Statins Use and Risk of Dementia among Patients with Diabetes and Comorbid Hyperlipidemia. 2021 , 58, 469580211019201	
607	Is Statin Use Associated With Risk of Thyroid Diseases? Results of a Retrospective Cohort Study. 2021 , 55, 1110-1119	1
606	Infection-Induced Rhabdomyolysis in an Elderly Patient on Stable Rosuvastatin Therapy: A Case Report and Review of the Literature. 2021 ,	1
605	Atorvastatin is associated with reduced cisplatin-induced hearing loss. 2021 , 131,	13
604	New molecular entities and structure-activity relationships of drugs designed by the natural product derivatization method from 2010 to 2018. 2021 , 69, 371-415	0
603	Diabetes and coronary circulation: From pathology to imaging. 2021 , 227-267	
602	Suppressive effects of quercetin on hydrogen peroxide-induced caveolin-1 phosphorylation in endothelial cells. 2021 , 69, 28-36	1
601	Retrospective cohort study of statin prescribing for primary prevention among people living with HIV. 2021 , 10, 20480040211031068	
600	Clustering of cardiometabolic risk factors in sub-Saharan Africans. 2021 , 38, 112	
599	Association between renal function and platelet reactivity during aspirin therapy in elderly patients with atherosclerotic cardiovascular disease. 2021 , 21, 75	0
598	Genetics of Smoking and Risk of Atherosclerotic Cardiovascular Diseases: A Mendelian Randomization Study. 2021 , 4, e2034461	11
597	Water Soluble Vitamins: B1, B2, B3, and B6. 2021 , 569-596	
596	Cardiac Prevention Guidelines. 2015 , 21-36	1
595	Vaccination to Prevent Cardiovascular Disease. 2017 , 29-52	1

594	Lifestyle Interventions for Primary and Secondary Prevention of Cardiovascular Disease. 2015 , 1695-1718	1
593	Translating Comparative Effectiveness Research Evidence to Real-World Decision Making: Some Practical Considerations. 2017 , 105-116	1
592	Management and Care of Older Cardiac Patients. 2018 , 245-265	6
591	PCSK9 inhibitors in the current management of atherosclerosis. 2017 , 87, 43-48	6
590	Dyslipidaemias and their treatment in high complexity centres in Colombia. 2020 , 32, 101-110	1
589	Statins for primary prevention in adults aged 75 years and older: A nationwide population-based case-control study. 2019 , 283, 28-34	14
588	A randomized controlled trial of eicosapentaenoic acid in patients with coronary heart disease on statins. 2017 , 70, 537-544	71
587	Comparison of Transatlantic Approaches to Lipid Management: The AHA/ACC/Multisociety Guidelines vs the ESC/EAS Guidelines. 2020 , 95, 998-1014	3
586	An integrated method of therapeutic lifestyle change for older adults with dyslipidaemia. 2017 , 148, 30-36	1
585	Recomendaciones para mejorar el control lipídico. Documento de consenso de la Sociedad Española de Cardiología. 2020 , 73, 161-167	20
584	[Diagnostic and Therapeutic Management of Carotid Artery Disease]. 2020 , 109, 705-723	2
583	Safety and efficacy of alirocumab in a real-life setting: the ODYSSEY APPRISE study. 2020 ,	5
582	Effectiveness of NPs and PAs in managing diabetes and cardiovascular disease. 2018 , 31, 39-45	9
581	First international consensus on the diagnosis and management of fibromuscular dysplasia. 2019 , 37, 229-252	48
580	Multicenter AIDS Cohort Study Quantitative Coronary Plaque Progression Study: rationale and design. 2018 , 29, 23-29	4
579	KDIGO Clinical Practice Guideline on the Evaluation and Care of Living Kidney Donors. 2017 , 101, S1-S109	209
578	MicroRNA-27a is a key modulator of cholesterol biosynthesis.	1
577	Patients who discontinued statin treatment: a protocol for cohort study using primary care data. 2015 , 5, e008701	4

576	Cardiovascular imaging to guide primary prevention. 2020 , 106, 1267-1275	1
575	Use and Customization of Risk Scores for Predicting Cardiovascular Events Using Electronic Health Record Data. 2017 , 6,	20
574	Unnecessary repeated total cholesterol tests in biochemistry laboratory. 2016 , 26, 77-81	2
573	Management of atherosclerosis risk factors for patients at high cardiovascular risk in real-world practice: a multicentre study. 2017 , 58, 535-542	12
572	Evaluation of direct-to-consumer low-volume lab tests in healthy adults. 2016 , 126, 1734-44	24
571	Statins for primary cardiovascular prevention in the elderly. 2015 , 12, 431-8	24
570	Decreased expression of Klotho in cardiac atria biopsy samples from patients at higher risk of atherosclerotic cardiovascular disease. 2016 , 13, 701-711	23
569	Cardiac drug therapy-considerations in the elderly. 2016 , 13, 992-997	5
568	2016 Chinese guidelines for the management of dyslipidemia in adults. 2018 , 15, 1-29	142
567	The rate of patients at high risk for cardiovascular disease with an optimal low-density cholesterol level: a multicenter study from Thailand. 2019 , 16, 344-353	1
566	Stroke Epidemiology and Risk Factor Management. 2017 , 23, 15-39	137
565	Non-HDL cholesterol is better than LDL-c at predicting atherosclerotic cardiovascular disease risk factors clustering, even in subjects with near-to-normal triglycerides: A report from a Venezuelan population. 7, 504	3
564	Statin non-adherence: clinical consequences and proposed solutions. 2016 , 5,	8
563	Comparing High-Intensity Versus Low-to Moderate-Intensity Statin Therapy in Korean Patients with Acute Myocardial Infarction. 2014 , 3, 97	6
562	The Potential Role of Biomarkers Associated with ASCVD Risk: Risk-Enhancing Biomarkers. 2019 , 8, 173-182	8
561	Primary prevention of cardiovascular disease in older adults in China. 2017 , 5, 349-359	10
560	Design of the New York City Macroscopic: Innovations in Population Health Surveillance Using Electronic Health Records. 2016 , 4, 1265	24
559	LSPR-based cholesterol biosensor using a tapered optical fiber structure. 2019 , 10, 2150-2160	46

558	Caveolin contributes to the modulation of basal and β -adrenoceptor stimulated function of the adult rat ventricular myocyte by simvastatin: a novel pleiotropic effect. 2014 , 9, e106905	18
557	Cost-effectiveness of coronary artery calcium testing for coronary heart and cardiovascular disease risk prediction to guide statin allocation: the Multi-Ethnic Study of Atherosclerosis (MESA). 2015 , 10, e0116377	70
556	Accumulation of cardiovascular and diabetes medication among apparently healthy statin initiators. 2015 , 10, e0117182	1
555	The Effect of Statin Therapy on Coronary Plaque Composition Using Virtual Histology Intravascular Ultrasound: A Meta-Analysis. 2015 , 10, e0133433	10
554	Strategies for Primary Prevention of Coronary Heart Disease Based on Risk Stratification by the ACC/AHA Lipid Guidelines, ATP III Guidelines, Coronary Calcium Scoring, and C-Reactive Protein, and a Global Treat-All Strategy: A Comparative-Effectiveness Modeling Study. 2015 , 10, e0138092	24
553	Statin Intensity or Achieved LDL? Practice-based Evidence for the Evaluation of New Cholesterol Treatment Guidelines. 2016 , 11, e0154952	7
552	Subclinical Inflammation and Endothelial Dysfunction in Young Patients with Diabetes: A Study from United Arab Emirates. 2016 , 11, e0159808	16
551	Statin Use and Self-Reported Hindering Muscle Complaints in Older Persons: A Population Based Study. 2016 , 11, e0166857	6
550	Coronary endothelial function is better in healthy premenopausal women than in healthy older postmenopausal women and men. 2017 , 12, e0186448	16
549	Treatment gaps and potential cardiovascular risk reduction from expanded statin use in the US and England. 2018 , 13, e0190688	11
548	Systematic examination of a heart failure risk prediction tool: The pooled cohort equations to prevent heart failure. 2020 , 15, e0240567	3
547	Cardiovascular risk and response to lipid lowering therapy in patients with HIV infection according to different recommendations. 2020 , 15, e0244675	0
546	Primary Biliary Cirrhosis and Primary Sclerosing Cholangitis: a Review Featuring a Women's Health Perspective. 2014 , 2, 266-84	16
545	The 2013 ACC/AHA Cholesterol Management Guideline: Clearing the Confusion from Noncontroversial Components. 2016 , 43, 313-4	1
544	Imaging to Stratify Coronary Artery Disease Risk in Asymptomatic Patients with Diabetes. 2018 , 14, 266-272	5
543	The Emerging Role of PCSK9 Inhibitors in Preventive Cardiology. 2014 , 9, 65-70	4
542	Assessing Atherosclerotic Cardiovascular Disease Risk with Advanced Lipid Testing: State of the Science. 2020 , 15, e56	6
541	Prevalence of Cholesterol Treatment Eligibility and Medication Use Among Adults--United States, 2005-2012. 2015 , 64, 1305-11	52

540	The efficacy and safety of statin in combination with ezetimibe compared with double-dose statin in patients with high cardiovascular risk: A meta-analysis. 2020 , 20, 169-182	3
539	Renal dysfunction as a predictor of acute stroke outcomes. 2017 , 22, 320-324	3
538	[Lipid-Lowering Therapy for Primary Cardiovascular Prevention in Older Adults. Consensus Statement of the Russian Association of Gerontologists and Geriatricians, National Society on Atherosclerosis, Russian Society of Cardiology, Association of Clinical Pharmacologists]. 2020 , 60, 1037	4
537	Assessing the association between medication adherence, as defined in quality measures, and disease-state control, health care utilization, and costs in a retrospective database analysis of Medicare supplemental beneficiaries using statin medications. 2020 , 26, 1529-1537	2
536	MortalityPredictors.org: a manually-curated database of published biomarkers of human all-cause mortality. 2017 , 9, 1916-1925	7
535	Aging and ischemic stroke. 2019 , 11, 2542-2544	70
534	The impact of the cumulative burden of LDL-c and hs-CRP on cardiovascular risk: a prospective, population-based study. 2020 , 12, 11990-12001	4
533	Genetic predisposition and induced pro-inflammatory/pro-oxidative status may play a role in increased atherothrombotic events in nilotinib treated chronic myeloid leukemia patients. 2016 , 7, 72311-72321 ²¹	
532	Radial artery intima-media thickness regresses after secondary prevention interventions in patients' post-acute coronary syndrome and is associated with cardiac and kidney biomarkers. 2017 , 8, 53419-53431	2
531	Association between the and polymorphisms and serum lipid levels. 2017 , 8, 114081-114094	3
530	The associations between serum biomarkers and stenosis of the coronary arteries. 2016 , 7, 39231-39240	4
529	Cardiovascular risk prediction in older adults with the use of biomarkers. 2018 , 6, S50	1
528	Legacy effect of statins: 20-year follow up of the West of Scotland Coronary Prevention Study (WOSCOPS). 2016 , 2016, e201635	7
527	Prevalencia de dislipidemias en una instituci3n prestadora de servicios de salud de Medell3n (Colombia), 2013. 2016 , 30, 3-13	4
526	Endothelial Dysfunction in Dyslipidaemia: Molecular Mechanisms and Clinical Implications. 2020 , 27, 1021-1040 ₁₀	
525	Current Drugs and Nutraceuticals for the Treatment of Patients with Dyslipidemias. 2019 , 25, 85-95	9
524	Non-Traditional Cardiovascular Risk Markers in the Era of Established Major Risk Factors and Multiple Guidelines. 2019 , 17, 270-277	2
523	Statins and Elderly: From Clinical Trials to Daily Practice. 2019 , 17, 233-238	2

522	The Incidence of Adverse Drug Reactions in Patients Treated with Statins in the Emirates: A Retrospective Cohort Study. 2020 , 18, 193-199	2
521	Postprandial Hypertriglyceridaemia Revisited in the Era of Non-Fasting Lipid Profile Testing: A 2019 Expert Panel Statement, Narrative Review. 2019 , 17, 515-537	12
520	Postprandial Hypertriglyceridaemia Revisited in the Era of Non-Fasting Lipid Profile Testing: A 2019 Expert Panel Statement, Main Text. 2019 , 17, 498-514	23
519	Impact of Lopinavir/Ritonavir and Efavirenz-Based Antiretroviral Therapy on the Lipid Profile of Chinese HIV/AIDS Treatment-Naïve Patients in Beijing: A Retrospective Study. 2019 , 17, 324-334	9
518	Epidemiology and management of antiretroviral-associated cardiovascular disease. 2015 , 9, 23-37	18
517	Infectious and Non-infectious Etiologies of Cardiovascular Disease in Human Immunodeficiency Virus Infection. 2016 , 10, 113-26	1
516	Cholesterol Screening and Statin Prescription is Low Among HIV-Infected Patients on Protease-Inhibitor Regimens in Botswana. 2017 , 11, 45-51	4
515	The Ready to Reduce Risk (3R) Study for a Group Educational Intervention With Telephone and Text Messaging Support to Improve Medication Adherence for the Primary Prevention of Cardiovascular Disease: Protocol for a Randomized Controlled Trial. 2018 , 7, e11289	4
514	Motivational Interviewing and Medication Review in Coronary Heart Disease (MIMeRiC): Protocol for a Randomized Controlled Trial Investigating Effects on Clinical Outcomes, Adherence, and Quality of Life. 2018 , 7, e57	5
513	Appropriate Use Criteria for PET Myocardial Perfusion Imaging. 2020 , 61, 1221-1265	16
512	Subclinical Coronary Atherosclerosis: Implication of Coronary Computed Tomography Angiography Findings among Statin Candidates according to the 2013 ACC/AHA Cholesterol Management Guidelines. 2019 , 20, 1156-1166	1
511	Endurance Training vs. Circuit Resistance Training: Effects on Lipid Profile and Anthropometric/Body Composition Status in Healthy Young Adult Women. 2020 , 17,	3
510	ApoB/ApoA-I ratio is independently associated with carotid atherosclerosis in type 2 diabetes mellitus with well-controlled LDL cholesterol levels. 2018 , 33, 138-147	13
509	Early efficacy and safety of statin therapy in Korean patients with hypercholesterolemia: Daegu and Gyeongbuk Statin Registry. 2020 , 35, 342-350	1
508	Contemporary use of lipid-lowering therapy for secondary prevention in Korean patients with atherosclerotic cardiovascular diseases. 2020 , 35, 593-604	4
507	Resveratrol. 2017 , 288-308	2
506	2020 Korean Society of Myocardial Infarction Expert Consensus Document on Pharmacotherapy for Acute Myocardial Infarction. 2020 , 50, 845-866	6
505	Association of 10-Year Atherosclerotic Cardiovascular Disease Risk Score with Carotid Intima-Media Thickness and Plaque. 2015 , 36, 310-5	8

504	Twelve-month prospective randomized study of pharmacists utilizing point-of-care testing for metabolic syndrome and related conditions in subjects prescribed antipsychotics. 2014 , 16,	9
503	Comparison of the Efficacy of Rosuvastatin Monotherapy 20 mg with Rosuvastatin 5 mg and Ezetimibe 10 mg Combination Therapy on Lipid Parameters in Patients with Type 2 Diabetes Mellitus. 2019 , 43, 582-589	10
502	Response: Comparison of the Efficacy of Rosuvastatin Monotherapy 20 mg with Rosuvastatin 5 mg and Ezetimibe 10 mg Combination Therapy on Lipid Parameters in Patients with Type 2 Diabetes Mellitus (2019;43:582-9). 2019 , 43, 915-916	2
501	Fibrates Revisited: Potential Role in Cardiovascular Risk Reduction. 2020 , 44, 213-221	10
500	The Benefits and Risks of Statin Therapy in Ischemic Stroke: A Review of the Literature. 2019 , 67, 983-992	9
499	Statins: Cholesterol guidelines and Indian perspective. 2015 , 19, 546-53	8
498	Health Status and Lifestyle Habits of US Medical Students: A Longitudinal Study. 2016 , 6, 341-347	17
497	Prevalence of Lipid Abnormalities and Cholesterol Target Value Attainment in Patients with Stable and Acute Coronary Heart Disease in the United Arab Emirates. 2019 , 20, 37-46	2
496	Awareness of Physicians and Clinical Pharmacists About ACC/AHA Guidelines for Dyslipidemia Management: A Cross-Sectional Study. 2019 , 11, 181-186	4
495	Prescribing statins among patients with type 2 diabetes: The clinical gap between the guidelines and practice. 2019 , 24, 15	15
494	Effects of Statin Use for Primary Prevention among Adults Aged 75 Years and Older in the National Health Insurance Service Senior Cohort (2002-2015). 2020 , 24, 91-98	3
493	The Need for Actions Against Polypharmacy in Older People With Frailty. 2018 , 22, 111-116	9
492	Prevalence of Low Levels of Vitamin D in Type 2 Diabetes at the City of Mangueirinha, Paraná;, Southern Brazil. 2016 , 06, 8-12	1
491	Quantitative angiographic characterisation of coronary artery disease in patients with human immunodeficiency virus (HIV) infection undergoing percutaneous coronary intervention. 2017 , 12, 1757-1765	6
490	Coronary artery calcium data and reporting system: Strengths and limitations. 2019 , 11, 126-133	3
489	Update of treatment of heart failure with reduction of left ventricular ejection fraction. 2016 , 1, e106-e116	8
488	High sensitive TROponin levels In Patients with Chest pain and kidney disease: A multicenter registry - The TROPIC study. 2017 , 24, 139-150	3
487	Effect of moderate-intensity statin therapy on plaque inflammation in patients with acute coronary syndrome: A prospective interventional study evaluated by 18F-FDG PET/CT of the carotid artery. 2020 , 27, 762-771	5

486	Serum Lipids During 20 Years in the Tehran Lipid and Glucose Study: Prevalence, Trends and Impact on Non-Communicable Diseases. 2018 , 16, e84750	8
485	Statin Dose and the Risk of Intracerebral Hemorrhage: A Population-Based Longitudinal Study in Taiwan. 2016 , 32, 23-30	7
484	A method to construct a points system to predict cardiovascular disease considering repeated measures of risk factors. 2016 , 4, e1673	6
483	The Association between Hemoglobin A1c and the Severity of Coronary Artery Disease in Non-diabetic Patients with Acute Coronary Syndrome. 2020 , 12, e6631	1
482	A Rapidly Progressive Case of Statin-induced Necrotizing Autoimmune Myopathy. 2020 , 12, e7021	2
481	Cardiometabolic management in severe mental illness requiring an atypical antipsychotic. 2017 , 7, 81-87	1
480	Evaluation of the Anti-Atherosclerosis Effect of Shanhuaxiaozi Formulation by Combination of GCâMs-Based Metabolomics and Tmt-Based Proteomics Technology.	
479	Effect of Statin Therapy on Diabetes Retinopathy in People With Type 2 Diabetes Mellitus: A Meta-Analysis. 2021 , 27, 10760296211040109	0
478	Serum lipid profile based on the prandial state among adult subjects. 2021 , 15, 15-21	
477	Apolipoprotein B and Cardiovascular Disease: Biomarker and Potential Therapeutic Target. 2021 , 11,	8
476	Effect of Financial Incentives for Process, Outcomes, or Both on Cholesterol Level Change: A Randomized Clinical Trial. 2021 , 4, e2121908	0
475	Cardiovascular Risk Awareness and Calculated 10-Year Risk Among Female Employees at Taibah University 2019. 2021 , 9, 658243	0
474	Association of Statin Therapy Initiation With Diabetes Progression: A Retrospective Matched-Cohort Study. 2021 , 181, 1562-1574	10
473	Sleep duration and risk of hyperlipidemia: a systematic review and meta-analysis of prospective studies. 2021 , 1	1
472	Prevalence and predictors of elevated liver enzyme levels in Mexico: The Mexican National Health and Nutrition Survey, 2016. 2021 , 26, 100562	2
471	Using pharmacy technicians and electronic health record capabilities to improve outcomes for patients with cardiovascular disease. 2021 ,	
470	Finding the Right Age for CAC Testing: How Low Should You Go?. <i>Journal of the American College of Cardiology</i> , 2021 , 78, 1584-1586	15.1
469	Subclinical hypothyroidism. 2021 , 46, 238-242	0

- 468 Association of patient, provider and facility related characteristics with statin associated side effects and statin use: Insight from the veteran's affairs healthcare system. **2021**, 1
- 467 Retrospective analysis of renal prognosis in elderly coronary artery disease patients complicated with renal insufficiency. **2021**, 13, 22856-22866
- 466 Classification of Cardiovascular Disease Risk and Cardiovascular Disease Prevention in Women. **2014**, 13-42
- 465 Impact of Diabetes Mellitus and the Metabolic Syndrome on the Female Heart. **2014**, 265-286
- 464 Dyslipidemia and Chronic Kidney Disease. **2014**, 71-82
- 463 Atherosclerotic Plaque Imaging for Evaluation of HDL Targeting Therapy. **2014**, 20, 282-294
- 462 Statins: Practical Considerations - A Review. **2014**, 9, 71-75 3
- 461 Dyslipidemia Treatment in Diabetes Mellitus Patients. **2014**, 87, 686
- 460 Lifestyle Interventions for Primary and Secondary Prevention of Cardiovascular Disease. **2014**, 1-29
- 459 Diabetes Mellitus. **2014**, 1-21
- 458 Epicardial Coronary Heart Disease in CKD: Diagnosis and Management. **2015**, 3-12
- 457 Optical Molecular Imaging of Inflammation and Calcification in Atherosclerosis. **2015**, 107-120
- 456 Which One to Endorse Among the Multitude of Lipid Guidelines?. **2015**, 11, 32-33
- 455 Approach to the Patient with Lipid Disorders. **2015**, 91-111
- 454 Ischemic Heart Disease. **2015**, 1-9
- 453 Association between LDL-C, Non HDL-C, and Apolipoprotein B Levels with Coronary Plaque Regression. **2015**, 105, 11-9 8
- 452 Effects of Exercise on Lipid-Lipoproteins. **2015**, 285-300
- 451 Cholesterol Metabolism and Vascular Disease. 1-12

- 450 The Evidence-Based Well Male Examination in Adult Men. **2016**, 103-124
- 449 Stable Ischemic Heart Disease. **2016**, 1159-1186
- 448 Assessment of Cardiovascular Calcium: Interpretation, Prognostic Value, and Relationship to Lipids and Other Cardiovascular Risk Factors. **2016**, 101-119
- 447 Coronary Artery Disease and Cardiomyopathy. **2016**, 1-21
- 446 Promoting Cardiovascular Health in Men. **2016**, 125-143
- 445 Additional Lipid Targets to Modulate Atherosclerotic Plaques beyond LDL-C Lowering. **2016**, 22, 217-227
- 444 Prevalence, Treatment Pattern and Resource Use in Patients with Mixed Dyslipidemia Using Lipid Modifying Agents in Korea (PRIMULA): An Observational Study. **2016**, 5, 121
- 443 Vascular Disease in Young Indians (20-40 years): Role of Dyslipidemia. **2016**, 10, OE01-5 3
- 442 Statins, Targets and Chronic Kidney Disease. **2016**, 6,
- 441 An Old Lady with a Twitching Abdomen!. **2016**, 6,
- 440 Diabetes Mellitus. **2017**, 1649-1668
- 439 In Reply. **2016**, 113, 643-644
- 438 Hypolipidemic drugs and their effect on endothelial function: a review of results of clinical trials. **2016**, 30, 38-45
- 437 The 2013 ACC/AHA Guidelines on Treatment of Blood Cholesterol to Improve Cardiovascular Outcomes: Implications for Statin Use and Dose vs. Target. **2016**, 1, 465-467 2
- 436 ASGR1 - a new target for lowering non-HDL cholesterol. **2016**, 2016, e201614 1
- 435 Postoperative Management of Obesity-Related Diseases. **2017**, 65-76
- 434 Treatment with Gefitinib, an Epidermal Growth Factor Receptor Inhibitor, Decreases Serum Cholesterol in Patients with Lung Cancer. **2016**, 25, 233-239 2
- 433 Coronary Calcium Scoring in 2017. **2016**, 2, 101-110

- 432 Coronary Artery Disease and Cardiomyopathy. **2017**, 1-21
- 431 Angina Pectoris. **2017**, 137-151
- 430 Coronary Artery Disease and Cardiomyopathy. **2017**, 637-657
- 429 PCSK9 Inhibitors for Lowering Cholesterol: Ready for Prime Time?. **2017**, 1, 30-37
- 428 Cardiovascular Risk Stratification and Statin Eligibility Based on the Brazilian vs. North American Guidelines on Blood Cholesterol Management. **2017**, 108, 508-517 2
- 427 Algorithm for predicting CHD death risk in Turkish adults: conventional factors contribute only moderately in women. **2017**, 17, 436-444 1
- 426 Efficacy of Lipid Lowering Therapy for the Patients with Ischemic Heart Disease. **2017**, 76, 245-248
- 425 Comparison of application of 2013 ACC/AHA guideline and 2011 European Society of Cardiology guideline for the management of dyslipidemias for primary prevention in a Turkish cohort. **2017**, 17, 92-96
- 424 Pharmacogenomics and Cardiovascular Disease. **2017**, 161-174
- 423 The Tip of The Iceberg: Non-Calcified Coronary Plaque and Epicardial Adipose Tissue. **2017**, 108, 383-385
- 422 Designing Phase 4 Trials. **2017**, 139-151
- 421 The Expected Cardiovascular Benefit of Plasma Cholesterol Lowering with or Without LDL-C Targets in Healthy Individuals at Higher Cardiovascular Risk. **2017**, 108, 518-525 2
- 420 Discordant Lipid Pattern and Carotid Atherosclerotic Plaque. Importance of Remnant Cholesterol. **2017**, 108, 526-532 2
- 419 Stable Ischemic Heart Disease. **2017**,
- 418 Acute Coronary Syndromes. **2017**,
- 417 An Epidemiological Perspective of Individual and Population Health Risk Prevention. **2018**, 357-368
- 416 Treatment of atherogenic dyslipidemia: modern principles and new possibilities. **2017**, 8, 51-58
- 415 Akut miyokard infarktünde trombosit/lenfosit oran-contrast nefropatisini değerlendirme.

- 414 Analysis of Cardiovascular Medication Use in Dementia Patients. **2017**, 27, 136-142
- 413 Chapter 15: Ischemic Heart Disease and Acute Coronary Syndrome. **2017**,
- 412 Generalizability of Indicators from the New York City Macroscopic Electronic Health Record Surveillance System to Systems Based on Other EHR Platforms. **2017**, 5, 25 7
- 411 Gender Differences in Metabolic Syndrome. **2018**, 15-33
- 410 Diabetes and Dislipidemia. **2018**, 51-70
- 409 What Do We Get from Recent Statin and CETP Inhibitors Trials?. **2018**, 7, 12 0
- 408 Low density lipoprotein. **2018**, 1-2
- 407 Lipids. **2018**, 137-151
- 406 Comparison of Efficacy and Safety of Fixed Dose Combination of Rosuvastatin and Choline Fenofibrate to Fixed Dose Combination of Rosuvastatin and Fenofibrate in Patients of Mixed Dyslipidemia: A Randomized, Open-label, Multicentre Clinical Trial in Indian Population. **2018**, 22, 627-631 2
- 405 The Basis of Atherosclerotic Guidelines—Time for a Change?. **2018**, 08, 337-352 1
- 404 Glucose Metabolism Disorder and Angioscopic Findings of Coronary Plaques. **2018**, 4, 33-38
- 403 Rings on the eyes, matters of the heart. **2018**, 66, 494
- 402 The new guidelines of high blood pressure substantially increase prevalence of hypertension in Argentina. **2018**, 2,
- 401 Features of the Lipid Profile in Patients with Arterial Hypertension and Cardiovascular Diseases According to Smoking Status. **2018**, 10, 8-14 1
- 400 Patterns of Statin Treatments During Acute Stroke Period and Clinical Outcomes in Patients with Ischemic Stroke. **2018**, 35, 184-195
- 399 The Ready to Reduce Risk (3R) Study for a Group Educational Intervention With Telephone and Text Messaging Support to Improve Medication Adherence for the Primary Prevention of Cardiovascular Disease: Protocol for a Randomized Controlled Trial (Preprint).
- 398 Evolocumab Lowers Low-Density-Lipoprotein Cholesterol and Lipoprotein (A) Levels in Nephrotic Syndrome. **2018**, 4, e415-e418
- 397 Caring for patients with chronic kidney disease. **2018**, 31, 11-12

- 396 Comparison of Adverse Events between High-intensity and Moderate- to Low-intensity Statin Group. **2018**, 28, 293-299 1
- 395 Diabetes and Dyslipidemia. **2019**, 1-20
- 394 Criteria for assigning laboratory measurands to models for analytical performance specifications defined in the 1st EFLM Strategic Conference. **2019**, 8, 93 2
- 393 Pharmacogenomics and Cardiovascular Disease. **2019**, 184-197
- 392 Concomitant use of policosanol and antiplatelet drugs in older patients. **2019**, 178,
- 391 Diabetes and Cardiovascular Disease. **2019**, 709-730
- 390 Low density lipoprotein. **2019**, 1531-1532
- 389 Prevalence of altered total cholesterol and fractions in the Brazilian adult population: National Health Survey. **2019**, 22Suppl 02, E190005.SUPL.2 2
- 388 Diabetes and Dyslipidemia. **2019**, 1-20
- 387 Pharmacogenetic Implications of Statin Therapy on Oxidative Stress in Coronary Artery Disease. **2019**, 629-644
- 386 Management of Coronary Artery Disease & Dyslipidemia and Pharmacist's Role. **2019**, 169-187
- 385 Minimization of Intraparenchymal Hemorrhagic Stroke Size by Optimization of Serum Lipids. **2019**, 11, e4406
- 384 Functional promoter polymorphisms govern the differential expression of HMG-CoA Reductase gene in rat models of essential hypertension.
- 383 How delayed treatment benefits and harms would impact the optimal timing of statin initiation for cardiovascular primary prevention.
- 382 Assessment of Patient Education about Statin Therapy on Quality Measures and Knowledge in an Independent Community Pharmacy. **2019**, 10,
- 381 [The problem of safety of lipid-lowering therapy]. **2019**, 59, 13-26 1
- 380 Lipid control and associated risk factors, before suffering from the first cardiovascular event. **2019**, 31, 141-151
- 379 Cholesterol goal achievement and lipid-lowering therapy in patients with stable or acute coronary heart disease in Singapore: results from the Dyslipidemia International Study II. **2019**, 60, 454-462 1

- 378 Trends and variation in prescribing of suboptimal statin treatment regimes: a cohort study in English primary care.
- 377 [Cardiovascular risk tables. Present and future]. **2019**, 36, 173-175
- 376 Calcium score as a screening method for cardiovascular disease diagnosis. **2019**, 153-161 1
- 375 Non-HDL cholesterol is better than LDL-c at predicting atherosclerotic cardiovascular disease risk factors clustering, even in subjects with near-to-normal triglycerides: A report from a Venezuelan population. 7, 504
- 374 Lipid disorders. **2020**, 2055-2097
- 373 Ischemic Heart Disease. **2020**, 1-10
- 372 Evaluation of the effectiveness of lipid-lowering agents. **2020**, 26, 78-85
- 371 2019 clinical trials in lipid lowering. **2020**, 35, 319-324 1
- 370 Drug-specific and dosage effects of statins and the risk of cancer: a population-based cohort study in South Korea. **2021**, 30, 188-194 0
- 369 Achievement of LDL-C Targets Defined by ESC/EAS (2011) Guidelines in Risk-Stratified Korean Patients with Dyslipidemia Receiving Lipid-Modifying Treatments. **2020**, 35, 367-376 1
- 368 Risk Factors for Developing Diabetic Foot Ulcer with Nephropathy, Diabetic Kidney Disease and Renal Failure Statistical Analysis of 10,680 PatientsâCohort. 0
- 367 Secondary prevention after acute coronary syndrome. **2020**, 66, 236-241
- 366 Comparison of different equations for estimation of low-density lipoprotein (LDL) âcholesterol. **2020**, 45, 601-611
- 365 Impact of cardiologist intervention on guideline-directed use of statin therapy. **2020**, 12, 419-426 0
- 364 Spontaneous Coronary Artery Dissection with Iliac Artery Dissection: A Case Report and Literature Review. **2020**, 5, 57-61
- 363 Statin Intolerance and Noncompliance: An Empiric Approach. **2021**, 1
- 362 Healthcare Resource Utilization, Cardiovascular Event Rate and Use of Lipid-Lowering Therapies in Secondary Prevention of ASCVD in Hospitalized Patients in Italy. **2021**, 1 0
- 361 Association of remnant cholesterol with intra- and extra-cranial atherosclerosis in Chinese community population. **2021**, 46, 20-20

- 360 Impact of Baseline LDL-C and Lp(a) Elevation on Coronary Revascularization in Patients with Acute Coronary Syndrome One-Year after First Percutaneous Coronary Intervention. **2020**, 10, 102-115
- 359 Fenofibrate and Crataegus oxyacantha is an effectual combo for mixed dyslipidemia. **2020**, 4, 259 1
- 358 Novel Eudragit[®] -based polymeric nanoparticles for sustained release of simvastatin. 56, 2
- 357 The 2018 AHA/ACC/Multisociety Cholesterol Guidelines: A Personalized Approach to Risk Reduction. **2021**, 179-200
- 356 Atorvastatin potentiates the chemosensitivity of human liver cancer cells to cisplatin via downregulating YAP1. **2021**, 21, 82 1
- 355 The Low-Density Lipoprotein Cholesterol Hypothesis: An Update. **2021**, 121-138
- 354 Echocardiographic Prevalence and Risk Predictors of Ventricular Dysfunction in Connective Tissue Disorders: Tertiary Care Hospital-Based Prospective Case-Control Study. **2020**, 1, 132-141
- 353 Efficacy and Safety of Pitavastatin in a Real-World Setting: Observational Study Evaluating SaFety in Patient Treated with Pitavastatin in Korea (PROOF Study). **2020**, 35, 882-891 1
- 352 How ApoB Measurements Could Improve Prevention of Cardiovascular Disease. **2021**, 545-563
- 351 Role of CT Coronary Calcium Scanning and Angiography in Evaluation of Cardiovascular Risk. **2021**, 417-439
- 350 Management of Dyslipidaemia in the Elderly. **2021**, 489-505
- 349 Transatlantic guidelines on dyslipidemia and cardiovascular risk: key differences across the pond. **2021**, 28, 114-121
- 348 Association between visceral/subcutaneous adipose tissue ratio and plasma inflammatory markers and score for cardiovascular risk prediction in a Brazilian cohort: PrE-Sa[®]e Study. **2021**, 54, e11521 1
- 347 The ADME Encyclopedia. **2021**, 1-13
- 346 The Association and Predictive Ability of ECG Abnormalities with Cardiovascular Diseases: A Prospective Analysis. **2020**, 15, 59 1
- 345 Water Soluble Vitamins: B1, B2, B3, and B6. **2020**, 1-28
- 344 Thyroid, Lipids, and Risk of Atherosclerosis. **2020**, 245-262
- 343 Macronutrients Having Pro-/Anti-Inflammatory Properties. **2020**, 46-79

- 342 Primary Prevention of Coronary Artery Disease. **2020**, 61-73
- 341 Statins: A distant hope and thousand dangers in near. **2020**, 11, 77
- 340 Impact of Exercise on Cardiovascular Risk Factors: Dyslipidemia. **2020**, 747-767
- 339 Origins of Cardiopulmonary Disease in Early Life. **2020**, 17-24
- 338 Diabetes and Dyslipidemia. **2020**, 51-70
- 337 Secondary Prevention of Coronary Artery Disease. **2020**, 75-82
- 336 Cardiovascular Disease in Women Part 2: Prevention, Identification, and Treatment of Cardiovascular Disease. **2020**, 361-374
- 335 Statin Therapy and Low-Density Lipoprotein Cholesterol Reduction after Acute Coronary Syndrome: Insights from the United Arab Emirates. **2020**, 21, 80-87
- 334 Unstable Angina/Non-ST Elevation Myocardial Infarction. **2020**, 99-110
- 333 Lipid Control Post Coronary Artery Bypass Graft: One Year Follow-Up of a Middle-Eastern Cohort. **2020**, 15, 12 1
- 332 Alirocumab Administration Experience to Achieve Low Density Lipoprotein Cholesterol Target Levels in Secondary Prevention of Cardiovascular Disease. **2020**, 16, 33-39 0
- 331 Intensity of statin therapy and renal outcome in chronic kidney disease: Results from the Korean Cohort Study for Outcome in Patients With Chronic Kidney Disease. **2020**, 39, 93-102 3
- 330 Recent Guideline for the Management of Dyslipidemia in Patients with Diabetes. **2020**, 21, 11-20 1
- 329 Impact of Prior Statin Use on Reperfusion Rate and Stroke Outcomes in Patients Receiving Endovascular Treatment. **2021**, 10, 0
- 328 Role of magnetic susceptibility-weighted imaging in characterization of cerebral microbleeds in acute ischemic stroke Egyptian obese patients. **2020**, 56,
- 327 Eosinophil percentage as a new prognostic marker in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. **2020**, 11, 146-153 0
- 326 MARKERS OF RISK FACTORS FOR CARDIOVASCULAR DISEASE. **2020**, 78-84
- 325 Pharmacoepidemiology in Cardiorenal Medicine. **2021**, 315-331

324	[Statin treatment as primary prevention in dyslipidaemic patients older than 75 years]. 2020 , 46, 464-471	
323	The potential value of discordant studies. 2014 , 4, 1-4	
322	Treating to target: ready, fire, aim. 2014 , 60, 541	2
321	Influence of dyslipidemia in control of arterial hypertension among type-2 diabetics in the western region of the Republic of Macedonia. 2014 , 4, 58-69	1
320	Atherogenic index of plasma in highly active antiretroviral therapy-naïve patients with human immunodeficiency virus infection in Southeast Nigeria. 2014 , 18, 631-6	6
319	PURLs: skip this step when checking lipid levels. 2015 , 64, 113-5	
318	Metabolic and cardiovascular complications in the liver transplant recipient. 2015 , 28, 183-192	27
317	A meta-analysis of the effects of statin treatment on cardiovascular events and all-cause mortality in diabetic dialysis patients. 2015 , 8, 8415-24	5
316	Issue 75!. 2015 , 14, 8-13	
315	High Density Lipoprotein Cholesterol Increasing Therapy: The Unmet Cardiovascular Need. 2015 , 12, 29-40	2
314	Implementation of the 2013 American College of Cardiology/American Heart Association Blood Cholesterol Guideline Including Data From the Improved Reduction of Outcomes: Vytorin Efficacy International Trial. 2015 , 16, 125-30	1
313	Effects of simvastatin and atorvastatin on biochemical and hematological markers in patients with risk of cardiovascular diseases. 2015 , 8, 13983-9	5
312	The Vilification of Cholesterol (for Profit?). 2014 , 13, 8-14	3
311	Alirocumab (Praluent): First in the New Class of PCSK9 Inhibitors. 2016 , 41, 28-53	6
310	HbA1c in Patients with Polycystic Ovary Syndrome: A Potential Marker of Inflammation. 2015 , 16, 203-6	2
309	Proton pump inhibitors and statins: a possible interaction that favors low-density lipoprotein cholesterol reduction?. 2015 , 19, 332-7	4
308	A case of abdominal pain with dyslipidemia: difficulties diagnosing cholesterol ester storage disease. 2015 , 19, 2628-2633	4
307	Vascular disease in the older adult. 2016 , 13, 727-732	9

- 306 Statin Therapy Prescribing for Patients with Type 2 Diabetes Mellitus: A Review of Current Evidence and Challenges. **2017**, 9, 80-87 18
- 305 Comparison of the low-density lipoprotein cholesterol target value and the preventive effect of statins in elderly patients and younger patients. **2017**, 14, 383-391
- 304 Effects of intensive pitavastatin therapy on glucose control in patients with non-ST elevation acute coronary syndrome. **2017**, 7, 89-96 3
- 303 Real-World Evidence: Promise and Peril For Medical Product Evaluation. **2018**, 43, 464-472 14
- 302 HIV-Related Cardiovascular Disease, Statins, and the REPRIEVE Trial. **2015**, 23, 146-9 65
- 301 The Use of Statins in Patients With Cirrhosis. **2018**, 14, 485-487 2
- 300 Comparison of Cardiovascular Outcomes Between Statin Monotherapy and Fish Oil and Statin Combination Therapy in a Veteran Population. **2018**, 35, 26-31
- 299 Metabolic Syndrome Presenting as Abdominal Pain. **2017**, 5, 172-174
- 298 Cardiovascular and Cancer Risk: The Role of Cardio-oncology. **2018**, 9, 160-176 14
- 297 Efficacy of Patient Aligned Care Team Pharmacist Services in Reaching Diabetes and Hyperlipidemia Treatment Goals. **2015**, 32, 42-47
- 296 Treatment Failure With Atorvastatin After Change From Rosuvastatin to Atorvastatin. **2015**, 32, 25-29
- 295 Therapeutic Interchange From Rosuvastatin to Atorvastatin in a Veteran Population. **2015**, 32, 20-24
- 294 Longitudinal hyperlipidemia outcomes at three student-run free clinic sites. **2015**, 47, 309-14 7
- 293 The Impact of Obesity on the Efficacy of Simvastatin for Lowering Low-Density Lipoprotein Cholesterol in a Veteran Population. **2017**, 34, 41-44
- 292 Impact of Pharmacist Interventions on the Long-Term Clinical Outcomes in Patients with Myocardial Infarction. **2019**, 35, 290-300 2
- 291 Group-Based Trajectory Models to Identify Sociodemographic and Clinical Predictors of Adherence Patterns to Statin Therapy Among Older Adults. **2019**, 12, 202-211 9
- 290 [Clinical value of apolipoprotein B versus low-density lipoprotein cholesterol in assessing risks of coronary artery disease]. **2017**, 37, 938-942
- 289 Molecular mechanisms underlying gallic acid effects against cardiovascular diseases: An update review. **2020**, 10, 11-23 10

288	Pitavastatin attenuates atherosclerosis by suppressing NF- κ B signaling in a high-cholesterol diet plus balloon catheter injury rabbit model. 2018 , 11, 351-358	
287	The association and joint effect of serum cholesterol, glycemic status with the risk of incident cancer among middle-aged and elderly population in china cardiometabolic disease and cancer cohort (4C)-study. 2020 , 10, 975-986	4
286	Efficacy of Ezetimibe/Simvastatin (10/10 mg) versus High Dose Statin in Dyslipidemia Patients: A Meta-Analysis of Randomized Controlled Trials. 2019 , 48, 1405-1417	
285	Linc-OIP5 working as a ceRNA of miR-616 promotes PON1 expression in HUEVC cells. 2020 , 13, 730-737	2
284	Consumption and market share of cholesterol-lowering drugs in high-risk patients before and after the release of the 2013 ACC/AHA cholesterol guidelines: a retrospective observational study. 2020 , 10, e036769	1
283	The Effectiveness of Target Low-Density Lipoprotein Cholesterol Achieved with Strict Management in Secondary Prevention of Long-Term Coronary Events in Japanese Patients. 2021 , 37, 65-73	
282	Impact of statin intensity on adverse cardiac and cerebrovascular events in older adult patients with myocardial infarction. 2021 , 18, 609-622	
281	De-risking primary prevention: role of imaging. 2021 , 15, 17539447211051248	1
280	Risky business: a scoping review for communicating results of predictive models between providers and patients. 2021 , 4, ooab092	0
279	Protective effects of atorvastatin and rosuvastatin on 3,4-methylenedioxymethamphetamine (MDMA)-induced spatial learning and memory impairment. 2021 , 29, 1807-1818	1
278	Behavioral Nudges as Patient Decision Support for Medication Adherence: The ENCOURAGE Randomized Controlled Trial. 2021 , 244, 125-125	3
277	New Approaches to Cardiovascular Disease and its Management in Kidney Transplant Recipients. 2021 ,	1
276	Evaluating algorithmic fairness in the presence of clinical guidelines: the case of atherosclerotic cardiovascular disease risk estimation.	1
275	Effect of Statin Intensity on the Progression of Cardiac Allograft Vasculopathy.. 2021 , 7, e15	
274	Prickly pear juice consumption after fat intake affects postprandial heart rate variability but not traditional risk factors of cardiovascular disease in healthy men.. 2021 , 96, 111555	2
273	Myeloperoxidase as an important predictor of cardiovascular risk in individuals with rheumatoid arthritis. 2021 , 29, 1819-1827	1
272	Association of Low-Density Lipoprotein Testing after an Atherosclerotic Cardiovascular Event with Subsequent Statin Adherence and Intensification. 2021 ,	0
271	Prevalence and significance of risk enhancing biomarkers in the United States population at intermediate risk for atherosclerotic disease: Risk Enhancing Factors in Intermediate Risk for ASCVD.. 2021 ,	0

270 Designing Phase 4 Trials. **2021**, 163-176

269 Capitated versus fee-for-service reimbursement and quality of care for chronic disease: a US cross-sectional analysis.. **2022**, 22, 19 0

268 A Cohort Analysis of Statin Treatment Patterns Among Small-Sized Primary Care Practices.. **2022**, 1 0

267 Impact of statin treatment on non-invasive tests based predictions of fibrosis in a referral pathway for NAFLD.. **2022**, 9,

266 Prevalence of statin intolerance: a meta-analysis.. **2022**, 8

265 Consumption and market share of cholesterol-lowering drugs in high-risk patients before and after the release of the 2013 ACC/AHA cholesterol guidelines: a retrospective observational study. **2020**, 10, e036769 1

264 Polyphenol extract and essential oil of equally alleviate hypercholesterolemia and modulate gut microbiota. **2021**, 12, 12008-12021 2

263 An Overview on the Role of Statins in Dyslipidemia Management in Primary Health Care. **2021**, 10, 33-37

262 Impact of Conventional Cardiovascular Risk Factors on Left Internal Mammary Artery Graft Disease.. **2021**, 8, 705765 0

261 Developing and Validating Risk Scores for Predicting Major Cardiovascular Events Using Population Surveys Linked with Electronic Health Insurance Records.. **2022**, 19, 0

260 Implementation of a self-determination based clinical program to reduce cardiovascular disease risk.. **2022**, 13591053211068124 0

259 Emerging Cholesterol Modulators for Atherosclerotic Cardiovascular Disease.. **2022**, 0

258 Attenuates Atherosclerosis by Regulating Cholesterol Metabolism and Inducing M2 Macrophage Polarization.. **2022**, 12, 0

257 Assessing the implementation of a clinical decision support tool in primary care for diabetes prevention: a qualitative interview study using the Consolidated Framework for Implementation Science.. **2022**, 22, 15 0

256 Global assessment improves risk stratification for major adverse cardiac events across a wide range of triglyceride levels: Insights from the KP REACH study.. **2022**, 9, 100319 0

255 Current Status and Evaluation of Randomized Clinical Trials of Traditional Chinese Medicine in the Treatment of Cardiovascular Diseases.. **2022**, 2022, 6181862

254 Secondary Prevention Using Cholesterol-Lowering Medications in Patients with Prior Atherosclerotic Cardiovascular Disease Events: A Retrospective Cohort Analysis.. **2022**, 9, 11-19

253 Prediction of Cardiovascular and All-Cause Mortality After Myocardial Infarction in US Veterans.. **2022**, 1

252	Care gaps in achieving cholesterol targets in people with diabetes: a population-based study in a universal health care setting.. 2021 , 109177	0
251	Cardiovascular Risk Prediction Parameters for Better Management in Rheumatic Diseases.. 2022 , 10,	0
250	Lipid-lowering drug adherence and combination therapy effects on gastrointestinal cancer in patients with dyslipidemia without diabetes: a retrospective cohort study in South Korea.. 2022 , 22, 156	0
249	Long-term clinical impact of low-density lipoprotein cholesterol target attainment according to lesion complexity after percutaneous coronary intervention.. 2022 ,	
248	Small, Dense Low-Density Lipoprotein-Cholesterol and Atherosclerosis: Relationship and Therapeutic Strategies.. 2021 , 8, 804214	0
247	Perinatal Outcomes After Statin Exposure During Pregnancy.. 2021 , 4, e2141321	2
246	Fluvastatin mitigates SARS-CoV-2 infection in human lung cells. 2021 , 24, 103469	6
245	Statin therapy prescribing for patients with type 2 diabetes mellitus: A review of current evidence and challenges. 2017 , 9, 80	14
244	Treatment Decisions. 2022 , 53-85	
243	Impact of Statin Treatment Intensity after Endovascular Revascularization on Lower Extremity Peripheral Artery Disease.. 2022 , 63, 333-341	
242	Effects of quercetin on the improvement of lipid metabolism through regulating hepatic AMPK and microRNA-21 in high cholesterol diet-fed mice. 2022 , 55, 36	1
241	Statin Prescription Patterns and Associated Factors Among Patients with Type 2 Diabetes Mellitus Attending Diabetic Clinic at Muhimbili National Hospital, Dar es Salaam, Tanzania.. 2022 , 15, 633-646	3
240	Influence of cholesterol level on long-term survival and cardiac events after surgical coronary revascularization. 2022 ,	2
239	A systematic review of the drug-drug interaction between statins and colchicine: patient characteristics, etiologies, and clinical management strategies.. 2022 ,	0
238	Cost-effectiveness of Ezetimibe plus statin lipid-lowering therapy: A systematic review and meta-analysis of cost-utility studies.	
237	Evaluating the Association Between Low-Density Lipoprotein Cholesterol Reduction and Relative and Absolute Effects of Statin Treatment: A Systematic Review and Meta-analysis.. 2022 ,	4
236	The Cost-Effectiveness of Hyperlipidemia Medication in Low- and Middle-Income Countries: A Review.. 2022 , 17, 18	0
235	A Mistake Not to Be Repeated: What Can We Learn from the Underutilization of Statin Therapy for Efficient Dissemination of Cardioprotective Glucose Lowering Agents?. 2022 , 1	0

234	Coronary Risk Estimation Based on Clinical Data in Electronic Health Records.. <i>Journal of the American College of Cardiology</i> , 2022 , 79, 1155-1166	15.1	1
233	Achievement of LDL-Cholesterol Goals after Acute Myocardial Infarction: Real-World Data from the City of Curitiba Public Health System.. 2022 ,		0
232	Frequency of Statin Prescription Among Individuals with Coronary Artery Calcifications Detected Through Lung Cancer Screening.. 2022 ,		
231	Dual versus mono antiplatelet therapy in mild-to-moderate stroke during hospitalization.. 2022 ,		
230	Breakfast consumption frequency is associated with dyslipidemia: a retrospective cohort study of a working population.. 2022 , 21, 33		0
229	Reducing Cardiovascular Risk in the Medicare Million Hearts Risk Reduction Model: Insights From the National Cardiovascular Data Registry PINNACLE Registry.. 2022 , CIRCOUTCOMES121007908		0
228	Self-rated health may be a predictor for metabolic syndrome and high hs-CRP prevalences in healthy adults in South Korea: Based on the 2015 Korea National Health and Nutrition Examination Survey.. 2022 , 102, 71-83		1
227	Factors associated with acute pancreatitis in patients with impacted duodenal papillary stones: a retrospective cohort study.. 2022 , 1-8		
226	Ten-year atherosclerosis cardiovascular disease (ASCVD) risk score and its components among an Iranian population: a cohort-based cross-sectional study.. 2022 , 22, 162		1
225	Association between statin use and Parkinson's disease in Korean patients with hyperlipidemia.. 2022 , 97, 15-24		2
224	Producing personalized statin treatment plans to optimize clinical outcomes using big data and machine learning.. 2022 , 104029		
223	Ten things to know about ten cardiovascular disease risk factors - 2022.. 2022 , 10, 100342		3
222	Validation of a novel method for determination of low-density lipoprotein cholesterol levels in Indian patients with type 2 diabetes.. 2022 , 16, 102448		0
221	Evaluating algorithmic fairness in the presence of clinical guidelines: the case of atherosclerotic cardiovascular disease risk estimation.. 2022 , 29,		1
220	The dose-response relationship of serum uric acid with Dyslipidaemia and its components: a cross-sectional study of a Chinese multi-ethnic cohort.. 2022 , 21, 36		
219	RSSDI consensus recommendations for dyslipidemia management in diabetes mellitus. 1		0
218	A community based cross sectional study on the prevalence of dyslipidemias and 10 years cardiovascular risk scores in adults in Asmara, Eritrea.. 2022 , 12, 5567		
217	2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.. <i>Journal of the American College of Cardiology</i> , 2022 ,	15.1	49

- 216 An office-based cardiovascular prediction model developed and validated in cohort studies of a middle-income country: Developing and validating an office-based model to predict cardiovascular mortality using cohorts of a middle-income country.. **2021**,
- 215 Primary and Secondary Prevention of CAD: A Review.. **2022**, 31, 16-26
- 214 Comparison of High-Statin Therapy vs Moderate-Statin Therapy in Achieving Positive Low-Density Lipoprotein Change in Patients After Acute Coronary Syndrome: A Randomized-Control Trial.. **2021**, 13, e20710
- 213 Prevalence, Pattern and Predictors for Dyslipidemia of Chinese Women With Polycystic Ovary Syndrome.. **2021**, 8, 790454 1
- 212 Apolipoprotein B/A1 Ratio Is Associated with Severity of Coronary Artery Stenosis in CAD Patients but Not in Non-CAD Patients Undergoing Percutaneous Coronary Intervention.. **2021**, 2021, 8959019 1
- 211 Potential Role of Natural Plant Medicine in the Treatment of Type 2 Diabetes Mellitus.. **2021**, 2021, 1655336 0
- 210 Coronary Artery Calcium Versus Pooled Cohort Equations Score for Primary Prevention Guidance: Randomized Feasibility Trial.. **2021**, 1
- 209 The Magnitude and Potential Causes of Sex Disparities in Statin Therapy in Veterans with Type 2 Diabetes: A 10-year Nationwide Longitudinal Cohort Study.. **2021**,
- 208 Effects of renin-angiotensin system inhibitor type and dosage on survival after transcatheter aortic valve implantation.. **2022**, 0
- 207 Association of Statins With Cerebral Atherosclerosis and Incident Parkinsonism in Older Adults.. **2022**, 0
- 206 Anterior Circulation Acute Ischemic Stroke in the Plateau of China: Risk Factors and Clinical Characteristics.. **2022**, 13, 859616
- 205 Aging biomarkers: Potential mediators of association between long-term ozone exposure and risk of atherosclerosis.. **2022**, 0
- 204 The Effects of Menopause Hormone Therapy on Lipid Profile in Postmenopausal Women: A Systematic Review and Meta-Analysis.. **2022**, 13, 850815 1
- 203 Prevalence of cardiovascular risk factors by HIV status in a population-based cohort in South Central Uganda: a cross-sectional survey.. **2022**, 25, e25901 0
- 202 Data_Sheet_1.pdf. **2020**,
- 201 Image_1.JPEG. **2020**,
- 200 Image_2.JPEG. **2020**,
- 199 Table_1.DOCX. **2020**,

- 198 DataSheet_1.docx. **2020**,
- 197 Table_1.DOCX. **2019**,
- 196 Image_1.pdf. **2020**,
- 195 Table_1.docx. **2020**,
- 194 Metabolic syndrome presenting as abdominal pain. **2017**, 5, 172 0
- 193 Atherogenic index of plasma in highly active antiretroviral therapy-naïve patients with human immunodeficiency virus infection in Southeast Nigeria. **2014**, 18, 631 10
- 192 The Impact of Age on Statin-Related Glycemia: A Propensity Score-Matched Cohort Study in Korea. **2022**, 10, 777
- 191 Macrovascular Complications. **2022**, 0
- 190 Effect of No-Charge Coronary Artery Calcium Scoring on Cardiovascular Prevention.. **2022**, 0
- 189 Evaluation of a Pharmacist-Led Telephonic Medication Therapy Management Program in Rural Arizona: Implications for Community Health Practice. **2022**, 12, 243-252
- 188 Timing of Statin Dose: A Systematic Review and Meta-analysis of Randomized Clinical Trials.. **2022**,
- 187 IDOL deficiency inhibits cholesterol-rich diet-induced atherosclerosis in rabbits.
- 186 High-Intensity Statin Use Among Patients With Atherosclerosis in the U.S.. *Journal of the American College of Cardiology*, **2022**, 79, 1802-1813 15.1 2
- 185 Epigenetics of type 2 diabetes mellitus and weight change - a tool for precision medicine?. **2022**, 1
- 184 IMPACTO DEL TRATAMIENTO PREVIO CON ESTATINAS SOBRE LA SUPERVIVENCIA DE LOS PACIENTES HOSPITALIZADOS CON COVID-19. **2022**,
- 183 Adherence to Lipid Monitoring and Its Impact on Treat Intensification of LDL-C Lowering Therapies at an Urban Academic Medical Center. **2022**, 1
- 182 Dioscin Ameliorates Hyperuricemia-Induced Atherosclerosis by Modulating of Cholesterol Metabolism through FXR-Signaling Pathway.. **2022**, 14, 1
- 181 Statin Therapy for Primary Prevention in Women: What is the Role for Coronary Artery Calcium?. **2022**, 0

- 180 Association of Long-term Statin Use With the Risk of Intracerebral Hemorrhage: A Danish Nationwide Case-Control Study.. **2022**, 1
- 179 High-Sensitivity C-Reactive Protein. **2022**, 347-375
- 178 Lack of Awareness of Own Hypercholesterolemia or Statin Medication among Adult Statin Users in the United States: Prevalence and Patient Characteristics in a Repeated Cross-Sectional Study. **2022**, 19, 6099
- 177 Evaluation of Cardiovascular Pharmacotherapy Guideline Adherence and Risk Factor Control in Portuguese Community Pharmacy Patients. **2022**, 19, 6170
- 176 Interactions Between Statins, Exercise, and Health: A Clinical Update. **2022**, 11, 54-61
- 175 Estrategias de tratamiento de las dislipemias en prevenci3n primaria y secundaria. Registro de la Sociedad Espa3ola de Arteriosclerosis. **2022**,
- 174 Investigating the effect of Fenofibrate on biomarkers of vascular inflammation in L-NAME induced hypertensive rats. **2022**, 69, 459-465
- 173 Coronary Artery Calcium Scoring: Current Status and Future Directions. 0
- 172 Lipid Testing Trends Before and After Hospitalization for Myocardial Infarction Among Adults in the United States, 2008-2019. Volume 14, 737-748
- 171 Burden and predictors of statin use in primary and secondary prevention of atherosclerotic vascular disease in the US: From the National Health and Nutrition Examination Survey 2017-2020. 0
- 170 Kinetics of Drug Action: A PKPD Approach. **2022**, 601-613
- 169 Custo-Efetividade do Emprego do Escore de C3lculo Coronariano na Orienta3o para a Decis3o Terap3utica na Preven3o Prim3ria, na Popula3o Brasileira. **2022**, 118, 1126-1131 0
- 168 Demographics and Characteristics of Patients Admitted With Acute Coronary Syndrome to the Coronary Care Unit at King Abdulaziz University. **2022**, 0
- 167 Statins and statin intensity in peripheral artery disease. 2
- 166 Rationale, Criteria, and Impact of Identifying Extreme Risk in Patients with Atherosclerotic Cardiovascular Disease. **2022**, 2, 114-123
- 165 Cost-effectiveness of Ezetimibe plus statin lipid-lowering therapy: A systematic review and meta-analysis of cost-utility studies. **2022**, 17, e0264563 0
- 164 Preadmission Statin Treatment and Outcome in Patients Hospitalized With COVID-19. **2022**, 2
- 163 Statin-related adverse drug reactions in UK primary care consultations: A retrospective cohort study to evaluate the risk of cardiovascular events and all-cause mortality.

- 162 Coronary Artery Calcium Data and Reporting System (CAC-DRS): A Primer. 30,
- 161 Changes in Sleep Patterns during Pregnancy and Predictive Factors: A Longitudinal Study in Saudi Women. **2022**, 14, 2633 1
- 160 Emphasizing Study Selection in a Review of Statin Treatment Effects and Low-Density Lipoprotein CholesterolâReply. 1
- 159 Prevalence and initiation of statin therapy in the oldest oldâlongitudinal population-based study.
- 158 Integrated guidance to enhance the care of children and adolescents with familial hypercholesterolaemia: Practical advice for the community clinician. 0
- 157 Valor Progn stico da Imagem de Resson ncia Magn tica Card aca de Perfus o em Estresse com Adenosina em Idosos com Doen a Arterial Coronariana Conhecida ou Suspeita. **2022**, 119, 97-106 0
- 156 Using deep learning-based natural language processing to identify reasons for statin nonuse in patients with atherosclerotic cardiovascular disease. **2022**, 2, 1
- 155 The Multi-Ethnic Study of Atherosclerosis-Calcium Score Improves Statin Treatment Allocation in Asymptomatic Adults. 9,
- 154 Assessment of the Quality of Drug Therapy in Patients with Stable Coronary Artery Disease in the Second Stage of the ALIGN Study. **2022**, 18, 306-310 1
- 153 Oncological Benefit versus Cardiovascular Risk in Breast Cancer Patients Treated with Modern Radiotherapy. **2022**, 11, 3889
- 152 Decoding microRNA drivers in atherosclerosis. **2022**, 42, 0
- 151 Statins and renal disease progression, ophthalmic manifestations, and neurological manifestations in veterans with diabetes: A retrospective cohort study. **2022**, 17, e0269982
- 150 Statin Eligibility for Primary Prevention of Cardiovascular Disease According to 2021 European Prevention Guidelines Compared With Other International Guidelines. 0
- 149 The Economic Burden of Disease in France From the National Health Insurance Perspective. Publish Ahead of Print, 1
- 148 The effect of various types and doses of statins on C-reactive protein levels in patients with dyslipidemia or coronary heart disease: A systematic review and network meta-analysis. 9,
- 147 Exploring Contemporary Data on Lipid-Lowering Therapy Prescribing in Patients Following Discharge for Atherosclerotic Cardiovascular Disease in the South of Italy. **2022**, 11, 4344
- 146 Coronary artery calcium to guide treatment in primary preventionâcan we afford not to?.
- 145 Estimating the accuracy of dual energy chest radiography for coronary calcium detection with lateral or anteroposterior orientations.

144	Stroke pathway an An evidence base for commissioning an An evidence review for NHS England and NHS Improvement. 2, 43	
143	Prediction performance and fairness heterogeneity in cardiovascular risk models. 2022 , 12,	0
142	Statins for primary cardiovascular disease prevention among people with HIV: emergent directions. 2022 , 17, 293-300	0
141	Statins in High Cardiovascular Risk Patients: Do Comorbidities and Characteristics Matter?. 2022 , 23, 9326	0
140	Metabolite Signature of Simvastatin Treatment Involves Multiple Metabolic Pathways. 2022 , 12, 753	2
139	Inverse association between low-density lipoprotein cholesterol and bone mineral density in young- and middle-aged people: The NHANES 2011 an 2018. 9,	1
138	The effect of statin therapy in combination with ezetimibe on circulating C-reactive protein levels: a systematic review and meta-analysis of randomized controlled trials.	0
137	2022 ACC Expert Consensus Decision Pathway on the Role of Nonstatin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk. 2022 ,	4
136	Holistic Approach in the Management of Nonalcoholic Fatty Liver Disease. 2022 , 12, S51-S58	
135	Provincial heterogeneity in the management of care cascade for hypertension, diabetes, and dyslipidaemia in China: Analysis of nationally representative population-based survey. 9,	
134	New Progress in Early Diagnosis of Atherosclerosis. 2022 , 23, 8939	
133	Concurrent use of statins decreases major bleeding and intracerebral hemorrhage in non-valvular atrial fibrillation patients taking direct oral anticoagulants an nationwide cohort study. 9,	0
132	Serum lipoprotein(a) and 3-year outcomes in patients undergoing percutaneous coronary intervention. 2022 , 101362	
131	Hypolipidemic effect and antioxidant properties of cassava-wheat flour composite bread in rats.	0
130	Adherence to secondary prevention measures after acute coronary syndrome in patients associated exclusively with the public and private healthcare systems in Brazil. 2022 , 29, 101973	0
129	Hypercholesterolemia treated with medicinal pad-separated moxibustion: A randomized clinical trial????????????-?????. 2022 , 32, 310-316	0
128	Recalibrating 10-Year Risk Models Using Population-Based Data. 2022 , 80, 1343-1345	0
127	Impact of low/no-charge coronary artery calcium scoring on statin eligibility and outcomes in women: The CLARIFY study. 2022 , 12, 100392	0

- 126 2022 Consensus Statement on the Management of Familial Hypercholesterolemia in Korea. **2022**, 11, 213 ○
- 125 Polypharmacology in Clinical Applications: Cardiovascular Polypharmacology. **2022**, 133-198 ○
- 124 Treating Anxiety Disorders in Patients with Cardiovascular Disease: How to Formulate Exposure Therapy When Anxiety Mimics the Heart. **2022**, 161-182 ○
- 123 Clinical and economic impact of changing reimbursement criteria for statin treatment among patients with type 2 diabetes mellitus in South Korea. 13, ○
- 122 Is Niacine a Potential Agent to Decrease Dyslipidemia Risk?. **2022**, 626-635 ○
- 121 Impact of Prior Statin Therapy on In-Hospital Outcome of STEMI Patients Treated with Primary Percutaneous Coronary Intervention. **2022**, 11, 5298 ○
- 120 Arterial Stiffness as a Cardiovascular Risk Factor After Successful Kidney Transplantation in Diabetic and Nondiabetic Patients. **2022**, ○
- 119 Non-high-density lipoprotein cholesterol and treatment targets in vascular surgery patients. 170853812211262
- 118 Novel Insights into the Management of Patients with Very High Cardiovascular Risk Eligible for PCSK9 Inhibitor Treatment: Baseline Findings from the PERI-DYS Study. ○
- 117 SARS-COV-ATE risk assessment model for arterial thromboembolism in COVID-19. **2022**, 12, ○
- 116 Recent Advances in PROTACs for Drug Targeted Protein Research. **2022**, 23, 10328 2
- 115 Ten-year atherosclerotic cardiovascular disease risk prediction for postmenopausal women: Impacts of isolated postchallenge hyperglycemia. **2022**, 101, e30352 ○
- 114 Association of venous thromboembolism between hydrophilic and lipophilic statin users among diabetic subjects. **2022**, 101, e30542 ○
- 113 Contemporary National Patterns of Eligibility and Use of Novel Lipid-Lowering Therapies in the United States. **2022**, 11, ○
- 112 Efficacy and safety of zhibitai in the treatment of hyperlipidemia: A systematic review and meta-analysis. 13, ○
- 111 Efficacy and Tolerability of Ezetimibe/Atorvastatin Fixed-Dose Combination Versus Atorvastatin Monotherapy in Hypercholesterolemia: A Phase III, Randomized, Active-Controlled Study in Chinese Patients. **2022**, ○
- 110 Evaluating the Cardiovascular Risk in an Aging Population of People With HIV: The Impact of Hepatitis C Virus Coinfection. **2022**, 11, ○
- 109 Associations of thiocyanate, nitrate, and perchlorate exposure with dyslipidemia: a cross-sectional, population-based analysis. ○

- 108 Functional Association of miR-133b and miR-21 Through Novel Gene Targets ATG5, LRP6 and SGPP1 in Coronary Artery Disease. ○
- 107 Secondary Prevention Using Cholesterol-Lowering Medications in Patients with Prior Atherosclerotic Cardiovascular Disease Events: A Retrospective Cohort Analysis. ○
- 106 Associations of Atrial Fibrillation with Mild Cognitive Impairment and Dementia: An Investigation Using SPRINT Research Materials. **2022**, 11, 5800 ○
- 105 Use of artificial intelligence on retinal images to accurately predict the risk of cardiovascular event (CVD-AI). ○
- 104 Patterns of Dyslipidemia in the Anemic and Nonanemic Hypertensive Saudi Population: A Cross-Sectional Study. Volume 15, 7895-7906 ○
- 103 Distribution of lipid levels and prevalence of hyperlipidemia: data from the NHANES 2007-2018. **2022**, 21, ○
- 102 Circulating Klotho Is Higher in Cerebrospinal Fluid than Serum and Elevated Among KLOTHO Heterozygotes in a Cohort with Risk for Alzheimer's Disease. **2022**, 1-13 ○
- 101 Patterns of Lipid Lowering Therapy Use Among Older Adults in a Managed Care Advantage Plan in the United States. 089719002211288 ○
- 100 Statins and Male Fertility: Is There a Cause for Concern?. **2022**, 10, 627 ○
- 99 Elevated Serum Low-Density Lipoproteins-Cholesterol Levels and B1B2/B2B2 CETP Genotype Are Positively Associated with Nonalcoholic Fatty Liver Disease in Women with Gallstone Disease. ○
- 98 An efficient, enantioselective total synthesis of atorvastatin calcium. ○
- 97 Effect of Atorvastatin on Serial Changes in Coronary Physiology and Plaque Parameters. **2022**, ○
- 96 Relationship Between Relative Grip Strength and Serum Total Cholesterol, High-Density Lipoprotein Cholesterol, Low-Density Lipoprotein Cholesterol, and Triglyceride Levels in Korean Middle-Aged or Older Adults: A Panel Regression Model. ○
- 95 Improved prediction of blood biomarkers using deep learning. ○
- 94 Dyslipidemia treatment strategies in primary and secondary prevention. Dyslipemia Registry of the Spanish Arteriosclerosis Society. **2022**, ○
- 93 High-density lipoprotein level is associated with hemorrhage transformation after ischemic stroke treatment with intravenous thrombolysis: A systematic review and meta-analysis. **2022**, 106, 122-127 1
- 92 Familial Hypercholesterolemia and Lipoprotein(a): A Gordian Knot in Cardiovascular Prevention. **2022**, 12, 1065 1
- 91 Cost-Effectiveness of Evolocumab in Adult Patients with Atherosclerotic Cardiovascular Disease from Chinese Healthcare Perspective. ○

- 90 The Year in Cardiothoracic and Vascular Anesthesia: Selected Highlights from 2022. **2022**, 0
- 89 Guidelines for the management of hyperlipidemia: How can clinicians effectively implement them?. **2022**, 0
- 88 Association of lipid, inflammatory, and metabolic biomarkers with age at onset for incident cardiovascular disease. **2022**, 20, 0
- 87 Statins for Smith-Lemli-Opitz syndrome. **2022**, 2022, 0
- 86 Racial, ethnic, and language differences in screening measures for statin therapy following a major guideline change. **2022**, 164, 107338 0
- 85 Use of fibrates is not associated with reduced risks of mortality or cardiovascular events among ESRD patients: A national cohort study. 9, 0
- 84 Effects of statins on fat oxidation improvements after aerobic exercise training. 1
- 83 Sinais e sintomas de pacientes com insuficiência cardíaca em cuidados paliativos: revisão de escopo. 26, 0
- 82 Statins in Primary Prevention in People Over 80 Years. **2023**, 187, 62-73 0
- 81 Non-association of stroke risk with intracranial hemodynamic steal in patients with symptomatic internal carotid artery occlusions. **2023**, 32, 106797 0
- 80 Exploration of Mechanism of Jiangzhi Tongmai Capsules in Anti-Atherosclerosis Based on Network Pharmacology and Molecular Docking. **2022**, 12, 11418-11429 0
- 79 Comprehensive Review of Cardiovascular Disease Risk in Nonalcoholic Fatty Liver Disease. **2022**, 9, 419 1
- 78 1â2 Drinks Per Day Affect Lipoprotein Composition after 3 WeeksâResults from a Cross-Over Pilot Intervention Trial in Healthy Adults Using Nuclear Magnetic Resonance-Measured Lipoproteins and Apolipoproteins. **2022**, 14, 5043 0
- 77 Statin therapy for primary prevention in men: What is the role for coronary artery calcium?. **2022**, 0
- 76 Recombinant Humanized IgG1 Antibody Promotes Reverse Cholesterol Transport through FcRn-ERK1/2-PPAR β Pathway in Hepatocytes. **2022**, 23, 14607 0
- 75 The Significance of Statin Associated Muscle Symptoms and Its Impact on Patients Adherence and Outcomes. **2022**, Publish Ahead of Print, 0
- 74 Pathophysiological Links Between Diabetes and Cardiovascular Diseases: at the Biochemical and Molecular Levels. **2022**, 191-229 0
- 73 Correlation of LP-PLA2 levels and the monocyte on population in the risk of atherosclerosis. 0

72	Performance of the pooled cohort equation in South Asians: insights from a large integrated healthcare delivery system. 2022 , 22,	o
71	Recommended and Observed Statin Use among U.S. Adults âNational Health and Nutrition Examination Survey, 2011-2018. 2022 ,	o
70	Primary Care Clinical Volumes, Cholesterol Testing, and Cardiovascular Outcomes. 2022 ,	o
69	Vertebrobasilar dolichoectasia in patients with cerebrovascular ischemic stroke: does it have a role in cerebral microbleeds?. 2022 , 58,	o
68	Impact of Statins on Survival and Limb Salvage in Patients Undergoing Peripheral Endovascular Intervention for Chronic Limb Threatening Ischemia. 2022 ,	1
67	The CCN2 Polymorphism rs12526196 Is a Risk Factor for Ascending Thoracic Aortic Aneurysm. 2022 , 23, 15406	o
66	Dynamics of Lipid Profile in Antiretroviral-Naïve HIV-Infected Patients, Treated with TAF-Based Regimens: A Multicenter Observational Study. 2022 , 10, 3164	o
65	INCLISIRAN (LEQVIO): A FIRST-IN-CLASS SMALL INTERFERING RNA THERAPEUTIC DRUG APPROVED BY FDA FOR TREATING PRIMARY HYPERCHOLESTEROLEMIA OR DYSLIPIDEMIA. 42-46	o
64	Risk stratification for sarcopenic obesity in subjects with nonalcoholic fatty liver disease. 2022 ,	o
63	A single-center pilot randomized controlled trial of atorvastatin loading for preventing ischemic brain damage after carotid artery stenting. 14,	o
62	Undertreatment and Underachievement of LDL-C Target among Individuals with High and Very High Cardiovascular Risk in the Malaysian Community. 2022 , 10, 2448	o
61	Influencing Appropriate Statin Use in a Charity Care Primary Clinic. 2022 , 10, 2437	o
60	The Presence of Residual Vascular and Adipose Tissue Inflammation on 18F-FDG PET in Patients with Chronic Coronary Artery Disease.	o
59	The Beneficial Health Effects of Nuts in the Diet.	o
58	Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on the number needed to treat. 9,	o
57	Survival impact of previous statin therapy in patients hospitalized with COVID-19. 2022 ,	1
56	Role of sodium-glucose cotransporter-2 inhibitors in risk of chronic kidney disease among patients with type 2 diabetes mellitus.	o
55	Identifying and comparing low-value care recommendations for coronary heart disease prevention, diagnosis, and treatment in the US and China. 2022 ,	o

- 54 Effect of ApoE ϵ gene polymorphism on the correlation between serum uric acid and left ventricular hypertrophy remodeling in patients with coronary heart disease. 9, ○
- 53 Association between statin therapy and the risk of stroke in patients with moyamoya disease: a nationwide cohort study. *svn-2022-001985* ○
- 52 Inadequate response to antiplatelet therapy in patients with peripheral artery disease: a prospective cohort study. **2023**, 21, ○
- 51 High- vs. Low-Intensity Statin Therapy and Changes in Coronary Artery Calcification Density after One Year. **2023**, 12, 476 ○
- 50 Anatomical and functional remodeling of left ventricle in patients with primary aldosteronism and concomitant albuminuria. **2023**, 14, 204062232211432 ○
- 49 Is There a Role for Coronary Calcium in Patients With Diabetes?. **2023**, 190, 98-101 ○
- 48 National Trends in Statin Use in Lithuania from 2010 to 2021. **2023**, 59, 37 ○
- 47 Women with familial hypercholesterolemia phenotype are undertreated and poorly controlled compared to men. **2023**, 13, ○
- 46 Safety and efficacy of short-term dual antiplatelet therapy combined with intensive rosuvastatin in acute ischemic stroke. **2023**, 78, 100171 ○
- 45 Changes in Clinical Manifestations Due to AFLD Retyping Based on the New MAFLD Criteria: An Observational Study Based on the National Inpatient Sample Database. **2023**, 13, 488 ○
- 44 Lipid Management in Korean People With Type 2 Diabetes Mellitus: Korean Diabetes Association and Korean Society of Lipid and Atherosclerosis Consensus Statement. **2023**, 12, 12 ○
- 43 Mathematical modelling of the effects of statins on the growth of necrotic core in atherosclerotic plaque. **2023**, 18, 11 ○
- 42 Evaluation of the Cardiovascular Risk Profile of Catholic Priests During Health Checkups at a Tertiary Hospital in Kerala, India. ○
- 41 Understanding and Addressing Disinformation in Gender-Affirming Health Care Bans. ○
- 40 Patients with diabetes with and without sodium-glucose cotransporter-2 inhibitors use with incident cancer risk. **2023**, 37, 108468 ○
- 39 Progress in Understanding Metabolic Syndrome and Knowledge of Its Complex Pathophysiology. **2023**, 4, 134-159 ○
- 38 The Relationship between Delirium and Statin Use According to Disease Severity in Patients in the Intensive Care Unit. **2023**, 21, 179-187 ○
- 37 Simple CarotID-VasC score to predict one-year risk of stroke in symptomatic carotid stenosis patients. **2023**, 446, 120578 ○

- 36 Lipidstoffwechselstörungen. **2022**, 287-302 ○
- 35 Sub-group analysis of inflammatory cytokines IL-1 and IL-6 in association with lipid profiles of coronary artery disease patients. **2023**, 30, 101748 ○
- 34 Longitudinal association of remnant cholesterol with joint arteriosclerosis and atherosclerosis progression beyond LDL cholesterol. **2023**, 21, ○
- 33 Updates in Cardiovascular Disease Prevention, Diagnosis, and Treatment in Women. **2023**, 107, 285-298 ○
- 32 The U-shaped association of non-high-density lipoprotein cholesterol with all-cause and cardiovascular mortality in general adult population. 10, ○
- 31 Small dense low-density lipoprotein or low-density lipoprotein for cardiovascular disease in Indians: Meta-analysis addressing the diagnostic dilemma. **2022**, 17, 931 ○
- 30 Cholesterol efflux capacity is associated with lipoprotein size and vascular health in mild to moderate psoriasis. 10, ○
- 29 Differences in HDL-related mortality risk between individuals with and without hypertension: a prospective cohort study in UK Biobank. ○
- 28 Association of clinical and genetic risk factors with management of dyslipidaemia: analysis of repeated cross-sectional studies in the general population of Lausanne, Switzerland. **2023**, 13, e065409 ○
- 27 The importance of low-density lipoprotein cholesterol measurement and control as performance measures: A joint clinical perspective from the National Lipid Association and the American Society for Preventive Cardiology. **2023**, 13, 100472 ○
- 26 Safety and Effectiveness of Evolocumab During Acute and Sub-acute Phases of Acute Coronary Syndrome (ACS): A Systematic Review and Meta-analysis. **2023**, ○
- 25 The importance of low-density lipoprotein cholesterol measurement and control as performance measures: A joint Clinical Perspective from the National Lipid Association and the American Society for Preventive Cardiology. **2023**, 17, 208-218 ○
- 24 Comparative efficacy and safety among high-intensity statins. Systematic Review and Meta-Analysis. **2023**, 12, ○
- 23 Machine-learning versus traditional approaches for atherosclerotic cardiovascular risk prognostication in primary prevention cohorts: a systematic review and meta-analysis. ○
- 22 Current Toolset in Predicting Acute Coronary Thrombotic Events: The "Vulnerable Plaque" in a "Vulnerable Patient" Concept. **2023**, 13, 696 ○
- 21 High-sensitive troponin T and N-terminal pro-B-type natriuretic peptide independently predict survival and cardiac-related events in adults with congenital heart disease. ○
- 20 Lipid-lowering Efficacy and Safety of High Doses of Atorvastatin and Rosuvastatin. **2023**, 63, 59-67 ○
- 19 Celiac Disease and Cardiovascular Risk: A Retrospective Case-Control Study. **2023**, 12, 2087 ○

- 18 Couple concordance in diabetes, hypertension and dyslipidaemia in urban India and Pakistan and associated socioeconomic and household characteristics and modifiable risk factors. **2023**, 77, 336-342 ○
- 17 Possible Implications of Obesity-Primed Microglia that Could Contribute to Stroke-Associated Damage. ○
- 16 A Novel, Microvascular Evaluation Method and Device for Early Diagnosis of Peripheral Artery Disease (PAD) and Chronic Limb Threatening Ischemia (CLTI) in Individuals with Diabetes. **2023**, 101101 ○
- 15 Management of Statin Intolerant Patients in the Era of Novel Lipid Lowering Therapies: A Critical Approach in Clinical Practice. **2023**, 12, 2444 ○
- 14 Catechins: Protective mechanism of antioxidant stress in atherosclerosis. 14, ○
- 13 Value of the clinical pharmacist interventions in the application of the American College of Cardiology (ACC/AHA) 2018 guideline for cholesterol management. **2023**, 18, e0283369 ○
- 12 Statin Eligibility and Prescribing Across Racial, Ethnic, and Language Groups over the 2013 ACC/AHA Guideline Change: a Retrospective Cohort Analysis from 2009 to 2018. ○
- 11 Hypertension medication from guidelines to practice: A cohort study in western Iran. ○
- 10 Emirates Heart Health Project (EHHP): A protocol for a stepped-wedge family-cluster randomized-controlled trial of a health-coach guided diet and exercise intervention to reduce weight and cardiovascular risk in overweight and obese UAE nationals. **2023**, 18, e0282502 ○
- 9 Suboptimal lipid management in patients with acute ischemic stroke. **2023**, 229, 107717 ○
- 8 Microcystins Exposure Associated with Blood Lipid Profiles and Dyslipidemia: A Cross-Sectional Study in Hunan Province, China. **2023**, 15, 293 ○
- 7 Presence of tophi and carotid plaque were risk factors of MACE in subclinical artherosclerosis patients with gout: a longitudinal cohort study. 14, ○
- 6 Soluble PCSK9 Inhibition: Indications, Clinical Impact, New Molecular Insights and Practical Approach—Where Do We Stand?. **2023**, 12, 2922 ○
- 5 Genetics of myocardial interstitial fibrosis in the human heart and association with disease. ○
- 4 Understanding the molecular mechanisms of statin pleiotropic effects. ○
- 3 Diabetic patients with and without sodium-glucose cotransporter-2 inhibitors use and cataract risk: real-world observational investigation. ○
- 2 Optimal Medical Management in Patients undergoing Peripheral Vascular Interventions for Chronic Limb Threatening Ischemia is associated with Improved Outcomes. **2023**, ○
- 1 Efficacy and Safety of Bempedoic Acid to Prevent Cardiovascular Events in Individuals at Risk of Cardiovascular Diseases: A Meta-Analysis of Randomized-Control Trials. **2023**, ○

